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ABSTRACT 
 
LAUREL CLAYTON TRANTHAM: PSA Surveillance Following Radical Prostatectomy: 
What We Know and Why it Matters 
(Under the direction of Andrea K. Biddle, PhD) 
 
Disease recurrence is common after initial therapy for prostate cancer, but little is 
known about how well men receive follow-up surveillance after initial treatment or how 
patterns of follow-up care may influence choice of initial treatment. The overall objectives 
of this dissertation were (1): to examine patterns of prostate-specific antigen (PSA) test 
receipt among elderly men treated with radical prostatectomy for non-metastatic prostate 
cancer, (2): to validate the radiation therapy variable in Surveillance, Epidemiology, and 
End Results (SEER) data by comparing treatment receipt with Medicare claims, and (3): 
to compare through a decision model a “wait and see” approach to radiation therapy in 
which radiation therapy is initiated only after evidence of disease recurrence to an 
approach of treating all qualifying men with radiation therapy adjuvant to surgery. This 
dissertation used population-based SEER-Medicare data to examine the first two aims. 
The decision model was constructed as a Markov cohort model and populated with data 
from clinical trials, retrospective studies, surveys, and Medicare fee schedules.  
Time from treatment was the dominant factor in predicting whether a man 
received a PSA surveillance test in a given year following surgery. In all men, test receipt 
decreased as time from surgery increased. I also found some evidence of racial/ethnic 
disparities in test receipt as well as evidence that test receipt is influenced by access to 
care and social support. I found that although there is some disagreement across SEER 
and Medicare in terms of documentation of adjuvant radiation therapy (ART) receipt, 
overall agreement is very high. This lends support to previous studies using SEER alone 
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to study ART. The results from the decision model suggest that most men will benefit 
more from a wait and see approach to radiation therapy than ART. However, if men do 
not receive appropriate PSA surveillance testing, ART may be a better option. This 
research highlights the need for long-term follow-up care plans for men treated with 
radical prostatectomy for prostate cancer.  
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1. INTRODUCTION 
1.1. Explanation of the Issue 
Approximately one-quarter to one-third of patients treated with radical 
prostatectomy for clinically localized prostate cancer will experience disease 
recurrence.1,2 In contrast to other common cancers, disease recurrence in this setting is 
signaled by the detection of a serum biomarker, prostate specific antigen (PSA). Though 
commonly used for population-based disease screening, PSA testing was originally 
developed and approved for the detection of disease recurrence following treatment.3 
Following radical prostatectomy, a man’s PSA level should be undetectable; if it is not, 
he is considered to have experienced biochemical recurrence. Patients with biochemical 
recurrence have no associated symptoms, and it is well established that a rising PSA 
level signals the early stages of treatment failure and disease recurrence.2 If left 
untreated, biochemical recurrence can progress to radiographically detectable, 
incurable, and symptomatic metastatic disease, with a median time of eight years from 
detectable PSA to distant metastasis.4  
PSA values over time, along with tumor characteristics and time from treatment 
to detectable PSA level, are important predictors of local versus distant recurrence and 
help determine the choice of secondary therapy, especially for patients initially treated 
with radical prostatectomy. The sooner biochemical failure is detected through rising 
PSA levels, the sooner secondary treatment may begin. Additionally, earlier intervention 
in the form of salvage radiation therapy for patients with rising PSA levels following 
radical prostatectomy has been associated with better outcomes.5  
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As disease recurrence is common after initial therapy, three recent clinical trials 
have addressed the efficacy of treating a subgroup of locally advanced prostate cancer 
patients with adjuvant radiation therapy (ART) immediately following radical 
prostatectomy. These trials sought to show whether ART would prevent future disease 
recurrence and result in improved outcomes.6-8 This strategy was compared to a “wait 
and see” approach in which salvage radiation therapy was initiated only in response to 
rising PSA levels. Although only one of these trials has thus far demonstrated 
metastases-free or overall survival benefits,9 all three demonstrated efficacy of 
immediate ART in terms of biochemically-defined recurrence-free survival.6-8  
These trials suggest benefits associated with ART, but the associated harms are 
unclear. On one hand, treating all qualifying patients with ART will result in treating 
individuals who would have lived recurrence-free without additional treatment. As the 
side effects of radiation therapy can have serious quality of life implications,10-13 the 
impact of radiation therapy on these patients and the associated costs should be 
carefully considered. On the other hand, the success of the wait and see approach is 
predicated upon frequent PSA testing and appropriate follow-up care in the event of a 
detectable PSA. Patterns of PSA surveillance after prostatectomy in real world practice 
are largely unknown.  
Although the three trials demonstrated the superiority of immediate ART over the 
wait and see approach in terms of biochemically-defined recurrence-free survival, it is 
unclear how ART and the wait and see approach compare in clinical practice, where the 
population of men differs from the population of clinical trial participants.14,15 The goal of 
the present research is to contribute to the understanding of post-treatment surveillance 
and secondary therapy in practice in the Medicare population, and to model the benefits 
and harms associated with ART versus the wait and see approach as they apply to the 
Medicare population.  
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With more than 200,000 new cases per year, prostate cancer is the most 
common noncutaneous malignancy in American men.16 More than 32,000 men died 
from the disease in 2010, making prostate cancer the second leading cause of cancer 
death in men.16 Between 2000 and 2007, 80% of prostate cancer cases diagnosed in 
Surveillance, Epidemiology, and End Results (SEER) reporting areas were localized at 
presentation.17 Approximately 10% were regional and 5% were distant. Relative survival 
is high, with more than 95% of all men alive at five years post-diagnosis.17 This high rate 
of survival along with the potential recurrence point to the importance of disease 
surveillance as a part of survivorship care.  
According to a 2011 study of initial treatment patterns in SEER Patterns of Care 
data, the vast majority of clinically localized cases receive definitive local treatment in the 
form of surgery or radiation therapy.18 A recent systematic review commissioned by the 
Agency for Healthcare Research and Quality failed to find evidence demonstrating 
superiority in terms of disease control for local disease of any one treatment over the 
others.19 Thus, primary treatment is often determined by patient and clinician 
preferences20 and varies by patient age, comorbidity, socioeconomic status, and 
geographic locality.21 Men diagnosed in 2002 most often received radical prostatectomy 
(44.7%), followed by external beam radiation therapy (20.1%) and brachytherapy 
(12.3%). Other common primary treatments included watchful waiting (9%), primary 
androgen deprivation (hormonal) therapy (8.5%), and brachytherapy in addition to 
external beam radiation therapy (5.4%). Radical prostatectomy was the most common 
treatment for all age groups, except men ages 75 and older, for whom external beam 
radiation therapy was the most common, followed closely by primary androgen 
deprivation therapy. These percentages may not capture the full range of treatment 
options, as men may receive more than one type of initial or secondary therapy. For 
example, in this study, men who received radical prostatectomy plus adjuvant or salvage 
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radiation therapy were classified as receiving radical prostatectomy rather than a 
combination of therapies. In the case of more advanced disease, combined treatments 
are more often recommended than any single approach.22  
 Without a treatment superior in disease control, patients may choose treatment 
based on potential side effects of each treatment and their relative preference for quality 
of life outcomes after treatment. In a qualitative study of prostate cancer patients’ 
concerns about treatment attributes, treatment effect on sexual, bowel, and urinary 
function were ranked as three of the top four concerns.23 In direct comparisons between 
radical prostatectomy and radiation therapy across sexual, urinary, and bowel domains, 
radical prostatectomy generally tends to result in worse sexual and urinary function, 
while radiation therapy results in worse bowel function.24  
 When choosing whether or not to receive ART, patients must weigh the potential 
for improved survival against the potential side effects and associated quality of life 
changes due to radiation therapy. Many studies evaluate the effect of a single treatment 
on quality of life,25-30 but few evaluate the effect of adjuvant or salvage therapies. Two 
recent longitudinal analyses of men in the Cancer of the Prostate Strategic Urologic 
Research Endeavor registry evaluated the effect of salvage radiation therapy on quality 
of life.31,32 In one study, men who received salvage radiation therapy had worse physical 
function before and after radiation therapy compared to men who received only radical 
prostatectomy.31 This finding is not surprising as the men who received salvage radiation 
therapy received salvage therapy due to disease recurrence, whereas the radical 
prostatectomy-only group could be considered recurrence-free.  
For patients diagnosed with prostate cancer in 2002, Medicare paid on average 
$18,261 for initial care.33 In comparison, initial costs for patients diagnosed in 1991 
totaled $200 more (in adjusted dollars). Medicare costs for initial treatment of breast, 
colorectal, and lung cancer in 2002 were $20,929, $41,134, and $39,891, respectively. 
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Although Medicare paid the least, on average, for initial treatment of prostate cancer, the 
high incidence of prostate cancer creates a high total cost burden. Additionally, many 
costs associated with prostate cancer treatment may be incurred several years after 
diagnosis. As an initial therapy, active surveillance leads to low initial costs but does not 
preclude surgery or radiation therapies in the future, which have much higher costs.  
1.2. Specific Aims 
The choice of initial treatment (and secondary therapy should initial treatment 
fail) involves balancing treatment side effects, the potential for disease control, current 
and future costs, and the intensity of surveillance care. The present research explores 
these trade-offs through three study aims:  
Aim 1: To examine patterns of PSA surveillance testing among elderly men 
treated with radical prostatectomy for non-metastatic prostate cancer. Rising PSA 
levels following surgery are the primary indication of disease recurrence, but little is 
known about how often PSA is measured in men after initial treatment. This aim uses 
SEER data linked with Medicare claims to fill this knowledge gap and to identify groups 
who may not be receiving high-quality survivorship care in terms of adherence to 
guideline-recommended PSA surveillance.  
Aim 2: To evaluate the validity of the SEER radiation therapy treatment 
variable. SEER provides information on whether radiation therapy was received, 
recommended, or not received, as well as information on the timing of radiation therapy 
administered adjuvant to surgery. Overall agreement is high in SEER-Medicare about 
receipt of radiation therapy,34 but no research has demonstrated whether this holds true 
for ART after prostatectomy. ART may be administered months after surgery and may 
be recommended only after examination of tumor pathology. These timing issues may 
lead to incomplete capture of ART in SEER, which could have implications for the use of 
SEER in examining treatment patterns.  
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Aim 3: To compare through a decision model the wait and see approach 
versus ART following radical prostatectomy. Part of the concern with treating all 
qualifying men with ART is the unnecessary treatment of men whose disease will never 
progress following surgery. To date, this additional treatment’s negative side effects 
have been described but neither quantified nor compared to potential survival benefits. I 
constructed a cost-utility model which allowed for the evaluation of the two treatment 
pathways in patient populations facing different risks of disease recurrence and allowed 
me to evaluate assumptions about disease progression and treatment-related side 
effects.  
1.3. Organization of this Dissertation 
To place my research into the context of current approaches to prostate cancer 
treatment, I conducted an extensive literature review that is presented in Chapter 2. This 
chapter provides more information on the staging and course of disease in prostate 
cancer, radiation therapy as implemented in practice and in clinical trials, and describes 
extant comparative and cost-effectiveness analyses in prostate cancer care. Chapter 3 
contains details about the data sources, sample construction, and methods used to fulfill 
the three specific aims. Chapters 4 through 6 are self-contained manuscripts addressing 
the specific aims. Each of these chapters contains an abstract, introduction, and 
conclusion relevant to the specific aim under examination. The last chapter discusses 
the research findings, examines the limitations and study strengths of the data, 
approaches and conclusions, and lays out a research agenda based upon the results 
from the research. 
  
 
2. BACKGROUND 
2.1. Prostate Cancer Diagnosis, Staging, and Treatment Guidelines 
The prostate is a small, walnut-sized gland located below the bladder and in front 
of the rectum. Luminal epithelial cells in the prostate produce prostate-specific antigen 
(PSA), and elevated PSA levels in the blood are most often the first sign of prostate 
cancer.35 (The value of PSA testing for cancer screening has received much attention in 
research and popular media,36 but an examination of the utility of PSA screening is 
beyond the scope of the current research.) Diagnosis is confirmed using a transrectal 
ultrasound-guided biopsy.37 The strongest risk factors for disease are age, race, and 
family history,38-41 while associations between hormone level, diet, obesity, and physical 
exercise and disease are suspected but less well-established.41 
Prostate cancer is staged according to the tumor, node, metastases (TNM) 
system, which incorporates primary tumor size and extension, lymph node involvement, 
and distant metastasis.37 In most patients, digital rectal exam is the primary method of 
assessing clinical stage. Complete pathological staging requires radical prostatectomy, 
regional node examination, and histological analysis. The clinical and pathologic 
American Joint Committee on Cancer (AJCC) primary tumor definitions (T and pT), 
described in Table 1, combined with description of lymph node involvement (N0 for no 
regional nodes, N1 for metastasis in regional nodes, and NX for not assessed), and an 
indicator for metastatic disease (M0 for no distant metastasis and M1 for distant 
metastasis) combine to form the TNM stage.  
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Table 1. American Joint Committee on Cancer Prostate Cancer Staging Definitions42 
Primary Tumor, Clinical 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically inapparent tumor neither palpable nor visible by imaging 
T1a Tumor incidental histologic finding in 5% or less of tissue resected 
T1b Tumor incidental histologic finding in more than 5% of tissue 
resected 
T1c Tumor identified by needle biopsy (for example, because of 
elevated PSA) 
T2 Tumor confined within prostate* 
T2a Tumor involves one-half of one lobe or less 
T2b Tumor involves more than one-half of one lobe but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostate capsule** 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal 
vesicles, such as external sphincter, rectum, bladder, levator 
muscles, and/or pelvic wall 
Primary Tumor, Pathological*** 
pT2 Organ confined 
pT2a Unilateral, one-half of one side or less 
pT2b Unilateral, involving more than one-half of side but not both sides 
pT2c Bilateral disease 
pT3 Extraprostatic extension 
pT3a Extraprostatic extension or microscopic invasion of bladder 
neck**** 
pT3b Seminal vesicle invasion 
pT4 Invasion of rectum, levator muscles, and/or pelvic wall 
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. 
The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) 
published by Springer Science and Business Media LLC, www.springer.com. 
*Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by 
imaging, is classified as T1c.  
**Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classified not as 
T3 but as T2.  
***There is no pathologic T1 classification 
****Positive surgical margin should be indicated by an R1 descriptor (residual microscopic 
disease).  
 
The Gleason score is the primary method of grading prostate cancer.37 The total 
Gleason score is the sum of two individual patterns (on a scale of one to five) associated 
with histopathological architecture.43 A Gleason score of seven or greater is generally 
thought to be indicative of higher grade disease.35 Gleason score, TNM stage, and PSA 
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value are all strongly related to prognosis and frame clinical risk stratification, which in 
turn frames treatment recommendations.22 The D’Amico risk groups, as described in 
Table 2, are commonly used to categorize patients with clinically localized disease by 
risk of disease recurrence following initial treatment.44  
Table 2. Definitions of D’Amico Risk Categories44 
Risk Stage 
 
PSA 
 
Gleason 
Total 
Low T1c, T2a AND ≤ 10 ng/mL AND ≤ 6 
Intermediate T2b OR >10 ng/mL, ≤20 ng/mL OR 7 
High T2c OR >20 ng/mL OR >7 
Note: PSA: Prostate-specific antigen; T-stage based on American Joint Committee on Cancer 
staging guidelines; ng/mL: nanograms per milliliter 
 
The National Comprehensive Cancer Network (NCCN) recommends treatment 
options based on a similar risk stratification scheme as that defined by D’Amico (Table 
3),22 with the addition of “Very Low” and “Very High” risk categories at either extreme. 
The treatment guidelines published by NCCN are based on clinical evidence, where 
available, and expert consensus where evidence is inconclusive. Active surveillance is a 
valid treatment option for all patients with very low or low risk disease, regardless of life 
expectancy. Patients with low risk disease and a life expectancy of more than 10 years 
are also recommended to consider external beam radiation therapy, brachytherapy, or 
radical prostatectomy (with the potential for future adjuvant or salvage treatment if the 
tumor specimen possesses adverse pathological features). Patients with intermediate 
risk disease may be treated with active surveillance (if life expectancy is less than 10 
years), external beam radiation therapy, brachytherapy, radical prostatectomy, or a 
combination of treatments with or without androgen deprivation therapy (ADT). Men with 
high or very high risk disease may be treated with external beam radiation therapy and 
ADT or radical prostatectomy (with ADT given for node positive disease). Androgen 
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deprivation therapy (hormone) is not recommended alone as an initial treatment modality 
except for in men with locally advanced or metastatic disease.22  
Table 3. National Comprehensive Cancer Network Recurrence Risk Groups for Clinically 
Localized and Locally Advanced Disease.  
Risk Stage 
 
PSA 
 
Gleason 
Total 
Very Low* T1c AND < 10 ng/mL AND ≤6 
Low T1-T2a AND < 10 ng/mL AND 2-6 
Intermediate** T2b-T2cb OR 10-20 ng/mL OR 7 
High** T3a OR >20 ng/mL OR 8-10 
Very High T3b-T4 
Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines®) for Prostate Cancer (V.1.2012) © 2012 National Comprehensive Cancer Network, 
Inc. Available at: NCCN.org. Accessed [March 24, 2012]. To view the most recent and complete 
version of the NCCN Guidelines®, go on-line to NCCN.org.  
 
*Additional necessary factors for very low risk include fewer than three biopsy cores positive, 
≤50% cancer in each core, and PSA density < 0.15 ng/mL/g, **Patients with multiple adverse 
factors may be shifted into the next highest group. 
 
Note: PSA: Prostate-specific antigen; T-stage based on American Joint Committee on Cancer 
staging guidelines, ng/mL: nanograms per milliliter; ng/mL/g: nanograms per milliliter per gram. 
 
In recent years, the overdiagnosis and overtreatment of low risk men have 
received much attention in research and popular media.45,46 Although these are major 
issues in prostate cancer care, there are still a significant number of men with 
intermediate and high risk disease for whom undertreatment may be the more pressing 
concern. Many of these men may face a risk of disease recurrence despite definitive 
local treatment with curative intent. The use of recurrence risk as a tool to choose initial 
treatment highlights the fact that for many men, initial treatment alone will not provide a 
cure.1,2 The end of initial treatment signals the transition from cancer patient to cancer 
survivor, and, according to the Institute of Medicine, individuals live as cancer survivors 
until disease recurrence, a second cancer, or death.47 Following receipt of definitive local 
therapy, prostate cancer survivors transition into a period of disease surveillance based 
primarily on serum PSA monitoring. Disease surveillance through the use of repeated 
PSA tests is a critical part of survivorship care, as increasing PSA levels, particularly 
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following radical prostatectomy, are often the first sign that initial treatment has failed to 
achieve complete disease control.2  
2.2. Prostate Cancer Surveillance Compared to Other Cancers 
In contrast to other common malignancies, the patterns of care and health 
services utilization of prostate cancer survivors have received less study, particularly in 
terms of surveillance. Surveillance, in contrast to screening, refers to tests and medical 
monitoring aimed at detecting disease recurrence rather than detecting new disease. 
Breast, colorectal, and prostate cancer treatment guidelines all contain guidance for 
post-treatment disease surveillance, specifically regarding the use of mammography,48 
colonoscopy,49,50 and PSA testing,22 respectively. The use of surveillance colonoscopy 
after colorectal cancer diagnosis and treatment has been well-documented in multiple 
populations,51-54 as has the use of mammography after breast cancer diagnosis and 
treatment.55-57 In contrast, there is a relative paucity of literature regarding the utilization 
of PSA testing among prostate cancer survivors following definitive primary treatment.  
A study of colorectal cancer patients enrolled in National Surgical Adjuvant 
Breast and Bowel Project clinical trials found high use of colonoscopy among 
survivors.52 Surveillance colonoscopies are recommended at 12 months after surgery58 
and at least once every five years, and among patients with five to seven years of 
survivorship, 96.5% had received a colonoscopy within the previous five years.52 This 
high rate of surveillance remained stable among patients with more than five to seven 
years of survivorship.  
As clinical trial enrollees may not be representative of the general colorectal 
cancer population, other studies have sought to document surveillance patterns in health 
maintenance organization (HMO)51,54 and population-based samples.53 In a study of the 
Cancer Care Outcomes Research and Surveillance study population, less than half of 
eligible colorectal cancer survivors received colonoscopy within 14 months after 
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treatment.53 Although the difference in surveillance between non-Hispanic whites and 
non-Hispanic blacks was not statistically significant, notable regional variations were 
observed.53 
Surveillance mammography has been shown to reduce mortality in elderly breast 
cancer patients diagnosed with and treated for early stage disease;59 however, not all 
women receive appropriate post-treatment surveillance. A recent study found that, 
regardless of race or dual Medicare/Medicaid eligibility, women who received breast 
conserving surgery with radiation therapy were more likely to receive surveillance 
mammography than women treated with breast conserving surgery alone.56 Another 
study reported that patients who are older, African-American, and unmarried were less 
likely than other women to receive surveillance mammography.60  
It is unknown whether the surveillance patterns related to region in colorectal 
cancer and race in breast cancer observed in colorectal and breast cancer apply to 
prostate cancer. Without knowledge of who is at risk for receiving inadequate follow-up 
care, it is impossible to design programs and policies to improve care in at-risk 
populations. Follow-up care, as an important component in cancer survivorship, presents 
another phase in cancer care where racial and socioeconomic disparities observed in 
treatment may persist. As part of this research I have identified these at-risk populations 
and documented the extent to which observed follow-up surveillance diverges from 
recommended surveillance. This analysis is presented in full in Chapter 4.  
2.3. Prostate-specific Antigen Testing in Prostate Cancer Surveillance Care 
Detectable or rising PSA levels after prostate cancer treatment are often the first 
indicator of recurrent disease, and an early diagnosis of treatment failure can facilitate 
initiation of salvage therapy.61 The effectiveness of post-prostatectomy salvage radiation 
therapy in achieving disease control as measured by PSA response has been 
demonstrated, 5 and the timing of salvage therapy initiation also may contribute to 
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improved outcomes. Multiple series have suggested that treatment response and long-
term survival rates are sensitive to bulk of disease, measured by PSA level, at time of 
salvage treatment.62-64 Whereas PSA monitoring following every type of initial treatment 
is recommended, PSA values following radical prostatectomy are more easily 
interpretable than PSA values following other types of treatment.65 It is for this reason 
that I have focused the present research on disease surveillance in patients receiving 
radical prostatectomy as a definitive local therapy.  
Given the putative benefits of early detection of recurrence in many patients, 
appropriate post-treatment surveillance is essential for men who receive prostatectomy 
to treat prostate cancer. The 1997 NCCN Guidelines called for PSA testing every 6 
months over five years and annually thereafter for men who received potentially curative 
initial therapy.66 The testing period for the first five years changed from every 6 months 
to every 6-12 months in the second version of the 2007 Guidelines.67 This remains the 
recommended testing period.22 Evidence is lacking, however, as to whether men actually 
receive recommended PSA surveillance after treatment of clinically localized prostate 
cancer.  
There is a paucity of data on follow-up surveillance in prostate cancer survivors 
despite demonstrated racial and geographic differences in prostate cancer treatment 
and mortality.68,69 In a small, community-based cohort study of patients diagnosed with 
prostate cancer between 1991 and 1992 receiving treatment in New Haven and 
Hartford, Connecticut, the proportion of men who did not receive a PSA test following 
prostate cancer diagnosis ranged from 22% to 29% in any given year after diagnosis.70 
Among those men who were followed for five full years, 7% never received a PSA test. 
Fewer than half of men (45%) received at least one test each year during the entire 
follow-up period, which ranged from one to nine years. African-American race, time 
since diagnosis, and older age were associated with fewer tests per year. Testing 
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frequency also varied with type of initial treatment. Annual testing was more common 
among those men who received radical prostatectomy, compared to those men who 
received radiation therapy or watchful waiting. The authors do not report rates of salvage 
radiation therapy. Additionally, this study did not account for patient socioeconomic 
characteristics such as insurance status, income, or education, and all of these factors 
are likely to be correlated with both race and follow-up care.71 Although this study is the 
only examination of post-diagnosis surveillance patterns in the literature, it is limited by 
the small sample and single location. Furthermore, the patient surveillance occurred in 
the mid-1990s, before formal recommendations for PSA surveillance practices were 
promulgated by practice guidelines panels.  
A slightly more recent survey of members of the American Urological Association 
(AUA) provides more information about the surveillance practices of U.S. and 
international urologists.72 This 1997 survey targeted urologists who performed 
prostatectomy procedures and provided patient follow-up. As there were no established 
guidelines in place for surveillance at the time of the study, the survey results serve to 
illustrate urologists’ recommendations rather than their actual adherence to a standard 
survivorship care plan. Nevertheless, the study findings provide the best available 
information about how urologists would ideally follow patients post-prostatectomy. Office 
visits, digital rectal exams (DREs), PSA testing, and urinalysis were the most commonly 
recommended follow-up practices and were typically recommended three or four times a 
year for the first year following surgery.72 The recommended frequency of tests 
decreased with increasing time from surgery. The majority of respondents recommended 
the same surveillance schedule for patients with stage T1-T2N0M0 disease as patients 
with stage T3a-T3cN0M0 disease.  
Despite recommending a rigorous follow-up schedule, only half of respondents 
felt that routine follow-up testing could detect a disease recurrence early enough to 
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provide curative treatment. In fact, the main motivating factors behind recommending 
follow-up testing were concerns about patient expectation, legal liability, and patient 
referrals. However, the results from this study does not reflect current surveillance 
motivations, as the survey took place nearly 15 years ago. Additionally, sample inclusion 
criteria are an obvious limitation, given that many patients may receive follow-up care 
from providers other than the urologist who performed their prostatectomy.73,74 Findings 
are also limited by self-report and the relatively small number of cases managed by each 
respondent on average.  
2.4. PSA Recurrence and Elevation after Initial Treatment and Disease Progression 
The seminal, and most commonly cited, description of prostate cancer 
progression following PSA elevation after radical prostatectomy comes from a cohort of 
1,997 men treated at the Johns Hopkins Hospital between 1982 and 1997 and followed 
for a median of 5.3 years.4 All men received PSA tests and DREs every three months for 
the first year following surgery, every six months for the second year, and annually in the 
third year and beyond. In this cohort, actuarial metastases-free survival at 15 years was 
82%. Median time from PSA elevation to metastatic disease was 8 years, and median 
time from metastatic disease to death was five years. The analysis did not include men 
who received salvage radiation therapy upon PSA elevation and responded to therapy 
(as evidenced by PSA response), as they were considered to have local recurrence 
only. Thus, the disease progression patterns in this cohort represent the course of 
prostate cancer in absence of curative secondary therapy.  
Based on the disease progression documented in the Hopkins cohort, when 
biochemical recurrence occurred, it most often (in approximately 75% of cases) occurred 
in the first five years following surgery.4 Among the men who experienced biochemical 
recurrence, 44.7% had elevated PSA levels in the first two years following surgery.4 
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These results highlight the importance of disease monitoring through PSA surveillance, 
particularly in the period immediately following treatment.  
2.5. Clinical Trials: Adjuvant Radiation Therapy and the Wait and See Approach 
For patients presenting with pathological stage T3 (pT3) disease, 10% to 50% of 
these men may not achieve disease control with prostatectomy alone.75 In 2005, the first 
of three major clinical trials evaluating the use of adjuvant radiation therapy (ART) after 
prostatectomy provided evidence of the benefit of ART for certain high-risk prostate 
cancer patients.7 The other two trials published similar results in 2006 and 2009.6,8 This 
time period also saw the publication of a large retrospective study reporting durable 
disease response to salvage radiation therapy following prostatectomy (discussed in 
Section 2.6).76 The 2010 NCCN Guidelines were revised accordingly to reflect the trial 
and retrospective study findings. Part of the “Principles of Radiation Therapy” in the 
2010 guidelines reads, “evidence supports offering adjuvant/salvage RT in all men with 
adverse pathologic features or detectable PSA and no evidence of disseminated 
disease.” (Section PROS-C)22 In this context, RT refers to external beam radiotherapy, 
and adverse pathologic features are positive margins, seminal vesicle invasion, 
extracapsular extension or detectable PSA.22 This recommendation was made with 
lower-level evidence and reflected NCCN consensus. In contrast, a recommendation in 
the 1999 NCCN Guidelines to consider “radiotherapy if status post-radical prostatectomy 
with positive margins of high-grade disease or gross residual disease” was classified as 
“somewhat controversial.”77  
Among the three clinical trials, patients have been followed the longest in the 
SWOG (formerly the Southwest Oncology Group) 8794 trial, which recruited patients in 
the United States between 1988 and 1997.8 This trial was designed to test the 
hypothesis that ART after prostatectomy results in improved progression-free survival 
compared to patients who receive either salvage radiation therapy upon biochemical 
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recurrence or no radiation therapy (the control group). Among patients randomized to 
receive ART, PSA relapse occurred in 34.9% of patients. PSA relapse occurred in 64% 
of the control group. Median time to PSA relapse in the adjuvant group was 10.3 years, 
which was significantly longer than the median PSA relapse-free survival in the control 
group (3.1 years). ART also increased disease relapse-free survival (defined by 
observable and measurable disease, excluding PSA relapse) and reduced the risk of 
initiation of hormonal therapy. Despite a median follow-up of more than 10 years, results 
showed no significant differences in metastases-free or overall survival.8 
A follow-up publication to the initial SWOG trial results (presented above) 
reported on metastases-free and overall survival.9 With a median follow-up of more than 
12 years, survival curves for the radiation therapy group and the control group differed 
significantly (p = 0.023). The 10-year estimate of metastases-free survival was 71% in 
the ART group and 61% in the control group (significant with p = 0.016).  
The European Organisation for Research and Treatment of Cancer (EORTC) 
22911 clinical trial began recruitment in 1992 to test the same hypothesis that ART after 
prostatectomy results in improved progression-free survival compared to patients who 
receive either salvage radiation therapy upon biochemical recurrence or no radiation 
therapy.7 The inclusion criteria for this study were the same as those for the SWOG 
study. Five-year biochemical progression-free survival was 74.0% in the ART group 
compared to 52.6% in the control group. With a median follow-up of only five years, the 
trial has not yet produced results on metastases-free or overall survival. More follow-up 
time will be needed to assess whether the survival benefits observed in the SWOG trial 
apply to the EORTC trial as well.  
Additional subgroup analysis of the tumor pathology of 552 patients in the 
EORTC trial revealed differential benefits associated with ART in patients with positive 
surgical margins.78 After controlling for patient characteristics, results indicated no 
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difference in biochemical recurrence-free survival between patients with negative 
margins in either the adjuvant or control groups (p > 0.1) and the patients with positive 
margins in the adjuvant group (p = 0.07). Only the patients with positive margins in the 
control group fared significantly worse at five years post-treatment. For every 1,000 
patients with positive margins, ART would prevent 291 cases of biochemical recurrence 
at five years. In contrast, ART would prevent only 88 biochemical recurrences for every 
1,000 patients with negative margins. Postoperative PSA, Gleason score, and seminal 
vesicle invasion were not found to be predictive of biochemical recurrence-free survival.  
Another European trial of the same hypothesis with comparable pathological 
stage inclusion criteria produced very similar results. Whereas the EORTC and SWOG 
trials did not require an undetectable PSA following prostatectomy, the ARO 96-02/AUO 
AP 09/95 trial (conducted by the German Cancer Society; hereafter referred to as ARO) 
added this feature as an additional inclusion criterion. Patients who achieved an 
undetectable PSA after radical prostatectomy were randomized to immediate radiation 
therapy or a wait and see approach to salvage radiation therapy. The results were 
remarkably similar to those seen in the other two trials, despite slightly different inclusion 
criteria and trial protocol. Biochemical recurrence-free survival at five years was 72% in 
patients randomized to ART, which was significantly greater than the 54% observed in 
the control group.6 Univariate (but not multivariate) subgroup analyses also indicate a 
progression-free survival benefit associated with ART for patients with positive surgical 
margins.6  
Together, these three trials and a contemporary retrospective series (discussed 
in the following section)76 support secondary (both adjuvant and salvage) radiation 
therapy after prostatectomy, but it is unclear whether ART is superior to salvage 
radiation therapy delivered at the first sign of biochemical recurrence. Many of the trial 
participants in the SWOG and EORTC trials never achieved an undetectable PSA level 
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following radical prostatectomy. In current-day practice, radiation therapy given to these 
patients would be considered salvage rather than adjuvant, as adjuvant radiation therapy 
is radiation therapy given to patients with no evidence of disease but a high risk of 
disease recurrence.  
Not all trial participants who experienced disease recurrence received salvage 
radiation therapy at the time of recurrence, and the trials were not consistent in their 
definition of biochemical recurrence. Three ongoing prospective trials are examining the 
comparison of ART to salvage therapy delivered at the first sign of biochemical 
recurrence,79-81 but until these results are published, the timing and delivery of secondary 
radiation therapy remains largely based on shared decision-making between patients 
and physicians.81  
2.6. Retrospective Studies of Adjuvant and Salvage Radiation Therapy 
In the absence of clinical trials demonstrating the superiority of ART over timely 
initiation of salvage radiation therapy, several retrospective studies have sought to 
quantify potential benefits associated with salvage radiation therapy and prognostic 
factors related to the success of salvage radiation therapy.76,82 One such study 
evaluated the outcomes from 501 patients with disease recurrence after radical 
prostatectomy between 1987 and 2002.76 In a multivariate analysis, negative surgical 
margins, a Gleason score of 8 to 10, pre-radiation therapy PSA greater than 2.0 ng/mL, 
seminal vesicle invasion, and a PSA doubling time of 10 months or less were associated 
with failure of salvage radiation therapy to prevent disease progression. That is, disease 
progression in these patients is more likely to be characterized as distant recurrence 
rather than local recurrence and therefore may not be curable with secondary local 
therapy.  
To better understand the probability of complete response to salvage radiation 
therapy following PSA recurrence after radical prostatectomy, the authors expanded 
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their retrospective cohort to 1,540 patients undergoing salvage radiation therapy 
between 1987 and 2005.5 In this cohort, the PSA level before the initiation of salvage 
radiation therapy was a significant predictor of the likelihood of success of salvage 
therapy, with lower PSA values associated with better outcomes. This finding 
emphasizes the importance of close PSA monitoring following radical prostatectomy, as 
there may be a window of opportunity following PSA recurrence where salvage 
treatment is most effective.  
Although the three recent clinical trials demonstrated improved biochemical 
recurrence-free survival associated with ART, particularly in select patient subgroups, it 
is not clear that ART is superior to a salvage approach in which salvage radiation 
therapy is administered at the first sign of an increasing PSA following surgery.5,76,83 The 
latter approach can result in fewer patients receiving additional therapy compared to the 
former approach, but its successful implementation is predicated upon appropriate 
follow-up care after surgery. ART for patients meeting eligibility criteria for the trials may 
result in additional treatment-related morbidity, but can decrease the risk of disease 
progression in patients who may otherwise not receive appropriate surveillance and 
follow-up.  
2.7. ART in Practice 
Although the three clinical trials clearly demonstrate the efficacy of ART over a 
wait and see approach, particularly in some subgroups, the effectiveness of ART in 
practice is not known. Clinical trial populations may differ in significant ways from the 
Medicare population,14 and population differences may reduce result generalizability. In 
the specific case of the ART trials, the average age of trial participants ranged from 64 to 
65, and all three trials limited recruitment to participants younger than age 76.6-8 In 
contrast, only 53% of Medicare enrollees were between the ages of 65 and 74 in 2009,84 
and the average age of the Medicare population at prostate cancer diagnosis is 67.85 To 
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the best of my knowledge, there has yet to be an analysis of the course of disease 
specifically in Medicare patients with pT3N0M0 tumors or pT2 tumors with positive 
surgical margins.  
Two recent studies evaluated the use of ART in the SEER population and 
established patterns of care in the period before and after the presentation and 
publication of clinical trial data.86,87 One study examined the use of ART in men 
diagnosed with prostate cancer between 2004 and 2005 with pT3 disease who had 
undergone radical prostatectomy and had extracapsular extension and positive surgical 
margins.87 In this small (by SEER standards) sample of 1,427 men, 18.2% received 
ART. Under the 2010 NCCN Guidelines, ART should be considered for these men 
(although salvage radiation therapy would still be an acceptable secondary therapy). 
Receipt of ART varied widely by SEER region, but there was no consideration of patient 
characteristics, and sample sizes for some regions were very small (ranging from 12 to 
352 men).  
A more thorough analysis of ART use in the SEER population focused on the 
recommendation for post-prostatectomy radiation therapy between 2000 and 2007.86 
Men in this sample underwent prostatectomy for N0M0 prostate cancer. Eligible men 
had tumors classified as pT3 or pT2 with positive surgical margins. Of the 21,917 men 
meeting inclusion criteria, 13.5% received a recommendation for ART. The authors 
document a surprising significant, negative relationship between year of diagnosis and 
recommendation for ART. That is, rates of ART recommendation decreased over time. 
There was no difference in recommendations in the periods before and after the 
presentation of results from EORTC 22911 and SWOG 8794. These results reflect 
treatment decisions made before the publication of the overall survival benefits 
associated with ART, so the lack of a trend may reflect clinician reluctance to 
recommend additional treatment without a proven survival benefit. However, rates of 
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ART for other cancers have responded to presentations of clinical trial results.88,89 
Regardless, it will be many years before the effect of the ART trial results on clinical 
practice patterns can be fully established.  
2.8. Measuring Adjuvant and Salvage Radiation Therapy in SEER 
 The SEER program (discussed in more detail in Chapter 3) provides information 
on first course of treatment following a cancer diagnosis for people living within registry 
areas.90 Historically, initial treatment was captured if it occurred within four months of 
diagnosis,90 but the newer editions of the SEER coding manual instruct that all 
treatments included in a documented treatment plan be considered as part of the initial 
course of therapy, regardless of when they occur.91 The most recent comparison of 
SEER and Medicare reports of radiation therapy treatment was published in 2002 and 
used data from patients diagnosed with prostate cancer from 1991 to 1996.34 Since this 
time, there has been growing recognition that ART may offer benefits for select prostate 
cancer patients, which combined with variations in the timing of ART warrants a 
contemporary comparison of SEER and Medicare treatment variables.  
Although the changes in the SEER coding manual are now designed to capture 
more initial therapy delivered over time, the four months from diagnosis window could 
easily fail to include ART delivered in earlier time periods. ART as defined in the clinical 
trials was initiated within approximately four months of surgery.8 In a study of men 
receiving care at Veterans Affairs Medical Centers, the mean time from diagnosis to 
surgery was 76 days for African-American men and 68 days for Caucasian men.92 
Although care received by men at Veterans Affairs Medical Centers may not be 
representative of care received by the Medicare population in general, it is quite likely 
that men may experience a two-month delay between diagnosis and surgery, as current 
surgical practice dictates a minimum of six weeks between biopsy and surgery.93 ART 
delivered four months after surgery would be delivered six months after diagnosis, 
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pushing it beyond the four month window historically captured by SEER. Additionally, the 
decision to provide adjuvant radiation therapy may not be made until after pathologic 
examination of surgical margins, so it is conceivable that radiation therapy delivered in 
the adjuvant setting might not be part of the initial documented treatment plan.  
 A number of studies in the breast cancer literature have sought to investigate the 
degree of agreement between the treatment reported in SEER and the actual treatment 
received.94-96 Two of these studies compared SEER records to Medicare claims,94,95 
whereas the third compared SEER records to self-reported treatment received.96 For 
women diagnosed from June 2005 to February 2007 in Los Angeles and Detroit, SEER 
records failed to capture radiation therapy for 21% of women who say they received it.96 
Rates of underascertainment varied by region, chemotherapy and mastectomy receipt, 
stage, income, and diagnosis at a hospital not accredited by the American College of 
Surgeons. Additionally, in Los Angeles, underascertainment was associated with 
younger age. The authors conclude that the use of SEER (or other registries) alone may 
result in underascertainment of radiation therapy, particularly when there is a delay or 
increased time between surgery and radiation therapy.96 These studies support further 
investigation of SEER treatment data quality in the setting of evolving standards of care 
for prostate cancer. The analysis presented in Chapter 5 addresses this issue by 
evaluating the suitability of SEER treatment data as a surrogate for full Medicare claims 
data.  
2.9. Comparative Effectiveness Research and Cost-utility Analysis 
Without strong clinical evidence demonstrating the superiority of a single prostate 
cancer treatment method over the others, treatments are often compared through the 
use of observational comparative effectiveness research. According to the Institute of 
Medicine, comparative effectiveness research compares the benefits and harms of 
alternative methods of disease prevention, treatment, diagnosis, or care delivery. The 
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purpose of comparative effectiveness research is to aid in informed decision making on 
the part of consumers, physicians, and policy makers.97  
Comparative effectiveness research has gained popularity in recent years due to 
funding provided by the American Recovery and Reinvestment Act of 2009.98 In contrast 
to comparative effectiveness research, cost-effectiveness research incorporates costs 
into the equation when evaluating treatment alternatives. Cost-effectiveness models 
compare the costs and outcomes associated with two or more competing options to aid 
decision makers in selecting the strategy that will result in the greatest net benefit.99 
Cost-effectiveness analysis can be used to compare a new intervention (which could be 
a treatment, a screening strategy, a surgical technique, etc.) to existing standard 
practice. Decision analysis, a particular type of cost-effectiveness analysis, incorporates 
variability and uncertainty about inputs.100 This type of analysis allows for sensitivity 
analyses in which assumptions about costs, probabilities, and outcomes can be modified 
to determine the stability of results.100  
Cost-utility analysis, a type of cost-effectiveness analysis, converts all benefits 
and risks of treatments into a standard measure called quality-adjusted life years 
(QALYs). This measure allows for the comparison of the relative effectiveness of 
interventions across diseases or techniques.101 The standard outcome in cost-utility 
studies is an incremental cost-effectiveness ratio (ICER), which is reported in dollars per 
QALY. As a well-designed cost-utility analysis incorporates all harms and benefits of 
given interventions, the ICER can be seen as the total cost per additional QALY gained 
provided by one intervention over another.102  
ICERs can range from cost-saving (or “dominating”), in which intervention A 
results in lower costs and better outcomes than intervention B, to “dominated,” whereby 
intervention A results in both higher costs and worse outcomes than intervention B. More 
commonly, cost-utility analysis results demonstrate that a new intervention both 
25 
 
improves outcomes and induces higher costs. Generally, in the U.S., an intervention or 
program is considered cost-effective if the ICER is less than $50,000 per QALY.103 
However, as this threshold is not based in theory or evidence and has not been adjusted 
for inflation in the cost of medical care,104 it is helpful to both consider the sensitivity of 
the ICER to model assumptions and to place the ICER in the context of the cost-
effectiveness of other health interventions. A recent survey of American Society of 
Clinical Oncology members found that U.S. medical oncologists were willing to prescribe 
treatments that cost more per QALY for life-prolonging therapies than for treatments that 
improved quality of life but did not improve survival.105 On average, survey respondents 
were willing to prescribe life-prolonging treatments with an ICER of $245,972 per QALY 
and quality of life-improving treatments with an ICER of $119,082. These results 
highlight the variation in the value of a QALY, even within the same sample. Additionally, 
the variation in the value of a QALY demonstrated in the relatively homogenous sample 
of U.S. medical oncologists highlights the difficulty in establishing a cost-effectiveness 
threshold that would be acceptable across a wide range of disciplines and interventions.  
2.10. Cost-utility Analysis in Cancer 
A review of cost-utility analyses in cancer found 242 original cancer-related 
studies published through 2007.101 These articles all were included in the Tufts Medical 
Center Cost-Effectiveness Analysis Registry, which currently maintains information on 
more than 2,400 peer-reviewed cost-effectiveness analyses.106 A relatively small 
proportion of all cost-utility analyses conducted during this time frame pertained to 
cancer (14%).101 Of the cancer cost-utility analyses included in the review, 73% 
evaluated interventions related to treatment and 19% evaluated secondary prevention 
measures such as cancer screening. Pharmaceuticals were most often analyzed (53% 
of studies), followed by medical procedures (18%) and screening strategies (16%). 
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Overall adherence to methodological standards in these studies is good and has been 
improving over time.101  
As the Tufts registry limits inclusion to those articles that present ICERs in terms 
of dollars per QALY, it may not provide a complete picture of cost-effectiveness and 
cost-utility analysis use in prostate cancer. Some recent prostate cancer decision 
analyses present outcomes in terms of dollars per life year saved.107,108 More common 
are analyses of utility or cost alone. Recent comparative effectiveness and cost-utility 
research studies in prostate cancer have focused on chemoprevention,107,109,110 PSA 
screening,108 treatment for early stage disease,111-114 treatment for biochemical 
recurrence,115 risk-prediction tools,116 and type of radiation therapy.117  
2.11. Modeling ART versus the Wait and See Approach to Salvage Radiation Therapy 
 A recent study performed a decision analysis comparing the quality of life 
benefits of ART and a wait and see approach to radiation therapy after radical 
prostatectomy.118 The authors found that the wait and see approach resulted in 6.8 
QALYs over ten years compared to 6.13 QALYs over ten years for ART. However, ART 
was found to be more effective than the wait and see approach in terms of 10-year PSA 
recurrence-free survival, metastasis-free survival, and overall survival.  
The model and analysis presented in Chapter 6 extends and improves upon this 
published study in several ways. First, the inclusion of cost in the decision analysis 
provides a way to compare ART to other interventions in cancer and prostate cancer. 
Second, I have evaluated the sensitivity of my results to all parameter assumptions 
through a full probabilistic sensitivity analysis rather than the three-way sensitivity 
analysis used in the previous model. Additionally, I followed patients for their lifetime 
rather than over a ten-year time period and incorporated discounting, which the previous 
model did not.  
  
 
3. DATA AND ANALYTICAL METHODS 
 This chapter introduces the data sources and methods for all three research 
aims. Aims 1 and 2 are retrospective studies using data from the linked Surveillance, 
Epidemiology, and End Results (SEER)-Medicare database, which is described below 
along with each aim’s sample inclusion criteria. Aim 3 was analyzed using a cost-utility 
model, which was populated with data from published literature. Model inputs included 
disease progression probabilities, utilities for prostate cancer disease states and 
treatment-related side effects, and costs related to adjuvant and salvage radiation 
therapy and treatment of metastatic disease. 
3.1. Data Sources 
3.1.1. SEER-Medicare Data (Aims 1 and 2) 
Data for the analyses of Aims 1 and 2 came from the linked SEER-Medicare 
claims database. The SEER program collects population-based data on all incident 
cancer cases among residents of areas with participating registries. These cancer cases 
can be linked to Medicare claims for Medicare participants who participate in fee-for-
service (FFS) insurance plans. Currently, 28% of the U.S. population lives in area 
captured by the SEER program, and the most recent SEER update contains information 
from registries covering 17 reporting areas on 27 cancer sites and sub-sites through 
2007. The SEER registries collect information on patient demographics, cancer site, 
extent of disease, tumor characteristics, initial treatment, and vital status follow-up.119 
Patient demographics include age at diagnosis, marital status, race/ethnicity, and county 
of residence at diagnosis. The SEER program conducts annual studies in SEER areas 
to evaluate the quality and completeness of the data reported to the registry.90  
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Medicare is the primary health insurance provider for 97% of the U.S. population 
aged 65 and older. All beneficiaries receive Part A benefits, which cover inpatient 
hospital care, skilled nursing facilities, home health, and hospice care. Ninety-five 
percent of beneficiaries pay a monthly premium for Medicare Part B, which covers 
physician services, outpatient care, and durable medical equipment and can take the 
form of a FFS or health maintenance organization (HMO) plan. The Medicare Enrollment 
Database, which can be linked to SEER data, contains information on enrollment, 
entitlement, HMO membership, and demographics for each individual in the Medicare 
program.90  
The first SEER registry data linkage to the Medicare Enrollment Database 
occurred in 1991.90 The current data linkage contains data on all cancer diagnoses 
through December 31, 2007, and all Medicare claims through December 31, 2009 for 
individuals participating in Medicare FFS plans.119 The Medicare files available through 
the linkage include claims from hospital, outpatient, physician, home health, and hospice 
providers. Each file contains patient demographics, date of service, diagnostic and 
procedure codes, and associated charges and reimbursement.90  
Detailed claims are not available for the 15% of Medicare participants enrolled in 
HMO plans. HMO penetration rates vary substantially across SEER reporting areas, with 
California having the highest HMO penetration at 38%.90 The proportion of Medicare 
beneficiaries in SEER areas enrolled in HMOs is greater than the nationwide proportion 
of beneficiaries enrolled in HMOs, but this difference has decreased over time.90 
Nationwide, the proportion of Medicare beneficiaries participating in HMO plans 
averaged 13% from 2001 to 2005, and 18% of Medicare beneficiaries in SEER areas 
participated in HMO plans over the same time period.120  
The SEER-Medicare dataset is composed of several different files. The Patient 
Entitlement and Diagnosis Summary File (PEDSF) contains all of the tumor and 
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treatment data reported by SEER registry, Medicare entitlement and enrollment 
information, and U.S. Census-linked socioeconomic information at the tract and ZIP 
code level. Each row of the dataset contains all information on all cancers for a single 
individual. The Medicare analysis and procedure file (MEDPAR) contains claims and 
billing data from inpatient hospitalizations, which are covered under Medicare Part A. 
The Medicare outpatient file contains claims from outpatient services rendered, which 
may be delivered at a number of facility types, including hospital outpatient departments, 
rural health clinics, and outpatient rehabilitation and dialysis facilities. The carrier claims 
file contains all bills from physicians and other health professionals. Services 
represented in the carrier file may be delivered at hospitals or office settings. Additional 
information about providers and facilities is available in the National Cancer Institute 
hospital file.121  
3.1.2. Inclusion/exclusion Criteria 
For both Aim 1 and Aim 2, the sample of interest was male Medicare 
beneficiaries diagnosed with primary cancer of the prostate gland. The following 
inclusion criteria have been used in previous studies of prostate cancer using SEER-
Medicare data122,123 and were reviewed by experts in urology and oncology. For included 
men, prostate cancer was the first and only cancer diagnosis, and men diagnosed at 
autopsy or on their death certificate were excluded. No men with end-stage renal 
disease (ESRD) as the reason for Medicare entitlement were included, nor were men 
with multiple prostate primary cancer sites. Subjects were at least 65 years old at 
diagnosis, had one full year of Medicare claims before their diagnosis, and were alive at 
12 months post-initial treatment. Additionally, they were continuously enrolled in 
Medicare Parts A and B (in the form of a FFS plan) from 12 months pre-diagnosis to at 
least 12 months after initial treatment. Although these restrictions resulted in the 
exclusion of many men with full cancer diagnosis data in the PEDSF file, complete 
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Medicare claims data are necessary to characterize surveillance care and secondary 
treatment.  
Men in the analytic sample for Aims 1 and 2 received radical prostatectomy as 
their initial cancer therapy within 6 months of prostate cancer diagnosis. Eligible surgical 
procedures as reported in SEER data were radical prostatectomy, total prostatectomy, 
prostatectomy with resection in continuity with other organs, and prostatectomy not 
otherwise specified. Men coded in SEER as having received transurethral resection of 
the prostate, local tumor destruction, local tumor excision, or surgery not otherwise 
specified were not considered to have received surgery as cancer treatment and were 
excluded from the analysis, as in these men, cancer is often an incidental finding during 
surgery for benign disease.91 Surgery receipt was confirmed through the examination of 
Medicare claims, and men must have had a record of surgery in both SEER and 
Medicare data to be included in the sample. Medicare codes used to identify surgery and 
other treatments are presented in Table 4. Men with SEER-reported initial treatment of 
watchful waiting were excluded, regardless of any surgical procedures they may have 
had during the study period. Many men who ultimately receive surgery as treatment for 
prostate cancer may have initially chosen watchful waiting or active surveillance as their 
primary therapy. 
Pathological rather than clinical disease stage was used to define the sample as 
the pathologic disease stage has more weight than the clinical stage in determining the 
course of future surveillance and treatments for patients who receive radical 
prostatectomy. Pathological disease stage was used as an additional inclusion criterion. 
Men with metastatic disease at diagnosis, missing pathological disease stage, pT4 
disease, or metastases in regional lymph nodes were excluded, leaving only those with 
pT2 and pT3 (that is, clinically localized) disease and no nodal disease.  
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Table 4. Billing Codes Used to Identify Relevant Procedures  
  
ICD-9 CPT/HCPCS 
PSA testing   84152-84154, G0103 
Radical prostatectomy 60.4, 60.5, 60.6x 
55810, 55812, 55815, 
55840, 55842, 55845, 
00865, 55866 
External beam 
radiation therapy* 92.24, 92.26  
77301, 77305, 77310, 
77315, 77321, 77371-
77373, 77380, 77381, 
77401, 77403-77409, 
77411-77414, 77416, 
77418, 77422, 77423, 
77520, 77522, 77523, 
77525, 77526, 0073T, 
G0178 
Brachytherapy and 
other radiation therapy 
92.20, 92.21, 
92.22, 92.25, 
92.23, 92.27, 
92.28, 92.29 
55859, 55860, 55862, 
55865, 55875, 76873, 
77470, 77750-77799, 
79005-79999, C1164, 
C1174, C1325, C1350, 
C1700, C1701, C1702, 
C1715-C1720, C1728, 
C1790-C1806, C2638, 
C2639, C2640, C2641, 
G0256, G0261, Q3001 
Hormone therapy 62.3, 62.4x 
54520, 54522, 54530, 
54535, 54690, J1050, 
J1051, J1950, J3315, 
S0175, J9000-J9999 
Chemotherapy 
99.25, V58.1x, 
V66.2, V67.2 
96400-96549, Q0083-
Q0085 
*These codes capture both salvage and adjuvant radiation therapy; the distinction between the 
two is made by examining treatment timing.  
 
Notes: ICD-9: International Classification of Diseases, 9th Revision; CPT: Current Procedural 
Terminology; HCPCS: Healthcare Common Procedure Coding System; PSA: Prostate-specific 
Antigen 
 
For Aims 1 and 2, adjuvant radiation therapy (ART) (as opposed to salvage or 
palliative radiation therapy) was defined as radiation therapy initiated within 180 days of 
surgery. As Aim 1 dealt with the period of surveillance following surgery, men were 
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excluded if they had any claim for brachytherapy, hormone therapy (surgical or medical), 
or chemotherapy within one year of surgery if they received surgery alone or within one 
year of the final radiation therapy treatment if they received surgery with ART. Radiation 
therapy was considered adjuvant rather than salvage if it was initiated within 6 months of 
surgery. Initiation of an additional therapy (brachytherapy, hormone therapy, or 
chemotherapy) was considered to mark a shift in the disease course from surveillance to 
active treatment, and PSA tests received following this shift may not have the same 
interpretation as PSA tests received during the surveillance period. Men were followed 
until death, a switch to an HMO plan, disease recurrence (marked by initiation of 
secondary treatment), or the end of the data period (December 31, 2009). The final 
sample size for Aim 1 was 10,761.  
Figures 1 and 2 summarize these inclusion and exclusion criteria. For Aim 1, 
men were diagnosed with prostate cancer between January 1, 1998 and December 31, 
2007, with follow-up through Medicare claims available through December 31, 2009. For 
Aim 2, men were diagnosed with prostate cancer between January 1, 2000 and 
December 31, 2007. Follow-up claims data were available for these men through 
December 31, 2009.  
 Men included in the Aim 2 sample could have received adjuvant or salvage 
hormonal therapy or chemotherapy in addition to surgery and any radiation procedures 
as the goal of this aim was to validate records of radiation receipt rather than document 
survival or follow-up care for a cohort of men receiving a specific treatment. Additionally, 
as adjuvant radiation is only recommended for consideration in men with pT2 disease 
with positive surgical margins or pT3 disease, men with pT2 disease and negative 
surgical margins were excluded. This resulted in a final sample size of 3,993.  
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Figure 1. Sample Counts for Included and Excluded Observations, Aim 1 
 
Men with primary prostate cancer in SEER areas diagnosed between 01/01/1998 and 12/31/2007 
n=371,133 
Other cancer diagnosis 
Missing diagnosis month 
Diagnosis at death or autopsy 
n=48,828 
Enrolled in Medicare HMO 12 months 
before diagnosis 
Missing pre-diagnosis claims 
Age at diagnosis <65 
n=176,767 
Missing pathologic stage 
Missing histology 
n=257 
Metastatic disease at diagnosis 
Nodal involvement 
n=15,022 
Prostate cancer first and only cancer diagnosis 
Not diagnosed at death or autopsy 
n=322,305 
Insufficient data for comorbidity index 
n=4,592 
Age at diagnosis 65+ 
Continuous Parts A & B Medicare coverage 12 
months pre-diagnosis 
No ESRD 
n=145,538 
No qualifying surgery 
Any neoadjuvant therapy 
n=97,107 
Other treatment, death, or HMO 
switch within one year of surgery 
n=1,374 
Stage pT2 or pT3 with histology information  
n=10,761 
Aim 1 sample with qualifying disease and insurance characteristics, n=10,761 
Note: SEER: Surveillance, Epidemiology and End Results; HMO: Health maintenance 
organization; ESRD: End stage renal disease; FFS: Fee-for-service 
No secondary therapy within one year of surgery 
Alive at one year post-surgery 
Enrolled in FFS at one year post-surgery  
n=11,018 
Clinical stage T1c-T3 
n=109,499 
Clinical stage Tis, T1a, T1b, T4 
n=16,426 
Qualifying surgery within 180 days of diagnosis 
No neoadjuvant therapy 
n=12,392 
Claims sufficient to calculate comorbidity index 
n=125,924 
Non-metastatic disease 
No nodal involvement 
n=130,516 
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Figure 2. Sample Counts for Included and Excluded Observations, Aim 2 
 
Men with primary prostate cancer in SEER areas diagnosed between 01/01/2000 and 12/31/2007 
n=335,119 
Other cancer diagnosis 
Missing diagnosis month 
Diagnosis at death or autopsy 
n=46,934 
Enrolled in Medicare HMO 12 months 
before diagnosis 
Missing pre-diagnosis claims 
Age at diagnosis <65 
n=157,727 
Missing pathologic stage 
Missing histology 
pT2 with negative margins 
SEER radiation receipt unknown 
n=8,742 
Metastatic disease at diagnosis 
Nodal involvement 
n=12,971 
Prostate cancer first and only cancer diagnosis 
Not diagnosed at death or autopsy 
n=288,185 
Insufficient data for comorbidity index 
n=5,551 
Age at diagnosis 65+ 
Continuous Parts A & B Medicare coverage 12 
months pre-diagnosis 
No ESRD 
n=130,458 
No qualifying surgery 
Any neoadjuvant therapy 
n=85,975 
Death or HMO switch within one year 
of surgery 
n=51 
Stage pT2 (with positive margins) or pT3 with 
histology information 
SEER  information on radiation receipt 
n=3,993 
Men with qualifying disease and insurance characteristics, n=3,993 
Note: SEER: Surveillance, Epidemiology and End Results; HMO: Health maintenance 
organization; ESRD: End stage renal disease; FFS: Fee-for-service 
Alive at one year post-surgery 
Enrolled in Medicare FFS at one year post-surgery 
n=12,735 
Clinical stage T1c-T3 
n=98,761 
Clinical stage Tis, T1a, T1b, T4 
n=13,175 
Non-metastatic disease 
No nodal involvement 
n=117,487 
Claims sufficient to calculate comorbidity index 
n=111,936 
Qualifying surgery within 180 days of diagnosis 
No neoadjuvant therapy 
n=12,786 
35 
 
3.1.3. Dependent, Key Independent, and Control Variables 
 This section presents an overview of the dependent and independent variables. 
Dependent variables and key independent variables are presented in Table 5 by aim. I 
discuss below how each was created and used in the analysis. The control variables 
used in Aims 1 and 2 are summarized in Tables 6 and 7. See Chapter 4 and Chapter 5 
for a discussion of the values taken by each variable along with tables of summary 
statistics. 
Table 5. Dependent and Key Independent Variables, by Aim 
Aim Variable Potential values Source 
Dependent Variables 
Aim 1 
Indicator of receipt of 
PSA surveillance test 0, 1 Claims 
Aim 2 
Match between SEER 
and Medicare on 
adjuvant radiation 
receipt 0, 1 
PEDSF, 
Claims 
Key Independent Variables 
Aim 1 
Years past primary 
treatment 
Year 1, 2, 3, 4, 5, 6+ 
indicators Claims 
Aim 1 Race/ethnicity 
Non-Hispanic white, 
non-Hispanic black, 
Hispanic, 
unknown/other PEDSF 
Aim 2 Tumor differentiation 
Well/moderately 
differentiated, poorly 
differentiated PEDSF 
Aim 2 
Pathologic disease 
stage pT2, pT3 PEDSF 
Note: PEDSF: Patient Entitlement and Diagnosis Summary File; PSA: Prostate-specific antigen; 
SEER: Surveillance, Epidemiology, and End Results 
 
Dependent Variables 
For Aim 1, the primary dependent variable of interest was a binary indicator of 
whether a man received a surveillance PSA test in a given year following treatment. As 
strict adherence to surveillance guidelines would require PSA testing every 6 months, an 
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alternative measure of testing receipt was defined using a binary variable indicating 
whether a patient received at least one test in a given 6-month interval.  
I examined claims data to find all instances of PSA testing beginning 60 days 
following surgery for men receiving surgery alone as a primary treatment and 60 days 
following the last radiation therapy treatment for men receiving surgery with ART. All 
claims containing a PSA test within five days of a previous PSA test were considered to 
be duplicate claims and not counted toward the annual test total. All PSA test claims 
occurring on the date of or after the initiation of secondary therapy were excluded. 
Secondary therapy procedures included salvage radiation therapy (more than 6 months 
after surgery), orchiectomy, androgen deprivation therapy, brachytherapy, and 
chemotherapy. Men must have had at least one full year of data following treatment to 
be included in the sample.  
I identified relevant procedures and claims, current and historic billing codes 
(Table 4) from journal articles,123,124 SEER-Medicare training information,125 International 
Classification of Diseases, 9th edition (ICD-9) codebooks,126,127 a Current Procedural 
Terminology (CPT) codebook,128 and online Healthcare Common Procedure Coding 
System (HCPCS) documentation.129 I extracted all claims with the relevant billing codes 
for men meeting the inclusion criteria detailed in Figures 1 and 2. Although revenue 
center codes are included in Medicare billing information and are often used to identify 
radiation procedures,34 there is no way to distinguish external beam radiation therapy 
from brachytherapy using revenue center codes alone. For this reason, I did not use 
revenue center codes as a way to identify relevant claims. Additionally, as I was 
interested in receipt of radiation therapy procedures rather than planning, I did not 
include codes related to treatment planning or management. I extracted all claims from 
30 days prior to diagnosis until HMO enrollment, death, or December 31, 2009.  
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Although PSA tests are coded differently for diagnostic/screening versus 
surveillance purposes, I included claims for PSA tests with either code to capture full 
disease surveillance. As all PSA tests for men in my sample occurred after a prostate 
cancer diagnosis, any tests with a diagnostic billing code were considered miscoded 
surveillance tests.  
For Aim 2, the dependent variable was a binary variable indicating whether 
SEER and Medicare agreed in terms of ART receipt. I first constructed two separate 
binary variables, one for documentation of ART receipt in SEER and one for 
documentation of ART receipt in Medicare claims. The dependent variable used in the 
analysis was equal to one if the SEER and Medicare binary variables matched and zero 
otherwise. There were two ways in which the records for an individual could not agree: 
either by having documentation of ART in SEER but not Medicare, or by having 
documentation of ART in Medicare but not SEER.  
SEER data contain a radiation therapy variable describing the type of radiation 
therapy administered as a first course of treatment.130 Radiation therapy is coded as 
none, received (by type of radiation therapy), refused, recommended, or unknown, and 
the possible types of radiation therapy are beam radiation, radioactive implants, 
radioisotopes, a combination of beam and other radiation therapy, and radiation therapy 
NOS. I created an indicator of ART receipt using this treatment variable. Men with 
combination therapy and radiation therapy NOS were considered to have received ART; 
men for whom radiation therapy was recommended (but receipt was unknown) and men 
who refused were considered not to have received radiation. Men who received 
radioactive implants and radioisotopes were not considered to have received ART these 
modalities are not recommended adjuvant to radical prostatectomy.22 Men with unknown 
radiation therapy receipt were excluded.  
38 
 
The Medicare ART receipt variable was constructed using claims data. Men with 
claims for external beam radiation therapy beginning within 6 months of surgery were 
given a value of one for the Medicare radiation therapy receipt binary variable. The 
variable was equal to zero for all other men. Radiation therapy delivered outside of the 
180-day window after surgery was also captured in Medicare claims. Radiation therapy 
in this setting could be considered salvage (delivered with curative intent in response to 
disease recurrence) or palliative (delivered in response to symptoms of metastatic 
disease), but it is not the intent of this research to distinguish between the two. 
Regardless, men who received any radiation therapy outside the 180 day window from 
surgery did not receive ART. The dependent variable for the Aim 2 analysis was 
constructed to indicate whether or not there was a match in the receipt of ART across 
SEER and Medicare records for each individual.  
Key Independent Variables, Aim 1 
Key independent variables for Aim 1 were the time elapsed since treatment 
(measured in years) and patient race/ethnicity. Each observation captured a single year 
for an individual, and only complete years of data were included in the sample. That is, a 
man with 6 and a half years between surgery and death is represented by 6 
observations in the sample. The year was measured as an indicator of whether the 
observation covered the first, second, third, fourth, fifth, or sixth or later year. That is, the 
sixth year and following were assumed to have the same effect on the likelihood of 
receiving a PSA test.  
The SEER version of race/ethnicity was used to measure patient race/ethnicity. 
Medicare claims also report race/ethnicity, but it is believed that the SEER data are 
superior, due in part to the use of a Spanish-surname algorithm.131 Race/ethnicity was 
coded as non-Hispanic white, non-Hispanic black, Hispanic, and other/unknown. The 
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largest race/ethnicity categories among the last group were Japanese (21%), other 
Asian or Pacific Islander (39%), and unknown race/ethnicity (15%). 
Key Independent Variables, Aim 2 
The decision to initiate ART may not be made until after examination of the 
surgical specimen, so pathologic disease stage and tumor differentiation were examined 
in the analysis to identify individuals with adverse disease features. Individuals with 
higher PSA levels, higher Gleason scores, and pT3 disease are those individuals for 
whom ART is most likely to be recommended, but that recommendation may hinge on 
surgical findings and may not be well documented in the initial treatment plan. Specific 
Gleason score and PSA level were not available for all years of data, so a collapsed 
measure of tumor differentiation based on Gleason score and pathologic disease stage 
were used as the key independent variables in the Aim 2 analysis.  
Control variables, Aim 1 
Individual-level measures of age, marital status, tumor characteristics, co-
morbidity, and Medicare state buy-in at diagnosis were used to control for the likelihood 
that an individual would receive a PSA surveillance test in a given year following initial 
treatment (Table 6). Tumor characteristics included an indicator of pathologic tumor 
stage (pT2 or pT3, where pT3 tumors are characterized by extraprostatic extension), 
and tumor histology, which was captured by a binary variable indicating whether the 
combined Gleason score of the tumor was less than or equal to 7 (well/moderately 
differentiated) or greater than 7 (poorly differentiated). Comorbidities documented in 
Medicare claims within the year prior to diagnosis were measured by the National 
Cancer Institute (NCI) Combined Comorbidity Index, which was developed specifically 
for use with SEER-Medicare data and includes prostate cancer-specific weights.132 
Medicare state buy-in at diagnosis was used to help control for income, healthcare 
access, and individual characteristics not otherwise captured. Although this indicator has 
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previously been used to identify individuals who are dually-eligible for Medicare and 
Medicaid, a recent paper cast doubt on the adequacy of the buy-in indicator to 
appropriately identify dually-eligible individuals.133  
Table 6. Aim 1 Control Variables, Values, and Sources 
Variable Type Potential Values Source 
Individual-level 
Age at diagnosis Continuous PEDSF 
Marital status Binary 
Married, not 
married PEDSF 
Co-morbid conditions, 
measured by the NCI 
Combined co-morbidity 
index Continuous Claims 
State buy-in at diagnosis Binary Yes, No PEDSF 
Pathologic tumor stage Binary pT2, pT3 PEDSF 
Tumor histology Binary 
Well/moderately or 
poorly differentiated PEDSF 
Diagnosis year Categorical 
1998, 1999, 2000, 
2001, 2002, 2003, 
2004, 2005, 2006, 
2007 PEDSF 
County-level 
Racial isolation index Continuous 
U.S. 
Census 
Persistent poverty indicator Binary Yes, No ERS, USDA 
Population density Continuous 
U.S. 
Census 
Social capital index Continuous 
NRCRD, 
PSU 
Medicare HMO Penetration Continuous 
RTI Spatial 
Database 
Note: PEDSF: Patient Entitlement and Diagnosis Summary File; SEER: Surveillance, 
Epidemiology, and End Results; PSA: Prostate-specific Antigen; HMO: Health maintenance 
organization; RTI: Research Triangle Institute; NCI: National Cancer Institute; ERS: Economic 
Research Service; USDA: United States Department of Agriculture; NRCRD, PSU: Northeast 
Regional Center for Rural Development, Penn State University 
 
County-level measures of population density,120 persistent poverty,134 racial 
isolation,135 social capital,136 and Medicare HMO penetration120 were included in the 
models to control for access to care and local practice patterns. These county variables 
were specific to the last known county in which each individual received a PSA test or 
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the county in which the individual was diagnosed for those with no record of PSA test 
receipt. Annual population density (measured as 1,000 individuals per square mile) was 
used to control for geographic isolation and as a potential measure of access to care. An 
additional control for access to care was an indicator of persistent poverty for the year 
2004, which indicates that at least 20% of the county population had a household 
income below the poverty level in the last 4 decennial U.S. censuses.134 A race/ethnicity-
specific measure of racial isolation/segregation was included to capture the social 
support networks available in each individual’s community.135 This measure is based on 
2000 U.S. Census data and has been shown to influence receipt of screening 
mammography in the Medicare population.137 I also included a measure of community 
social capital, which may influence an individual’s ability to seek and obtain medical 
care. This 2005 county-level measure is a composite index based on the number of civic 
and non-profit organizations in county, voter turn-out, and Census return rates.136 Finally, 
a county-level measure of the percent of Medicare-eligible beneficiaries participating in 
an HMO plan was used to control for variations in practice patterns that may be 
attributable to a managed care spillover effect.138 This measure was available for the 
years 2001-2005; the 2001 value was assigned to observations from 1998-2001 and the 
2005 value was assigned to observations from 2005-2009. 
Control variables, Aim 2 
Previous validation studies in the breast cancer literature have found differences 
in the likelihood of a registry-claims match by age at diagnosis,94,96 but there is little 
evidence that other demographic and socioeconomic characteristics affect the likelihood 
that registry and claims records would agree on ART receipt. However, these 
characteristics may be related to disease severity as well as the type of treatment 
received,68,139,140 so I included age at diagnosis, marital status, and race/ethnicity as 
control variables. Table 7 presents the full set of control variables.  
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Table 7. Aim 2 Control Variables, Values, and Sources 
Variable Type Potential Values Source 
Individual-level 
Age at diagnosis Continuous  PEDSF 
Race/ethnicity Categorical 
Non-Hispanic 
white, non-Hispanic 
black, Hispanic, 
unknown/other PEDSF 
Marital status Binary 
Married, not 
married PEDSF 
SEER Region Categorical 
San Francisco, 
Connecticut, 
Detroit, Hawaii, 
Iowa, New Mexico, 
Seattle, Utah, 
Atlanta, San Jose, 
Los Angeles, rural 
Georgia, Greater 
California, 
Kentucky, 
Louisiana, New 
Jersey PEDSF 
Community-level    
Medicare HMO Penetration Continuous 
RTI Spatial 
Database 
Hospital-level 
Bed size of surgical facility Continuous NCI file 
NCI Cancer Center 
designation Binary Yes, No NCI file 
Medical school affiliation Binary Yes, No NCI file 
Radiation treatment 
provided at surgical facility Binary Yes, No NCI file 
Note: PEDSF: Patient Entitlement and Diagnosis Summary File; SEER: Surveillance, 
Epidemiology, and End Results; PSA: Prostate-specific antigen; HMO: Health maintenance 
organization; RTI: Research Triangle Institute; NCI: National Cancer Institute 
 
Agreement on radiation therapy receipt was found to vary across SEER regions 
in a previous study of radiation receipt in SEER data,34 so SEER region at diagnosis was 
included to control for potential differences in how well different registries capture 
treatment information. Surgical facility characteristics, particularly bed size and National 
Cancer Institute (NCI) affiliation (defined as being a clinical or comprehensive 
designated cancer center) were also hypothesized to affect the type of treatment 
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received as well as the documentation and reporting of treatments.96 The surgical facility 
characteristics were included as control variables rather than the diagnosing facility 
characteristics as the surgery results may play a larger role in determining the course of 
future treatment than results from a diagnostic biopsy. NCI affiliation was available only 
for 2002 and 2005; the 2002 affiliation was used for diagnoses between 2000 and 2003 
and the 2005 affiliation was used for diagnoses between 2004 and 2007. Other surgical 
facility characteristics included in the models were medical school affiliation and the 
whether the facility provided therapeutic radiology services or not. A facility was 
classified as affiliated with a medical school if affiliation was major, limited, or graduate-
level only. Other than NCI affiliation, all facility level variables were available for 2000-
2007.  
3.1.2. Aim 3 Data 
Cost-utility models require event probabilities, utilities in terms of quality-adjusted 
life years (QALYs), and costs as inputs. Disease and treatment-related probabilities and 
utilities came from the peer-reviewed literature. I conducted a PubMed search using the 
following terms alone and in combination: prostate cancer, cancer, quality of life, utility, 
cost-effectiveness, cost-utility, QALY, willingness to pay, quality of life, comparative 
effectiveness, and health-related quality of life. This search process began in May 2011, 
and was periodically repeated between May and December 2011 to capture any new 
publications. Additionally, I reviewed the table of contents of new issues of 19 relevant 
journals to find new publications. Titles and abstracts located through the PubMed 
searches and table of contents were reviewed to identify articles that contained relevant 
model inputs. I also reviewed reference lists of relevant articles to identify any additional 
publications that might contain data relevant to the model. Costs came from the 
Medicare physician fee schedule141 and the 2010 Red Book.142 This section provides 
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information on the methods used to collect these inputs, and Chapter 6 contains tables 
detailing the input values and distributions.  
Probabilities 
Results from clinical trials and retrospective series were used to derive transition 
probabilities for the model. Probabilities associated with biochemical recurrence 
following radical prostatectomy and biochemical recurrence following ART came from a 
recent clinical trial.6 Probabilities for progression from disease recurrence to metastatic 
disease and progression from hormonally responsive metastatic disease to hormone-
refractory disease came from retrospective studies,4,5,83,143 and biochemical recurrence 
following salvage radiation therapy (SRT) and survival following hormone-refractory 
disease were calculated using peer-reviewed risk prediction nomograms.5,144 Additional 
probabilities of disease progression following radical prostatectomy, ART, and SRT were 
derived for subgroups of men with and without positive surgical margins and with and 
without seminal vesicle invasion. When available, event counts were used to create beta 
distributions around the base-case probability. If event counts were not presented in the 
source article, a beta distribution was approximated from a mean and standard 
deviation.100 If no distribution information was available, I assumed that the standard 
deviation was 20% of the base-case value and approximated a beta distribution from this 
information. All probabilities were converted from annual or multiple year probabilities to 
quarterly probabilities.100 The annual probability of death from background causes was 
obtained from the 2007 U.S. life tables for men.145 
The probabilities for developing short- and long-term urinary, sexual, and 
gastrointestinal adverse effects following radical prostatectomy and radiation therapy 
came from a random-effects meta-analysis conducted by Hayes et al.112 Short-term 
adverse events resolved within 3 months of treatment, whereas long-term adverse 
events persisted from 3 months until death. Following the methods of Elliot et al.,118 the 
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probabilities of developing adverse events were considered to be the probability of 
developing the given adverse event alone and in combination with other adverse events.  
Utilities 
Substantial research exists on prostate cancer-related quality of life and health 
states.146 Titles and abstracts located through the PubMed searches described above 
were reviewed to identify articles that reported utility values rather than quality of life or 
functioning scores. Although many instruments are used to evaluate quality of life in 
prostate cancer patients,147 few of these instruments generate utility measures, which 
are essential in construction of a cost-utility model. Many of the articles identified in the 
initial search were cost-effectiveness or cost-utility studies that referenced utility values 
from a previous study, so reference lists of relevant articles were reviewed to identify any 
additional publications.  
I identified 30 studies reporting utilities and used them to create a database of 
prostate cancer-specific utility values containing 289 utility values. Values were 
categorized as describing a treatment state, adverse event, short-term effect, and/or 
long-term effect. The quality of each measure and its relevance to the current study were 
evaluated by examining the population from which the value was elicited, the elicitation 
technique, the sample size, and the utility scale endpoints. Utilities from scales using 
anchors other than death and perfect health were excluded. Utility values derived from 
expert opinion also were excluded unless they were the only ones representing a 
specific health state. To ensure the consistency of the evaluated outcomes, studies were 
excluded if cancer patients were asked to evaluate the utility of their current health state 
rather than a standard health state description. 
Seventeen of the studies presenting prostate cancer-related utilities involved 
utilities related to metastatic disease. Of these 17 studies, seven met the inclusion 
criteria described above, however 3 studies appeared to use the same data set, bringing 
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the total number of studies with useful utility data to 5.113,115,148-150 Two of these 5 studies 
reported more than one utility measure.149,150 Since the model had two metastatic 
disease states, utilities were separated by whether or not the disease was responsive to 
hormonal therapy (specifically, leuprolide). In cases where the authors did not 
specifically state the level of disease advancement, the disease description used in the 
utility exercise was used to properly categorize the utility. This process resulted in a final 
group of 4 estimates from 2 studies for the utility of living with metastatic prostate cancer 
responsive to hormonal therapy149,150 and 7 utility estimates from 5 studies for the utility 
of living with metastatic prostate cancer that is no longer hormonally responsive.113,115,148-
150
 For hormonally responsive disease, the utility value mean and standard deviation 
were determined by examining the means, standard deviations (where available), and 
interquartile ranges (where available) to derive a single mean and standard deviation 
reflective of the ranges reported in the two studies. For metastatic disease no longer 
responsive to hormonal therapy, the utility value mean and standard deviation were 
taken from Stewart et al.148 as this study focused specifically on the preferences of men 
aged 60 and older, used the standard gamble technique (which, all else equal, is 
preferred to the time trade off technique used in the other studies for preference 
elicitation102), and falls in the middle of the range of utilities reported in the five studies.  
The utilities associated with living with adverse effects related to treatment were 
taken from Stewart et al.148 In contrast to other utility studies that examine the utilities of 
adverse effects separately, Stewart et al. elicited utilities for adverse effects singularly 
and in combination. These combinations are essential for evaluating health states 
following prostate cancer treatment, as individuals may experience multiple treatment-
related adverse effects, and no model exists to accurately predict joint health state 
utilities from the component single health state utilities.151  
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Costs 
With the exception of drug costs, all cost data for the analysis were derived from 
established Medicare fee schedules. Costs were from the calendar year 2011 fee 
schedule,141 which is based on Healthcare Common Procedure Coding System 
(HCPCS) codes. As the difference in salvage and adjuvant radiation therapy is only in 
the timing of the treatment rather than the dosage or administration, both arms of the 
model incorporate essentially the same costs. The model did not include costs 
associated with radical prostatectomy or surgical follow-up, as all individuals 
experienced this procedure prior to the beginning of the model. Included costs are those 
costs associated with radiation therapy administration and follow-up and management of 
metastatic disease.  
The Centers for Medicare and Medicaid Services (CMS) provides information on 
both the national payment amount and Part B carrier-specific payment amounts. The 
national payment amount was used in the base-case analysis, and the carrier-specific 
amounts were used to create a distribution for probabilistic analysis. Input Analyzer 
(Arena Version 13.9, Rockwell Automation, Inc., Wexford, PA) was used to analyze the 
entire set of payment amounts and create distributions to best fit the data.  
Metastatic disease was assumed to be initially treated with gonadotropin-
releasing hormone agonist (leuprolide) rather than orchiectomy, and hormone-refractory 
disease was assumed to be treated with bicalutamide. Drug prices were obtained from 
the 2010 edition of the Red Book142 and adjusted for inflation using the medical care 
component of the Consumer Price Index.152 All individuals were assumed to receive 
semi-annual PSA tests regardless of timing of radiation so this was cost excluded. As 
the adverse effects included in the model were considered to be minor rather than 
requiring substantial medical intervention, there were no additional costs associated with 
adverse effects.  
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3.2. Analytical Methods 
3.2.1. Aim 1 
This aim examined PSA surveillance in men diagnosed with prostate cancer 
between January 1, 1998 and December 31, 2007. The use of PSA surveillance testing 
was characterized as an annual binary indicator of whether a man received at least one 
test during a given year. The 1997 National Comprehensive Cancer Network (NCCN) 
Guidelines called for PSA testing every 6 months over the first 5 years and annually 
thereafter for men who received potentially curative initial therapy, which includes radical 
prostatectomy and radiation therapy.66 In the revised 2007 Guidelines, the testing 
interval for the first 5 years changed from every 6 months to every 6 to 12 months.67 
Additional definitions of surveillance, specifically the receipt of at least one test in a 6-
month period and at least one test in a 9-month period, were examined and compared to 
assess the sensitivity of the results to different measures of surveillance. 
I first used descriptive statistics and bivariate statistical tests to examine the data. 
To examine whether there might be differences in men who always received an annual 
test and those who did not, I calculated and compared summary measures of 
demographic, socioeconomic, and tumor characteristics for men who received at least 
one test per year and men who did not receive at least one test per year over the first 
five years following treatment. In addition, I calculated unadjusted associations between 
selected patient characteristics and PSA test receipt using bivariate statistical tests such 
as the t-test and Chi-square test.153 Specifically, I tested whether receiving at least one 
PSA test per year was significantly different across racial groups and initial treatment 
types. I used a 0.05 level of significance to determine statistical significance.154  
Logistic models, estimated using a generalized estimating equations (GEE)-
based approach, were used to evaluate the influence of covariates on whether an 
individual received a PSA test in a given year. Analysis was conducted at the person –
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year level (or the person-period level for the 6-month and 9-month models). I tested 
functional forms for independent variables (log and polynomial specifications as well as 
continuous versus categorical specifications) as well as the appropriate use of 
interaction terms by using Wald test statistics154 and the quasi-likelihood under the 
independence model information criterion (QIC).155 I used Stata version 10.0 (Stata 
Corporation, College Station, Texas) and SAS version 9.1 (SAS Institute, Inc., Cary, 
North Carolina) to compile the data. All statistical analyses were conducted in Stata. 
3.2.2. Aim 2 
In this aim I compared the agreement between receipt of ART as coded in SEER 
and billing codes included on Medicare claims. The sample for this aim included men 
diagnosed with prostate cancer between January 1, 2000 and December 31, 2007 who 
received radical prostatectomy as initial treatment.  
For the initial descriptive analysis I calculated the percentage of men who 
received ART according to SEER records. I calculated unadjusted associations between 
selected patient characteristics and ART receipt using bivariate statistical tests such as 
the t-test and Chi-square test.153 I then calculated rates of agreement across the two 
data sources by registry, year of diagnosis, and patient characteristics. As there may be 
differences between men who have a record of ART receipt in one source but not the 
other, I compared summary characteristics across three groups of men: those who had a 
record of ART in both sources, those who had a record of ART in SEER but not 
Medicare, and those who had a record of ART in Medicare but not SEER. All statistical 
tests were conducted using a significance level of 0.05.154  
The main analysis for this aim consisted of a logistic regression model.153 The 
dependent variable was an indicator of agreement between SEER and Medicare on 
receipt of ART. This agreement was modeled as a function of individual and hospital 
characteristics described previously. I tested functional forms for independent variables 
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(log and polynomial specifications and continuous versus categorical specifications) as 
well as the appropriate use of interaction terms by using Wald test statistics and 
examining changes in the likelihood ratio test statistic.154 All statistical tests used a 
significance level of 0.05. Observations were clustered at the surgical facility level to 
help control for correlation in observations from a single institution.154  
I compiled the data both in SAS, version 9.1 (SAS, Cary, NC) and Stata, version 
10 (StataCorp, College Station, TX). I performed all data analysis in Stata.  
3.2.3. Aim 3 
For the Aim 3 analysis I constructed a cohort Markov model to estimate the cost-
utility of the current wait and see approach to salvage radiation therapy compared to an 
alternative policy of ART within six months of prostatectomy for all qualifying patients. In 
addition to calculating the cost and utility of each approach, I also estimated the 
proportions of the sample who would experience disease recurrence, develop metastatic 
disease, and die of prostate cancer under each alternative. Each policy was modeled 
separately, and the model outputs were compared to identify the superior strategy. All 
modeling and analyses were performed in TreeAge Pro 2011 (TreeAge Software, Inc., 
Williamstown, MA).  
In the model of outcomes following ART, all individuals begin in the state “NED 
(no evidence of disease) after RT” (Figure 3). In each period of the model, defined as 
three months, individuals could remain in their current disease state or move from their 
current disease state to a new one with different associated costs and utilities.102 
Movement from one state to another was determined by the transition probabilities 
defined previously. In each three month period, individuals made one transition 
(represented by a single arrow) through the model. In this way, all individuals moved 
through the model until they ended in an absorbing state, that is, one that does not allow 
outward movement. In this model, individuals eventually cycled into the absorbing states 
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or death from prostate cancer (“Death, CaP”) or death from other causes (“Death, other 
cause”). Individuals could transition into death from other causes from any state in the 
model (other than death from prostate cancer) at any time, while individuals could only 
transition to death from prostate cancer after developing metastatic disease. The model 
for the wait and see approach is similar, but individuals begin in a state of “no evidence 
of disease following radical prostatectomy” and must transition through “PSA recurrence 
after radical prostatectomy” before entering the “NED after RT” state as depicted in 
Figure 3.  
Figure 3. Markov Model for ART Approach 
 
Note: NED: No evidence of disease; RT: Radiation therapy; PSA: Prostate-specific antigen; CaP: 
Prostate cancer 
 
Each state in the model and the associated events had costs and utilities, which 
contributed to the overall cost and utility of each approach. All costs and utilities 
occurring in the future were discounted at 3% per year to account for the time value of 
money and utility.102,156 I populated the model from the payer perspective (Medicare) 
over the time horizon from initial treatment to death. In contrast to a societal perspective 
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that includes all costs, the payer perspective does not include costs associated with 
productivity loss and patient time.99  
 I used the model to calculate the total cost and the total utility associated with the 
ART approach and the total cost and the total utility associated with the wait and see 
approach. In addition, the proportion of the cohort experiencing disease recurrence, 
receiving radiation therapy, developing metastatic disease, and dying from prostate 
cancer were calculated for each alternative. These cost and utility totals were used to 
calculate the incremental cost-effectiveness ratio (ICER), as demonstrated by: 
ICER = (Cost(adjuvant) – Cost(wait and see))/(Benefit(adjuvant) – Benefit(wait and see)) 
The ICER either will be positive or negative, and the interpretation of the ICER 
can most easily be seen by plotting the incremental costs (y-axis) and benefits (x-axis) 
on an x-y axis (called the incremental cost-effectiveness plane). Incremental cost and 
effectiveness are plotted as a point, and ICER is the slope of the line from the origin to 
the point. When the point estimate ICER falls in northwest or southeast quadrants, one 
alternative is clearly superior to the other, that is, it costs less and is more effective than 
the other.102 Points (and therefore ICER values) falling in northeast or southwest 
quadrants represent alternatives with a trade-off between cost and effectiveness. The 
standard practice is to establish a threshold for the maximum willingness to pay (WTP) 
per QALY.102 The slope of a line running through the origin of the x-y axis represents this 
WTP threshold. An ICER above the threshold indicates the superiority of the wait and 
see approach, whereas an ICER below the threshold indicates the superiority of ART. 
Generally, in the U.S., an intervention or program is considered cost-effective if the ICER 
is less than $50,000 per QALY.103  
Clearly, a single estimate of the ICER is insufficient for drawing conclusions 
about the relative costs and benefits of the two approaches to radiation therapy. 
Although a single estimate for each parameter was chosen for the base-case scenario, 
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one-way and probabilistic sensitivity analyses were used to test the sensitivity of the 
results to changes in each parameter.102 
In one-way sensitivity analyses, one parameter at a time was varied over its 
range of plausible values to determine how much influence that single parameter had on 
the ICER.102 Parameters that have a large influence on the ICER, particularly ones that 
cause the ICER to move from one quadrant to another, indicate areas in which more 
information would be most valuable. That is, narrowing down the range of values that 
parameter might take would lead to a more concise estimate of each alternative’s 
relative value.102  
In the probabilistic sensitivity analysis, all parameters varied simultaneously.102 
Whereas the one-way sensitivity analysis requires only a range for each parameter, the 
probabilistic sensitivity analysis requires both a range and a defined distribution.102 All 
probabilities are estimated from a binomial proportion, thus beta distributions were 
assumed.100 The distributions for the Medicare cost parameters were created from the 
source data,141 which indicated that the lognormal and gamma distributions were the 
best fit. The use of these distributions is supported by the skewed nature of cost data.100 
The 2010 Red Book provided 8 prices for bicalutamide and 4 prices for leuprolide,142 
which were used to calculate means and standard deviations. The method of moments 
approach was then used to create gamma distributions from the means and standard 
deviations.100  
The probabilistic sensitivity analysis used a Monte Carlo simulation of 1,000 
iterations which selected the values of parameters from the assigned distributions for a 
cohort moving through the model. The output of the probabilistic sensitivity analysis is 
1,000 ICERs, which can be interpreted as the range of potential outcomes.102 
The resulting ICERs are plotted on the x-y axis and interpreted as described 
above. Multiple ICERs allow for the calculation of the percentage of ICERs falling in 
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each quadrant. If all ICERs fall in a single quadrant, then it can be said with some 
certainty that the true value lies in that quadrant, provided the model is comprehensive 
and correctly constructed. It is more likely that the ICERs fall in multiple quadrants, or 
that they fall in the northeast or southwest quadrants, where the determination of the 
superior treatment depends on how much the payer, in this case, Medicare, is willing to 
pay per QALY gained.  
Results from the probabilistic sensitivity analysis results also were used to plot a 
cost-effectiveness acceptability curve (CEAC). The CEAC shows the probability that one 
intervention is more cost-effective than its comparator over a range of WTP per QALY 
thresholds.102 For a given threshold, the CEAC indicates the probability that 
implementing the intervention would be the “right” choice, that is, that the cost per QALY 
gained would be equal to or below the WTP per QALY gained. The inverse of this 
probability is the likelihood that the intervention would be the wrong choice.102 Plotting 
the CEAC requires the calculation of the incremental net benefit (INB) for each iteration 
of the Monte Carlo simulation, where the INB is defined as:  
INB = λ*(Benefit(adjuvant) – Benefit(wait and see)) - (Cost(adjuvant) – Cost(wait and see)) 
and λ is the societal WTP for a QALY.157 In this case, if the INB is positive, the ART 
approach offers a greater net benefit. If the INB is negative, the wait and see approach 
offers a greater net benefit. For a range of λ values, the CEAC represents the proportion 
of iterations in which the INB is positive.100  
In scenario analyses, cohort characteristics were changed to evaluate outcomes 
for men with different disease characteristics than those men represented by the base-
case. In contrast to the base-case, in which the probability of receiving SRT at disease 
recurrence was constant over time at 0.75, I created a scenario in which the probability 
of receiving SRT upon disease recurrence following radical prostatectomy was assumed 
to be 0.75 for recurrences in the first two years following surgery, 0.50 for recurrences in 
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years 3-4, and 0.25 thereafter. In an additional scenario to evaluate the effect of 
increasing PSA values over time since radical prostatectomy, PSA level at initiation of 
SRT was 0.5 ng/ml for recurrences in the first two years following surgery, 1 ng/ml in 
years 3-4, and 1.5 ng/ml in year 5 and beyond. Scenario analyses also evaluated 
outcomes for four groups: men with and without positive surgical margins and with and 
without seminal vesicle invasion. 
  
 
4. USE OF PROSTATE-SPECIFIC ANTIGEN TESTING AS A DISEASE 
SURVEILLANCE TOOL FOLLOWING RADICAL PROSTATECTOMY 
 
4.1. Introduction 
Survivors of prostate cancer comprise by far the largest proportion of male 
cancer survivors (41%).47 Nearly half of men diagnosed in 2002 received radical 
prostatectomy, making it the most common form of curative treatment overall and in all 
age groups except men ages 75 and older.18 Approximately one-quarter to one-third of 
patients treated with radical prostatectomy for clinically localized prostate cancer will 
experience disease recurrence.1,2 Detectable or rising prostate-specific antigen (PSA) 
levels after prostate cancer treatment are often the first indicator of recurrent disease, 
and an early diagnosis of treatment failure can facilitate initiation of potentially curative 
salvage therapy.61 PSA surveillance is a cornerstone of prostate cancer survivorship 
care, since patients with a biochemical recurrence (marked by rising PSA levels) have 
no associated symptoms. If left untreated, biochemical recurrence can progress to 
radiographically detectable, incurable, and often symptomatic metastatic disease, with a 
median time from detectable PSA to distant metastasis of 8 years.4 
PSA values over time, along with tumor characteristics and time elapsed from 
treatment to detectable PSA, are important predictors of local versus distant recurrence 
and help to determine the choice of secondary therapy, especially for patients initially 
treated with radical prostatectomy.4,5 Patients receiving salvage radiation therapy after 
biochemical recurrence appear to have a survival benefit compared to those who do not 
receive salvage radiation therapy.82 Furthermore, the effectiveness of post-
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prostatectomy salvage radiation in achieving disease control appears to be greatest 
among patients who receive it at lower PSA levels, typically shortly after detection of 
recurrent disease.5 Given the frequency of biochemical recurrence after definitive 
surgical therapy, the availability of potentially curative salvage treatment, and the above-
outlined apparent benefits of early detection of recurrence, appropriate post-treatment 
surveillance is essential for the large number of prostate cancer patients who receive 
prostatectomy. The 1997 National Comprehensive Cancer Network (NCCN) Guidelines 
called for PSA testing every 6 months over the first 5 years and annually thereafter for 
men who received potentially curative initial therapy, which includes radical 
prostatectomy and radiation therapy.66 In the revised 2007 Guidelines, the testing 
interval for the first 5 years changed from every 6 months to every 6 to 12 months.67  
Although post-treatment surveillance guidelines exist,22 little research has been 
done to document the patterns of care, surveillance, and health services utilization of 
prostate cancer survivors, particularly in contrast to other common malignancies. 
Breast48 and colorectal49,50 cancer treatment guidelines contain guidance for post-
treatment disease surveillance. The use of surveillance colonoscopy after colorectal 
cancer diagnosis and treatment has been well-documented in multiple populations,51-54 
as has the use of mammography after breast cancer diagnosis and treatment.55-57 
Evidence is lacking, however, regarding the extent to which men actually receive 
recommended PSA surveillance after initial treatment for prostate cancer with radical 
prostatectomy. 
This paucity of research on follow-up surveillance in prostate cancer survivors is 
surprising as there are demonstrated racial and geographic differences in prostate 
cancer treatment and mortality.68,69 The only study to measure PSA surveillance testing 
patterns examined men diagnosed more than 20 years ago who received radical 
prostatectomy, radiation therapy, or active surveillance as initial treatment.70 In this 
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small, community-based cohort study of patients diagnosed with prostate cancer 
between 1991 and 1992 receiving treatment in New Haven and Hartford, Connecticut, 
the proportion of men who did not receive a PSA test following prostate cancer diagnosis 
ranged from 22% to 29% in any given year after diagnosis.70 Fewer than half of men 
(45%) received at least one test each year during the entire follow-up period, which 
ranged from one to 9 years. Testing frequency varied with type of initial treatment, race, 
age, and time since diagnosis.  
PSA surveillance may be especially important in groups of men facing higher 
disease recurrence risk. As a consequence of documented cancer treatment disparities, 
racial and ethnic minorities, in particular African-American men, who may present with 
more advanced disease, have more frequent disease recurrence and shorter disease-
free survival times.68,69 This research seeks to document PSA surveillance patterns in 
men treated with radical prostatectomy for NCCN-defined intermediate-risk and high-risk 
prostate cancer (see Chapter 2 for risk group definitions) and to identify groups 
potentially at risk for not receiving follow-up care in accordance with treatment 
guidelines.  
4.2. Methods 
4.2.1. Data 
Data were obtained from the linked Surveillance, Epidemiology, and End Results 
(SEER)-Medicare database.158 SEER data are commonly used to describe trends in 
cancer diagnosis, treatment, and mortality in the U.S.,16,69 and the linked SEER-
Medicare data are frequently used to examine treatment patterns in prostate 
cancer.68,123,139,159,160 The SEER program of cancer registries collects population-based 
data on all incident cancer cases among residents of the 17 participating reporting areas 
and is considered to be representative of the U.S. population. Twenty-eight percent of 
the U.S. population is covered by the SEER registries, which collect information on 
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patient demographics (including residence at first cancer diagnosis), cancer site, extent 
of disease, tumor characteristics, initial treatment, and vital status follow-up.119 Medicare 
is the primary health insurance provider for 97% of the U.S. population aged 65 and 
older, and claims are available for Medicare beneficiaries participating in fee for service 
(FFS) plans (85% of all beneficiaries). Medicare claims are not available for Medicare 
participants enrolled in health maintenance organization (HMO) plans. HMO penetration 
rates vary substantially across SEER reporting areas, with California having the highest 
HMO penetration at 38%.90 The proportion of Medicare beneficiaries in SEER areas 
enrolled in HMOs is greater than the nationwide proportion enrolled in HMOs, but this 
difference has decreased over time.90 Nationwide, the proportion of Medicare 
beneficiaries participating in HMO plans averaged 13% from 2001 to 2005, and 18% of 
Medicare beneficiaries in SEER areas participated in HMO plans over the same time 
period.120  
County-level contextual data were obtained from the RTI International Spatial 
Impact Factor Data, which includes public-use data from a variety of sources, including 
the U.S. Census, the Centers for Medicare and Medicaid Services, and the U.S. 
Department of Agriculture Economic Research Service.120 These data were linked to 
SEER-Medicare records by county and year (when measures were available for multiple 
years) and were included in this analysis to help control for factors that may affect 
access to and utilization of care that are not captured in the SEER-Medicare data.  
4.2.2. Study Population 
Men eligible for this study satisfied the following inclusion criteria, which have 
been used in previous studies of prostate cancer using SEER-Medicare data122,123 and 
were reviewed by experts in urology and oncology. To be eligible for inclusion, men must 
have received a prostate cancer diagnosis between January 1, 1998 and December 31, 
2007 (Figure 4). Medicare claims for these men were available through December 31, 
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2009. Cases were limited to men for whom the prostate cancer diagnosis was their first 
and only cancer diagnosis; men diagnosed at autopsy or on their death certificate were 
excluded. All eligible men were at least 65 years old with one full year of Medicare 
claims before their diagnosis and continuously enrolled in a Medicare FFS plan from one 
year pre-diagnosis to at least one year post-initial treatment. A full year of pre-diagnosis 
claims was required to capture pre-diagnosis comorbidities. No men with end-stage 
renal disease as the reason for Medicare entitlement were included, nor were those men 
with multiple primary cancer sites or metastatic disease upon diagnosis. The sample 
was further refined by focusing on men who were diagnosed with American Joint 
Committee on Cancer pathologic stage pT2-pT3N0M0 disease and received radical 
prostatectomy within 180 days of diagnosis. Men who received adjuvant radiation 
therapy were included where adjuvant radiation therapy was defined as external beam 
radiation therapy initiated within 180 days of surgery.22 Men who received any type of 
neoadjuvant therapy or secondary treatment in the form of salvage radiation therapy 
(radiation therapy initiated more than 180 days after surgery), hormone therapy, or 
chemotherapy in the first year following surgery were excluded as these therapies may 
indicate that radical prostatectomy was not fully effective in achieving disease control. 
Men who received any type of secondary treatment more than one year past surgery 
were included in the sample until initiation of secondary therapy. Men who received 
adjuvant radiation therapy are included because in these men, radiation therapy is 
considered to be part of the initial curative treatment rather than a response to disease 
recurrence.  
The final sample consisted of 10,761 men. The unit of observation was the 
person-period (where a period was 1 year or 6 months), resulting in a total of 47,042 
observations for the 1 year model and 102,464 observations for the 6 month model. 
Partial periods of data were not included.  
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Figure 4. Sample Counts for Included and Excluded Observations, Aim 1 
 
Men with primary prostate cancer in SEER areas diagnosed between 01/01/1998 and 12/31/2007 
n=371,133 
Other cancer diagnosis 
Missing diagnosis month 
Diagnosis at death or autopsy 
n=48,828 
Enrolled in Medicare HMO 12 months 
before diagnosis 
Missing pre-diagnosis claims 
Age at diagnosis <65 
n=176,767 
Missing pathologic stage 
Missing histology 
n=257 
Metastatic disease at diagnosis 
Nodal involvement 
n=15,022 
Prostate cancer first and only cancer diagnosis 
Not diagnosed at death or autopsy 
n=322,305 
Insufficient data for comorbidity index 
n=4,592 
Age at diagnosis 65+ 
Continuous Parts A & B Medicare coverage 12 
months pre-diagnosis 
No ESRD 
n=145,538 
No qualifying surgery 
Any neoadjuvant therapy 
n=97,107 
Other treatment, death, or HMO 
switch within one year of surgery 
n=1,374 
Stage pT2 or pT3 with histology information  
n=10,761 
Aim 1 sample with qualifying disease and insurance characteristics, n=10,761 
Note: SEER: Surveillance, Epidemiology and End Results; HMO: Health maintenance 
organization; ESRD: End stage renal disease; FFS: Fee-for-service 
No secondary therapy within one year of surgery 
Alive at one year post-surgery 
Enrolled in FFS at one year post-surgery  
n=11,018 
Clinical stage T1c-T3 
n=109,499 
Clinical stage Tis, T1a, T1b, T4 
n=16,426 
Qualifying surgery within 180 days of diagnosis 
No neoadjuvant therapy 
n=12,392 
Claims sufficient to calculate comorbidity index 
n=125,924 
Non-metastatic disease 
No nodal involvement 
n=130,516 
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4.2.3. Study Outcome Measure 
The primary measure of PSA surveillance testing was a binary variable indicating 
whether a patient received at least one PSA test during a given year following initial 
treatment. The surveillance period began 60 days after prostatectomy or the final 
radiation therapy treatment for men receiving adjuvant radiation therapy and continued 
to death (using SEER date of death), initiation of secondary therapy (salvage radiation 
therapy, hormonal therapy, or chemotherapy), a switch from Medicare FFS to HMO, or 
the end of available claims data (December 31, 2009). Initiation of secondary therapy is 
generally a response to disease recurrence and thus marks the end of the surveillance 
period following initial therapy. Men who received salvage radiation therapy more than 
one year past surgery were included in the sample until initiation of radiation therapy, 
whereas men who received salvage radiation therapy within one year of surgery were 
not included.  
PSA surveillance tests were identified in Medicare claims by Healthcare 
Common Procedure Coding System (HCPCS) codes (84152, 84153, 84154, and 
G0103), and initial and secondary therapies were identified using SEER treatment 
variables and Medicare claims (Table 8). As strict adherence to surveillance guidelines 
would require PSA testing every 6 months, a measure of testing receipt was defined 
using a binary variable indicating whether a patient received at least one test in a given 
6-month interval. The sensitivity of results to the measurement of guideline adherence 
also was examined by the use of a 9-month surveillance interval in addition to the 1-year 
and 6-month time intervals. 
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Table 8. Billing Codes Used to Identify Relevant Procedures in Medicare Claims 
  
ICD-9 CPT/HCPCS 
PSA testing   84152-84154, G0103 
Surgery 60.4, 60.5, 60.6x 
55810, 55812, 55815, 55840, 
55842, 55845, 00865, 55866 
External beam 
radiation therapy* 92.24, 92.26  
77301, 77305, 77310, 77315, 
77321, 77371-77373, 77380, 
77381, 77401, 77403-77409, 
77411-77414, 77416, 77418, 
77422, 77423, 77520, 77522, 
77523, 77525, 77526, 0073T, 
G0178 
Brachytherapy and 
other radiation therapy 
92.20, 92.21, 
92.22, 92.25, 
92.23, 92.27, 
92.28, 92.29 
55859, 55860, 55862, 55865, 
55875, 76873, 77470, 77750-
77799, 79005-79999, C1164, 
C1174, C1325, C1350, C1700, 
C1701, C1702, C1715-C1720, 
C1728, C1790-C1806, C2638, 
C2639, C2640, C2641, G0256, 
G0261, Q3001 
Hormone therapy 62.3, 62.4x 
54520, 54522, 54530, 54535, 
54690, J1050, J1051, J1950, 
J3315, S0175, J9000-J9999 
Chemotherapy 
99.25, V58.1x, 
V66.2, V67.2 96400-96549, Q0083-Q0085 
*These codes capture both salvage and adjuvant radiation therapy; the distinction between the 
two is made by examining treatment timing relative to radical prostatectomy.  
 
Note: ICD-9: International Classification of Diseases, 9th Revision; CPT: Current Procedural 
Terminology; HCPCS: Healthcare Common Procedure Coding System; PSA: Prostate-specific 
antigen 
 
4.2.4. Key Independent and Control Variables 
Key independent variables were time elapsed since completion of initial 
treatment and patient race/ethnicity. Time elapsed was measured as an indicator of 
whether the observation captured the first, second, third, fourth, fifth, or sixth or later 
year. The sixth year and beyond were combined to reflect the change in surveillance 
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guidelines at five years post-treatment. The SEER version of race/ethnicity was used to 
measure patient race/ethnicity. Medicare claims also report race/ethnicity, but it is 
believed that the SEER data are superior, due in part to SEER’s use of a Spanish-
surname algorithm.131 Race/ethnicity was coded as non-Hispanic white, non-Hispanic 
black, Hispanic, and other/unknown. Details of how collapsed categories were created, 
along with potential values and ranges of all control variables can be found in Table 9. 
Table 9. Control Variables, Values, and Sources, continued on next page 
Variable Type Potential Values/Range Source 
Individual-level (10,359 individuals) 
Race/ethnicity Categorical 
Non-Hispanic White (Caucasian 
not otherwise specified), non-
Hispanic Black (Black), Hispanic 
(Caucasian, Spanish origin or 
surname), Other/Unknown 
(American Indian/Alaska Native, 
Chinese, Japanese, Filipino, 
Hawaiian, Other Asian or Pac. 
Islander, Unknown, Other 
unspecified) PEDSF 
Age at diagnosis Continuous* 65 - 94 PEDSF 
Marital status Binary 
Married, not married (single, 
separated, divorced, widowed, 
unknown) PEDSF 
Co-morbid 
conditions, 
measured by the 
NCI Combined co-
morbidity index Continuous* 0 - 2.6  Claims 
State buy-in at 
diagnosis Binary Yes, No PEDSF 
Pathologic tumor 
stage Binary pT2, pT3 PEDSF 
Tumor histology Binary 
Well/moderately (combined 
Gleason score of 7 or less) or 
poorly differentiated (combined 
Gleason score of 8 or more) PEDSF 
Diagnosis year Categorical 
1998, 1999, 2000, 2001, 2002, 
2003, 2004, 2005, 2006, 2007 PEDSF 
*Categorical approximations examined in models 
Note: SD: Standard deviation; PEDSF: SEER Patient Entitlement and Diagnosis Summary File; 
SEER: Surveillance, Epidemiology, and End Results; HMO: Health maintenance organization; 
RTI: Research Triangle Institute; NCI: National Cancer Institute; ERS: Economic Research 
Service; USDA: United States Department of Agriculture; NRCRD, PSU: Northeast Regional 
Center for Rural Development, Penn State University 
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Table 9. Control Variables, Values, and Sources, continued from previous page 
Variable Type Potential Values/Range Source 
County-level (683 counties) 
Racial isolation 
index Continuous 
Varies by race:  
Non-Hispanic White: 0.16 - 1.00 
(mean 0.83, SD 0.16) 
Non-Hispanic Black: 0 - 0.85 
(mean 0.15, SD 0.19) 
Hispanic: 0 - 0.87 (mean 0.13, SD 
0.17) 
Pacific Islander: 0 - 0.17 (mean 
0.004 SD 0.012) 
American Indian/Alaska Native: 0 
- 0.84 (mean 0.03, SD 0.10) 
Other Asian: 0 - 0.54 (mean 0.03, 
SD 0.06) 
U.S. 
Census 
Persistent poverty 
indicator Binary Yes, No (mean 0.12, SD 0.33) 
ERS, 
USDA 
Population density 
(people per square 
mile) Continuous 
0.27 - 71,190 (mean 574, SD 
3,248) 
U.S. 
Census 
Social capital index Continuous 
-2.60 - 4.50 (mean -0.36, SD 
1.27) 
NRCRD, 
PSU 
Medicare HMO 
Penetration Continuous 0 - 0.53 (mean 0.07 SD 0.11) 
RTI 
Spatial 
Database 
*Categorical approximations examined in models 
Note: SD: Standard deviation; PEDSF: SEER Patient Entitlement and Diagnosis Summary File; 
SEER: Surveillance, Epidemiology, and End Results; HMO: Health maintenance organization; 
RTI: Research Triangle Institute; NCI: National Cancer Institute; ERS: Economic Research 
Service; USDA: United States Department of Agriculture; NRCRD, PSU: Northeast Regional 
Center for Rural Development, Penn State University 
 
Individual-level measures of age, marital status, tumor characteristics, co-
morbidity, and Medicare state buy-in at diagnosis were used to control for the likelihood 
that an individual would receive follow-up surveillance as part of post-treatment care. 
Tumor characteristics included an indicator of pathologic tumor stage (pT2 or pT3, 
where pT3 tumors are characterized by extraprostatic extension), and tumor histology, 
which was captured by a binary variable indicating whether the combined Gleason score 
of the tumor was less than or equal to 7 or greater than 7. Comorbidities at diagnosis 
were measured using the prostate cancer-specific condition weights of the National 
Cancer Institute (NCI) Combined Comorbidity Index, which was developed specifically 
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for use with SEER-Medicare data.132 Medicare state buy-in at diagnosis was used to 
help control for income, healthcare access, and individual characteristics not otherwise 
captured. Although this indicator has previously been used to identify low-income 
individuals who are dually-eligible for Medicare and Medicaid, a recent study cast doubt 
on the adequacy of the buy-in indicator to appropriately identify all dually-eligible 
individuals.133  
County-level measures of population density,120 persistent poverty,134 racial 
isolation,135 social capital,136 and Medicare HMO penetration120 were included in the 
models to control for access to care, community-level social support and local practice 
patterns. These county variables were specific to the last known county in which each 
individual received a PSA test, based on address from the associated Medicare claim. 
Using the claim address rather than the SEER registry address (recorded at the time of 
first cancer diagnosis) may be important as patients may move from the area in which 
they were diagnosed. A continuous measure of annual population density (1,000 
individuals per square mile) was used to control for geographic isolation and as a 
potential measure of access to care. An additional control for access to care was an 
indicator of persistent poverty for the year 2004, which indicates that at least 20% of the 
county population had a household income below the poverty level in the last 4 
decennial U.S. censuses.134 A race-specific measure of racial isolation/segregation was 
included to capture the social support networks available in each individual’s 
community.135 This measure is based on 2000 U.S. Census data and has been shown to 
influence receipt of screening mammography in the Medicare population.137 This index 
measures the extent to which racial minority members are exposed to (live in counties 
with) members of their own race rather than non-minority members. Each index value is 
race- and county-specific, so each individual in the sample has an index value that 
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corresponds to the likelihood they will come into contact with members of their own race 
within their county of residence.  
A measure of community social capital that may influence an individual’s ability to 
seek and obtain medical care was also included. This 2005 county-level measure is a 
composite index based on the number of civic and non-profit organizations in the county, 
voter turn-out, and Census return rates.136 Finally, a county-level measure of the percent 
of Medicare beneficiaries participating in an HMO plan was used to control for variations 
in practice patterns that may be attributable to a managed care spillover effect.138 This 
phenomenon occurs when managed care penetrates a local health care market and 
affects the diffusion of technologies and/or local practice patterns. These effects have 
been shown to exist in colorectal cancer screening practices among FFS Medicare 
enrollees.161,162 This measure was available for the years 2001-2005; the 2001 value 
was assigned to observations from 1998-2001 and the 2005 value was assigned to 
observations from 2005-2009.  
4.2.5. Statistical Analysis 
To examine the data, I calculated summary statistics and performed bivariate 
statistical tests, specifically t-tests for continuous variables and chi-square tests for 
binary and categorical variables.154 I estimated logistic regression models, using a 
generalized estimating equations (GEE)-based approach to account for the correlation 
between the person-year observations, to evaluate the influence of covariates on 
receiving a PSA test in a given time interval. Separate models were used to estimate the 
likelihood of receiving one test over 1-year, 6-month, and 9-month time intervals. All 
models were estimated using a limited set of control variables consisting of year or 
period indicators to measure time elapsed since treatment and a full set of control 
variables including individual, tumor, and county-level factors. The appropriateness of 
model specification and error term correlation structure were evaluated using Wald test 
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statistics154 and the quasi-likelihood under the independence model information criterion 
(QIC).155 Individual coefficients are reported in terms of odds ratios (ORs), and statistical 
significance was determined by examining the estimated z-statistics, using an alpha of 
.05.154 All models were estimated using robust standard errors, which essentially clusters 
on the individual. Stata, version 10 (StataCorp, College Station, TX), which was used for 
the data analysis, does not allow for clustering on additional panel variables in the GEE 
framework, so no adjustment was made for SEER registry or county of residence. Thus 
the county contextual variables may exhibit redundancy among individuals within the 
same county, leading to potential overstated statistical significance for the associated 
coefficients. Results related to county- and registry-level variables should therefore be 
interpreted cautiously. However, clustering at the registry level may be unadvised as the 
small number of clusters and unbalanced cluster size could increase rather than 
decrease bias in the standard error estimates.163 Additionally, individual-level clustering 
was considered superior to county-level clustering as this analysis placed primary 
importance on the interpretation of individual-level coefficients. 
I compiled the data both in SAS, version 9.1 (SAS, Cary, NC) and Stata, version 
10 (StataCorp, College Station, TX). I performed all data analysis in Stata. This research 
was approved by the Institutional Review Board at the University of North Carolina at 
Chapel Hill.  
4.3. Results 
4.3.1. Descriptive Statistics 
The average age at diagnosis for men in the sample was 69.5 years (standard deviation 
[SD] = 3.1), and follow-up times ranged from one to 11 years. Average follow-up time 
overall was 4.5 years (SD = 2.7). The sample was primarily non-Hispanic White (83.3%), 
with an additional 5.8% non-Hispanic Black, 6.1% Hispanic, and 4.8% of other/unknown 
race/ethnicity, of whom 21% were Japanese, 39% were other Asian or Pacific Islander, 
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and 15% were of unknown race/ethnicity. Eighty-two percent of the men were diagnosed 
with pT2 disease (as opposed to pT3), and most men (84.5%) had well/moderately 
differentiated tumors, defined by a combined Gleason score of 7 or less.  
Table 10. Sample Characteristics for Men Receiving at Least One PSA Test per Year 
versus Men with at Least One Year with no PSA Test, over First 5 Years of Surveillance, 
continued on next page  
Overall % or 
mean (SD) 
One or 
more years 
with no test 
At least one 
annual test p-value† 
Number of observations 10,761 2,606 8,155  
Age at diagnosis 69.5 (3.1) 69.6 (3.2) 69.5 (3.0) .0285 
Age by category (%) .0592 
65-69 57.3 55.3 58.0  
70-74 35.6 37.0 35.1  
75 + 7.1 7.7 7.0  
Married at diagnosis (%) 82.0 79.5 82.8 .0002 
State buy-in at diagnosis 
(%) 6.4 8.7 5.7 < .0001 
Tumor Histology (%)   .0029 
Well/Moderately 
differentiated 84.5 82.6 85.1  
Poorly differentiated 15.5 17.4 14.9  
Pathologic stage T2 (%) 82.3 85.4 81.3 < .0001 
NCI Comorbidity Index at 
diagnosis 0.10 (0.25) 0.11 (0.26) 0.10 (0.25) .3199 
NCI Comorbidity Index by 
category (%)    .4855 
0 78.3 77.8 78.5  
> 0 21.7 22.2 21.5  
Race (%) .0065 
Non-Hispanic White 83.3 81.6 83.8  
Non-Hispanic Black 5.8 6.5 5.6  
Hispanic 6.1 7.3 5.7  
Other/Unknown 4.8 4.6 4.9  
† p-values obtained using t-tests and chi-square tests and apply to differences in percentages or 
means across columns 3 and 4.  
 
Note: PSA: Prostate-specific antigen; HMO: Health maintenance organization; NCI: National 
Cancer Institute; SD: Standard deviation 
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Table 10. Sample Characteristics for Men Receiving at Least One PSA Test per Year 
versus Men with at Least One Year with no PSA Test, over First 5 Years of Surveillance, 
continued from previous page  
Overall % or 
mean (SD) 
One or 
more years 
with no test 
At least one 
annual test p-value† 
Year of diagnosis (%) < .0001 
1998 4.3 6.3 3.7  
1999 4.5 6.5 3.9  
2000 7.8 9.9 7.1  
2001 9.5 13.1 8.4  
2002 10.5 14.2 9.3  
2003 10.7 14.1 9.7  
2004 12.4 12.9 12.2  
2005 11.8 9.7 12.5  
2006 12.8 7.9 14.4  
2007 15.6 5.4 18.9  
Years in sample 4.5 (2.7) 5.7 (2.4) 4.1 (2.6) < .0001 
County-level persistent 
poverty (%) 3.3 3.7 3.2 .2445 
Race-specific isolation 
index 0.71 (0.21) 0.71 (0.21) 0.71 (0.21) .9403 
County-level social capital 
index -0.68 (1.03) -0.63 (1.06) -0.70 (1.01) .0023 
County population density 
(1000s per square 
mile) 1.28 (2.03) 1.30 (2.25) 1.28 (1.95) .6653 
County-level HMO 
penetration 16.3 (15.1) 16.1 (15.3) 16.4 (15.0) .4571 
† p-values obtained using t-tests and chi-square tests and apply to differences in percentages or 
means across columns 3 and 4.  
 
Note: PSA: Prostate-specific antigen; HMO: Health maintenance organization; NCI: National 
Cancer Institute; SD: Standard deviation 
 
Overall, men received an average of 2.0 (SD = 1.0) PSA tests per year after 
treatment, but nearly 25% went at least one year without a test during the first 5 years 
after treatment. Table 10 presents characteristics of the study sample stratified by men 
who received at least one test each year for the first 5 years after treatment and those 
men who did not. Non-Hispanic White men, men diagnosed and treated at younger 
ages, married men, and men diagnosed with stage pT3 disease were more likely to 
receive at least one annual test during the first 5 years after treatment than other races; 
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men treated at older ages; single, widowed, or divorced men; and men with stage pT2 
disease, respectively. The t-test results revealed that social capital was the only county-
level variable differing significantly across men who received at least one annual test 
versus those who did not.  
Figures 5 and 6 present the proportion of the sample receiving annual PSA tests 
by year of diagnosis and time elapsed since treatment. Regardless of year of diagnosis, 
almost all men receive at least one PSA test in the first year after treatment, ranging 
from 94% for men diagnosed in 1999 to 97% for men diagnosed in 2005 (p = .0026) 
(Figure 5). Over time post-treatment, the percentage of men receiving at least one test 
falls significantly (p < 0.0001 for the percentage of men receiving a test in year 1 versus 
the percentage of men receiving a test in year 5). By 5 years after treatment, there is no 
significant difference in test receipt by year of diagnosis; the percentage ranges from 
80% for men diagnosed in 1999 to 81% for men diagnosed in 2003. The drop in annual 
receipt of testing is even greater when using a strict guideline-concordant PSA 
surveillance definition of receipt of at one test in each 6-month period (Figure 6). At least 
85% of men receive one PSA test in the first 6 months after treatment, regardless of 
year of diagnosis, but this falls to approximately 55% of men 5 years (10 6-month 
periods) after treatment.  
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Figure 5. Percentage of Sample Receiving at Least One Surveillance Prostate-specific 
Antigen Test, for Selected Years of Diagnosis 
 
 
Figure 6. Percentage of Sample Receiving at Least One Surveillance Prostate-specific 
Antigen Test in each 6-month Interval, for Selected Years of Diagnosis 
 
 
By race, non-Hispanic Whites and those of other/unknown race have consistently 
higher rates of annual test receipt in the years following treatment than non-Hispanic 
Blacks and Hispanics (Figure 7), although the minority sample sizes are relatively small. 
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All 4 racial groups (non-Hispanic White, non-Hispanic Black, Hispanic, other/unknown) 
begin with high rates of test receipt. The largest gap in the first year following treatment 
is observed between non-Hispanic Whites (96.7%) and Hispanics (94.7%) (p = .0119). 
The gap between races widens as time from treatment increases. By 5 years post-
treatment, the test receipt rate among non-Hispanic Whites is highest, at 82.3% and is 
6.5 percentage points higher than the lowest testing rate, which is observed in Hispanics 
(75.8%) (p = .0039). A large difference was also observed between non-Hispanic Whites 
and non-Hispanic Blacks at 5 years post-treatment (82.3% versus 76.5%) (p = .0196).  
Figure 7. Percentage of Sample Receiving at Least One Surveillance Prostate-specific 
Antigen Test, by Race/ethnicity 
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Figure 8. . Percentage of Sample Receiving at Least One Surveillance Prostate-specific 
Antigen Test in each 6-month Interval, by Race/ethnicity 
 
 
Hispanics also have consistently lower rates of surveillance PSA testing than 
other racial groups when defining PSA test receipt as at least one test in a 6-month 
interval (Figure 8). Unlike the results found when considering a 1-year testing interval, 
the difference between the most frequently and least frequently tested groups does not 
appreciably increase over time. In the first 6-month interval following treatment, 89.7% of 
non-Hispanic Whites receive a PSA test, compared to 84.8% of Hispanics (a difference 
of 4.9 percentage points) (p = .0001). By the 10th 6-month interval, the difference 
between the two racial groups was 5.6 percentage points (p = .0565). Although there is 
a downward trend, testing rates are not strictly decreasing over time, that is, the rate in a 
given interval is not necessarily less than the rate in the previous interval. This is 
particularly true for non-Hispanic Whites and non-Hispanic Blacks.  
4.3.2. Multivariate Logistic Regression Analysis 
To better understand the observed decrease in testing each interval past 
treatment, I estimated logistic models to examine the effect of time elapsed since 
treatment on test receipt. These models were run with (fully-adjusted) and without 
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(partially-adjusted) other control variables. Table 11 presents these results for the receipt 
of at least one test in a 1-year interval. In both models, the effect of time elapsed since 
treatment is large and significant. Without controlling for individual or county-level 
characteristics, men 2 years past treatment have lower odds of receiving at least one 
test than men one year past treatment (OR = 0.37, 95% confidence interval [CI] = 0.33-
0.42). The odds are lower for men 3 years past treatment (OR = 0.25, 95% CI = 0.22-
0.28), and lower still for men 4 years past treatment (OR = 0.19, 95% CI = 0.17-0.22). 
The largest decrease in odds from one year to the next (for estimated coefficients) is 
seen between years 2 and 3. All estimated odds ratios are statistically significant and 
statistically different from one another. Similar results were observed when restricting the 
sample to men with at least 5 years of observation (results not reported).  
Table 11. Logistic Regression Results for Receipt of One PSA Surveillance Test During 
a 1-year Interval, continued on next page 
Partially-adjusted Fully-adjusted 
OR 95% CI OR 95% CI 
Years since treatment (1 is reference) 
2 0.37*** 0.33-0.42 0.36*** 0.32-0.40 
3 0.25*** 0.22-0.28 0.24*** 0.21-0.26 
4 0.19*** 0.17-0.22 0.18*** 0.16-0.21 
5 0.16*** 0.14-0.18 0.15*** 0.14-0.18 
6 or more 0.11*** 0.10-0.12 0.10*** 0.09-0.12 
Age at diagnosis 0.98** 0.97-0.99 
Not married at diagnosis 0.83*** 0.75-0.92 
State buy-in at diagnosis 0.68*** 0.57-0.81 
Tumor poorly differentiated 0.95 0.85-1.06 
Pathologic stage T2 0.83** 0.74-0.93 
NCI Comorbidity Index at Diagnosis 0.94 0.80-1.10 
Race (Non-Hispanic White is 
reference) 
Non-Hispanic Black 0.78* 0.64-0.94 
Hispanic 0.76** 0.63-0.91 
Other/Unknown 0.99 0.76-1.30 
* significant at 5%, ** significant at 1%, *** significant at 0.1%, robust standard errors used 
 
Note: OR: Odds ratio; CI: Confidence interval; PSA: Prostate-specific antigen; HMO: Health 
maintenance organization; NCI: National Cancer Institute; QIC: Quasi-likelihood under the 
independence model information criterion  
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Table 11. Logistic Regression Results for Receipt of One PSA Surveillance Test During 
a 1-year Interval, continued from previous page 
Partially-adjusted Fully-adjusted 
OR 95% CI OR 95% CI 
Year of diagnosis (1998 is reference) 
1999 0.83 0.68-1.00 
2000 0.95 0.79-1.15 
2001 0.93 0.78-1.12 
2002 0.99 0.83-1.18 
2003 1.02 0.85-1.22 
2004 1.09 0.89-1.32 
2005 1.11 0.90-1.37 
2006 0.91 0.73-1.14 
2007 0.87 0.68-1.10 
County-level persistent 
poverty 0.82 0.65-1.04 
Race-specific isolation index 0.74 0.53-1.01 
County-level social capital index 0.98 0.94-1.02 
County population density  1.01 0.99-1.03 
County-level HMO 
penetration 1.18 0.85 - 1.64 
Person-year observations 48,426 47,033 
Men 10,761 10,496 
QIC 35,927 34,713 
* significant at 5%, ** significant at 1%, *** significant at 0.1%, robust standard errors used 
 
Note: OR: Odds ratio; CI: Confidence interval; PSA: Prostate-specific antigen; HMO: Health 
maintenance organization; NCI: National Cancer Institute; QIC: Quasi-likelihood under the 
independence model information criterion 
 
The results from the fully-adjusted multivariate regression model mirror those 
results found in the bivariate analyses. Men who were not married, had state buy-in at 
diagnosis, and who were diagnosed at older ages had lower odds of receiving at least 
one PSA test in a given year. Men with pT2 tumors had 0.83 lower odds (95% CI = 0.74-
0.93) of receiving at least one PSA test than men with pT3 tumors. Tumor differentiation 
and comorbidities at diagnosis were not found to be significant predictors of the 
likelihood of receiving at least one test in a given year. None of the coefficients 
associated with county-level factors were significant, nor was the year of diagnosis. The 
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inclusion of individual and county characteristics only slightly changed the estimated 
odds ratios associated with years elapsed since treatment (Table 11). All odds ratios for 
years elapsed since treatment remain statistically significant individually, are statistically 
significantly different from one another, and decrease with time elapsed since treatment.  
The odds ratios estimated for racial characteristics reflect the results shown in 
Figures 7 and 8. Men of other/unknown race had odds of test receipt equivalent to non-
Hispanic Whites, whereas non-Hispanic Blacks and Hispanics had significantly lower 
odds than non-Hispanic Whites (OR = 0.78 with 95% CI = 0.64-0.94 for non-Hispanic 
Black and OR = 0.76 with 95% CI = 0.63-0.91 for Hispanic, with non-Hispanic White as 
the referent). The odds for non-Hispanic Black and Hispanic were not significantly 
different from one another.  
Most of the factors that affect the likelihood an individual will receive at least one 
test in a year also affect the likelihood that he will receive at least one test in a 6-month 
interval, with the exception of age at diagnosis (Table 12). In contrast to the results for 
the 1-year interval, 4 of the 5 county-level factors affect the odds of receiving at least 
one test within a 6-month interval. Higher Medicare HMO penetration and population 
density are associated with higher odds of receiving at least one test (OR = 1.420 with 
95% CI = 1.17-1.72 and OR = 1.01 with 95% CI = 1.00-1.03, respectively). Higher levels 
of the county-level social capital index and the race-specific county-level isolation index 
are associated with lower odds of receiving one test (OR = 0.97 with 95% CI = 0.94-0.99 
for the social capital index and OR = 0.74 with 95% CI = 0.61-0.89 for the isolation 
index). With the exception of 2004, year of diagnosis has no influence on the odds a 
man will receive at least one test in a 6-month interval. 
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Table 12. Logistic Regression Results for Receipt of One PSA Surveillance Test During 
a 6-month Interval, continued on next page 
Partially-adjusted Fully-adjusted 
OR 95% CI OR 95% CI 
6-month periods since treatment (1 is reference) 
2 0.69*** 0.64-0.74  0.68*** 0.63-0.74 
3 0.36*** 0.34-0.39  0.36*** 0.34-0.39 
4 0.35*** 0.32-0.37  0.34*** 0.32-0.37 
5 0.22*** 0.21-0.24  0.22*** 0.21-0.24 
6 0.23*** 0.22-0.25  0.23*** 0.22-0.25 
7 0.18*** 0.17-0.20  0.18*** 0.17-0.20 
8 0.20*** 0.18-0.21  0.20*** 0.18-0.21 
9 0.15*** 0.14-0.16  0.15*** 0.14-0.17 
10 0.16*** 0.15-0.17  0.16*** 0.15-0.18 
11 or more 0.11*** 0.10-0.11  0.11*** 0.10-0.12 
Age at diagnosis    0.99 0.99-1.00 
Not married at diagnosis    0.89*** 0.84-0.95 
State buy-in at diagnosis    0.75*** 0.67-0.84 
Tumor poorly differentiated    0.99 0.93-1.06 
Pathologic stage T2    0.83*** 0.78-0.89 
NCI Comorbidity Index at Diagnosis 1.01 0.92-1.12 
Race (Non-Hispanic White is reference)   
Non-Hispanic Black 0.86* 0.77-0.97 
Hispanic 0.80*** 0.71-0.89 
Other/Unknown 0.92 0.79-1.08 
Year of diagnosis (1998 is reference)   
1999 0.93 0.82-1.05 
2000 1.01 0.90-1.13 
2001 0.98 0.88-1.10 
2002 1.03 0.92-1.15 
2003 1.12 1.00-1.25 
2004 1.12* 1.00-1.26 
2005 1.11 0.98-1.24 
2006 1.11 0.99-1.26 
2007 1.12 0.99-1.28 
* significant at 5%, ** significant at 1%, *** significant at 0.1%, robust standard errors used 
 
Note: OR: Odds ratio; CI: Confidence interval; PSA: Prostate-specific antigen; HMO: Health 
maintenance organization; NCI: National Cancer Institute; QIC: Quasi-likelihood under the 
independence model information criterion 
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Table 12. Logistic Regression Results for Receipt of One PSA Surveillance Test During 
a 6-month Interval, continued from previous page 
Partially-adjusted Fully-adjusted 
OR 95% CI OR 95% CI 
County-level persistent poverty 1.00 0.86-1.15 
Race-specific isolation index 0.74** 0.61-0.89 
County-level social capital index 0.97* 0.94-0.99 
County population density  1.01* 1.00-1.03 
County-level HMO penetration 1.42*** 1.17-1.72 
Person-year observations 102,464   99,736 
Men 10,636   10,425 
QIC 121,293   117,346 
* significant at 5%, ** significant at 1%, *** significant at 0.1%, robust standard errors used 
 
Note: OR: Odds ratio; CI: Confidence interval; PSA: Prostate-specific antigen; HMO: Health 
maintenance organization; NCI: National Cancer Institute; QIC: Quasi-likelihood under the 
independence model information criterion 
 
The odds ratios for receipt of surveillance PSA associated with 6-month intervals 
beyond treatment are nearly identical in the fully-adjusted model and the partially-
adjusted model (Table 12). Generally, each 6-month period elapsed since treatment is 
associated with lower odds of receiving a test, but the odds are not strictly decreasing 
after five 6-month periods (2 ½ years) past treatment. After the fifth interval, the odds 
increase and decrease with respect to the previous period, reflecting the percentages 
graphed in Figures 6 and 8. With the exception of the odds ratios for period 3 compared 
to period 4, period 5 compared to period 6, and period 9 compared to period 10, all 
period-related odds ratios are significantly different from the next 6-month period.  
All racial categories are associated with lower odds of receiving a test in a 6-
month interval compared to non-Hispanic Whites, although the difference is only 
significant for non-Hispanic Blacks (OR = 0.86 with 95% CI = 0.77-0.97) and Hispanics 
(OR = 0.80 with 95% CI = 0.71-0.89). The difference in odds ratios between non-
Hispanic Black and Hispanic is larger in magnitude than the corresponding difference 
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from the results of the model examining receipt of at least one test in a year, but the 
odds ratios are not statistically different from one another (p = .2907).  
To further test the sensitivity of the results to the time interval, additional models 
were estimated using a 9-month interval. The estimated coefficients from the 9-month 
partially- and fully-adjusted models are similar to those for the 1-year interval models 
and are not presented. 
4.4. Discussion 
Overall, most men were found to be receiving post-treatment surveillance PSA 
tests in line with guideline recommendations. With an average of two tests per year 
during the entire observation period, men met the recommended surveillance schedule 
of a PSA test every 6 months. During the study period, the NCCN Guidelines changed 
the recommended surveillance interval from every 6 months to every 6 to 12 months for 
the first five years after treatment. By this revised schedule, approximately 80% of men 
received surveillance in accordance with guidelines in the fifth year past treatment, 
regardless of year of diagnosis. By a strict adherence definition of a test every 6 months 
(which was recommended under the NCCN Guidelines from 1998 to 2007), 
approximately 55% of men overall received the recommended surveillance in the fifth 
year after treatment. 
By far, the most important factor influencing whether a man receives a PSA test 
is time elapsed since treatment. This is supported not only by the comparison of results 
from the partially-adjusted and fully-adjusted models, but by the relative size of the odds 
ratios associated with the time period variables compared with the estimated odds ratios 
associated with other control variables. Test receipt drops significantly each year for the 
first 5 years after treatment. This is troubling given that most prostate cancer 
recurrences generally occur in the first 5 years after local therapy,4 and 25%-30% of 
these men could be expected to experience PSA recurrence.1 The majority of men at 5 
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years from treatment do, however, receive at least one test during the year, which 
suggests that these men are still receiving some form of follow-up care, although it is 
unknown whether this test is administered by a general practitioner as part of usual care 
or by a urologist (or other health practitioner) as part of a cancer survivorship plan.  
The observed rate of surveillance test receipt is high compared to a study of 
surveillance mammography following breast cancer treatment which found that only 19% 
of the study sample was in compliance with surveillance recommendations at 3 years 
following treatment.56 A study of colorectal cancer survivors reported that more than half 
of the sample did not receive a guideline-recommended surveillance colonoscopy within 
14 months of treatment.53 Despite these comparatively low surveillance rates, care 
should be taken not to overstate any differences in post-treatment surveillance between 
prostate cancer survivors and breast and colorectal cancer survivors as PSA testing is 
less invasive and less costly than either mammography or colonoscopy. 
Although time elapsed since treatment dominates the results, there are other 
interesting findings. Non-Hispanic Blacks and Hispanics have lower odds of receiving 
tests than non-Hispanic Whites and men of other/unknown race for both the 1-year and 
6-month intervals. There was no significant difference in surveillance intensity between 
non-Hispanic Blacks and Hispanics. This finding of a racial disparity between non-
Hispanic Whites and other groups is in accord with previously reported racial differences 
in prostate cancer treatment and mortality,68,69 and the difference in test receipt between 
non-Hispanic Blacks and non-Hispanic Whites is in line with the results reported in the 
only other study to focus on post-treatment PSA receipt.70 Although the racial disparity 
results in no way suggest that differences in surveillance lead to differences in mortality, 
they do suggest that the difference in surveillance by race may be clinically significant in 
addition to statistically significant. Given that previous research has demonstrated a 
racial disparity in prostate cancer overall survival among Medicare surgery patients 
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when controlling for individual and tumor characteristics,159 the link between surveillance 
and outcomes in minority prostate cancer patients is a topic worthy of future 
investigation. 
The year of diagnosis does not appear to affect the likelihood of receiving a PSA 
test in either the 1-year or 6-month interval. Graphical results suggested that there may 
have been higher receipt of surveillance testing in men diagnosed in later years, but the 
regression results did not support this pattern.  
Many of the county-level variables had an effect on the odds of receiving a test in 
a 6-month interval but not in a 1-year interval. The four significant county-level variables 
in the 6-month model represent two constructs that may affect care utilization. Medicare 
HMO penetration and population density are highly correlated with urbanicity, which 
implies better access to care. Social capital and isolation are correlated with social 
support systems. The high rates of surveillance over the 1-year interval could indicate 
that an annual surveillance test is a low threshold of care that is easily met. Getting 
tested every 6 months may require more resources and motivation, thus access to care 
and social support may play a larger role in the likelihood an individual will receive a 
PSA test in a 6-month period.  
Particularly, higher isolation indices were associated with lower odds of receipt of 
a test in a 6-month interval. That is, individuals living in areas where they are more likely 
to come into contact with individuals of their own race or ethnicity (e.g. more racially 
segregated/isolated) have lower odds of test receipt. This index has previously been 
found to have differential effects by race and geographic region on the receipt of 
mammography,137 and future investigation is warranted to determine whether the same 
patterns hold for PSA testing and other dimensions of prostate cancer care.  
The odds ratios from the 6-month model suggest that access to care is more 
important than social support in positively affecting PSA test utilization. It is possible 
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however, that instead of measuring social support, the racial isolation index is capturing 
geographic disparities in care related to race. The effects of race and geographic area 
are difficult to tease apart since individuals of different races and ethnicities are not 
randomly distributed across geographic areas. For example, if all Hispanic men in the 
sample live in areas where access to Spanish-speaking providers is limited, low 
surveillance rates in this population may be inappropriately attributed to ethnicity rather 
than access to care. The relationship between race/ethnicity and place could be 
explored in future work by modeling the effect of the isolation index and other 
community-level factors on PSA testing in each state individually. The existing literature 
on disparities in prostate cancer treatment and outcomes has not focused on the role 
communities may play in access to care and social support, and future work also could 
examine the influence of community characteristics on outcomes other than surveillance. 
This study is limited by the use of claims data to identify PSA testing, as claims 
provide no information on test motivation. That is, there is no way to distinguish between 
men who are receiving multiple tests to follow-up on previous test results and men who 
are receiving multiple tests due to lack of communication across providers. Furthermore, 
the results of the PSA tests are not available in these data, which limits the ability to 
draw conclusions regarding the frequency of abnormal (in this context, detectable) PSA 
results and any actions (i.e., initiation of salvage treatment) that might be indicated on 
the basis of those results.  
The limitation of the sample to men with Medicare FFS insurance means that 
results may not be generalizable to the entire prostate cancer population or to the entire 
Medicare population. Medicare HMO penetration rates had a significant effect on the 
odds of receiving a test in the 6-month interval model, so there is suggestion of an HMO 
spillover effect. Men living in counties with higher Medicare HMO penetration had higher 
odds of receiving a test in a 6-month interval than men who lived in areas with lower 
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Medicare HMO penetration rates. This suggests that HMO penetration in an area 
impacts local practice patterns even among individuals who are not part of a managed 
care plan. These spillover effects have been shown to exist in colorectal cancer 
screening practices although there is geographic variation in the size and direction of the 
effect.161,162,164 Individual state-level models could help to clarify the role of HMO 
penetration in PSA surveillance test receipt. 
The results of this study are also only applicable to the portion of prostate cancer 
patients and survivors who receive radical prostatectomy soon after diagnosis. As more 
than 80% of the men in SEER-Medicare with qualifying disease characteristics did not 
meet the surgical inclusion criteria for this study, the group of men to whom these results 
can be generalized is relatively small. Future research should investigate whether the 
same testing patterns are observed in men treated with radiation therapy or active 
surveillance. Additionally, findings of this study may not apply to younger men who are 
not covered by Medicare as these men may face a different set of competing health risks 
and experience different treatment patterns.16,18 Finally, given the relatively long natural 
history of clinically localized prostate cancer, with a median of 8 years from the time of 
PSA recurrence after treatment to the development of metastatic disease,4 future study 
in cohorts with long-term follow-up is needed to ascertain the relationship between post-
treatment PSA surveillance, secondary treatment with salvage therapy, and metastasis-
free, disease-specific and overall survival. Surveillance for early detection of recurrent 
cancer after treatment with curative intent is predicated on the fundamental assumption 
that effective salvage treatment may alter the natural history of disease progression. 
Evidence supporting this fundamental assumption could justify the consideration of post-
treatment surveillance as a process measure for quality of cancer care. 
The primary finding of this study is that most men are receiving surveillance PSA 
testing in line with current NCCN Guideline recommendations following radical 
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prostatectomy. Nevertheless, adherence rates are not perfect, and, perhaps more 
importantly, test receipt declines as time from treatment increases, a result that was 
robust across model specifications, patient groups, and testing intervals. These results 
suggest that one way to improve test receipt may be to focus on creating educational 
interventions underscoring the rationale for follow-up strategies that span many years 
following treatment and to highlight the significance of long-term follow-up as part of a 
survivorship care plan. Although there were some differences in test receipt across racial 
groups, individual characteristics, and tumor stage at diagnosis, the magnitude of the 
odds ratios associated with these factors compared to the odds ratios associated with 
time intervals from treatment suggest that decreasing these disparities may not be the 
most efficient strategy to increase overall long-term surveillance. Therefore, emphasizing 
the importance of disease surveillance through regular PSA testing to all patients and 
providers is key to high-quality long-term care as patients make the transition from 
cancer patient to cancer survivor. 
  
 
5. VALIDATION OF ADJUVANT RADIATION THERAPY RECEIPT FOLLOWING 
RADICAL PROSTATECTOMY IN SURVEILLANCE, EPIDEMIOLOGY, AND END 
RESULTS DATA 
 
5.1. Introduction 
Recent clinical trial results have demonstrated that adjuvant radiation therapy 
(ART) improves recurrence-free survival in men with high-risk features in their radical 
prostatectomy surgical pathology.6,7,9 As a result, the National Comprehensive Cancer 
Network (NCCN) revised their guidelines to suggest that ART be offered to all men with 
adverse pathological features or detectable prostate-specific antigen (PSA) level after 
prostatectomy.22 The clinical trial results, along with the NCCN change, have sparked 
interest in quantifying the percentage of men for whom ART should be recommended 
who actually receive it.  
Two recent studies using Surveillance, Epidemiology, and End Results (SEER) 
data to examine the receipt of ART in men with qualifying disease characteristics in the 
period before and after the presentation and publication of clinical trial data have found 
low rates of ART, but they did not confirm radiation receipt using claims data.86,87 
Although it may be several years before the effect of the ART trial results on clinical 
practice patterns can be fully established, an enhanced understanding of the 
dissemination of ART in real-world practice could potentially inform the design of future 
interventions targeted to populations who may not be receiving guideline-recommended 
care. 
The Surveillance, Epidemiology, and End Results (SEER) program provides 
information on first course of treatment following a cancer diagnosis for people living 
within registry areas.90 Historically, SEER data captured initial treatment occurring within 
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four months of diagnosis,90 but beginning in 1998, SEER coding manuals instructed that 
all treatments included in a documented treatment plan be considered as part of the 
initial course of therapy, regardless of when they occur.165 The most recent comparison 
of SEER primary treatment documentation and Medicare claims for radiation therapy 
was published in 2002 and used data from patients diagnosed with prostate cancer from 
1991 to 1996.34 In addition to changes in coding standards, since this time, there has 
been growing recognition that ART may offer benefits in terms of recurrence-free 
survival for select prostate cancer patients. These changes in documentation and 
treatment patterns warrant a contemporary comparison of SEER and Medicare radiation 
treatment variables.  
 A number of studies in the breast cancer literature have sought to investigate the 
concordance between the treatment reported in cancer registries and treatment received 
according to claims data.94,96,166 Two of these studies compared registry records to 
Medicare claims,94,166 whereas the third compared SEER records to self-reported 
treatment received.96 For women diagnosed from June 2005 to February 2007 in Los 
Angeles and Detroit, SEER records failed to capture radiation therapy for 21% of women 
who say they received it.96 Rates of underascertainment varied by region, chemotherapy 
and mastectomy receipt, stage, income, and characteristics of the diagnosis hospital. 
Additionally, in Los Angeles, underascertainment was associated with younger age. The 
authors conclude that the use of SEER data (or data from other registries) alone may 
result in underascertainment of radiation therapy, particularly when there is a delay or 
increased time between surgery and radiation therapy.96 These findings support the 
motivation for the present study as the decision to deliver ART may not be made until 
after radical prostatectomy and surgery recovery, resulting in variations in time from 
surgery to radiation as well as modifications to the original treatment plan. 
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5.2. Methods 
5.2.1. Data and Population 
Data for the analysis came from the linked SEER-Medicare database. The SEER 
program collects population-based data on all incident cancer cases among residents of 
participating reporting areas. Twenty-eight percent of the U.S. population is covered by 
the SEER program, and the most recent SEER update contains information from 17 
reporting areas on 27 cancer sites and sub-sites through 2007. The SEER registries 
collect information on patient demographics, cancer site, extent of disease, tumor 
characteristics, initial treatment, and vital status follow-up.119 Patient demographic 
characteristics include age at diagnosis, race/ethnicity, marital status, and county of 
residence at diagnosis.  
Medicare is the primary health insurance provider for 97% of the U.S. population 
aged 65 and older.90 All beneficiaries receive Part A benefits, which cover inpatient 
hospital, skilled nursing facility, home health, and hospice care. Ninety-five percent of 
beneficiaries pay a monthly premium for Medicare Part B, which covers physician 
services, outpatient care, and durable medical equipment. Parts A and B together can 
take the form of a fee-for-service (FFS) or HMO plan. The Medicare Enrollment 
Database contains information on enrollment, entitlement, HMO membership, and 
demographic characteristics for each individual in the Medicare program.90  
The current SEER-Medicare data linkage contains data on all cancer diagnoses 
and all Medicare claims for individuals participating in a Medicare FFS plan. Cancer 
diagnosis information is available through December 31, 2007, and Medicare claims are 
available through December 31, 2009.119 The Medicare files available through the 
linkage include claims from hospital, outpatient, physician, home health, and hospice 
providers. Each file contains patient demographic characteristics, date of service, 
diagnostic and procedure codes, and associated charges and reimbursement.90 Claims 
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are not available for Medicare participants enrolled in HMO plans. HMO penetration 
rates vary substantially across SEER reporting areas, with California having the highest 
HMO penetration at 38%.90 The proportion of Medicare beneficiaries in SEER areas 
enrolled in HMOs is greater than the nationwide proportion enrolled in HMOs, but this 
difference has decreased over time.90 Nationwide, the proportion of Medicare 
beneficiaries participating in HMO plans averaged 13% from 2001 to 2005, and 18% of 
Medicare beneficiaries in SEER areas participated in HMO plans over the same time 
period.120  
5.2.2. Inclusion Criteria 
Men eligible for this study satisfied the following inclusion criteria, which have 
been used in previous studies of prostate cancer using SEER-Medicare data122,123 and 
were reviewed by experts in urology and oncology. Men in the sample received a 
prostate cancer diagnosis between January 1, 2000, and December 31, 2007. The year 
2000 was chosen as the beginning of the sample period as the NCCN Guidelines as it 
marks a change in NCCN Guidelines. The 1999 NCCN Guidelines recommendation to 
consider “radiotherapy [in patients] post-radical prostatectomy with positive margins of 
high-grade disease or gross residual disease” was classified as “somewhat 
controversial,”77 whereas the 2000 Guidelines recommendation that radiation therapy be 
considered in men with positive surgical margins was made with “uniform NCCN 
consensus based on lower level evidence.”167 This remained the recommendation until 
2010, when the Guidelines were updated to recommend offering adjuvant or salvage 
radiation therapy to all patients with adverse pathologic features or detectable PSA and 
no evidence of disseminated disease” (Section PROS-C).22 In this context, RT refers to 
external beam radiotherapy, and adverse pathologic features are positive margins, 
seminal vesicle invasion, extracapsular extension or detectable PSA.22  
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Figure 9. Sample Counts for Included and Excluded Observations, Aim 2 
 
Men with primary prostate cancer in SEER areas diagnosed between 01/01/2000 and 12/31/2007 
n=335,119 
Other cancer diagnosis 
Missing diagnosis month 
Diagnosis at death or autopsy 
n=46,934 
Enrolled in Medicare HMO 12 months 
before diagnosis 
Missing pre-diagnosis claims 
Age at diagnosis <65 
n=157,727 
Missing pathologic stage 
Missing histology 
pT2 with negative margins 
SEER radiation receipt unknown 
n=8,742 
Metastatic disease at diagnosis 
Nodal involvement 
n=12,971 
Prostate cancer first and only cancer diagnosis 
Not diagnosed at death or autopsy 
n=288,185 
Insufficient data for comorbidity index 
n=5,551 
Age at diagnosis 65+ 
Continuous Parts A & B Medicare coverage 12 
months pre-diagnosis 
No ESRD 
n=130,458 
No qualifying surgery 
Any neoadjuvant therapy 
n=85,975 
Death or HMO switch within one year 
of surgery 
n=51 
Stage pT2 (with positive margins) or pT3 with 
histology information 
SEER  information on radiation receipt 
n=3,993 
Men with qualifying disease and insurance characteristics, n=3,993 
Note: SEER: Surveillance, Epidemiology and End Results; HMO: Health maintenance 
organization; ESRD: End stage renal disease; FFS: Fee-for-service 
Alive at one year post-surgery 
Enrolled in Medicare FFS at one year post-surgery 
n=12,735 
Clinical stage T1c-T3 
n=98,761 
Clinical stage Tis, T1a, T1b, T4 
n=13,175 
Non-metastatic disease 
No nodal involvement 
n=117,487 
Claims sufficient to calculate comorbidity index 
n=111,936 
Qualifying surgery within 180 days of diagnosis 
No neoadjuvant therapy 
n=12,786 
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For men in the sample, prostate cancer was the first and only cancer diagnosis. 
Men diagnosed at autopsy or on their death certificate were excluded. Subjects were at 
least 65 years old at diagnosis and had one full year of traditional Medicare FFS 
eligibility (enrolled in both Part A and B) before their diagnosis (to capture comorbidities 
at diagnosis). Additionally, they were continuously enrolled in Medicare Parts A and B at 
diagnosis and for at least one year following diagnosis. Figure 9 summarizes all 
inclusion and exclusion criteria. 
Men were alive and enrolled in a FFS plan at one year after surgery. No men 
with end-stage renal disease as the reason for Medicare entitlement were included, nor 
were those men with multiple prostate primary cancer sites or metastatic disease upon 
diagnosis. Among eligible men, the study focused on men who received radical 
prostatectomy within 180 days of diagnosis. Additionally, men who received any type of 
neoadjuvant therapy prior to surgery were excluded. Documentation of a qualifying 
surgical procedure was required in both Medicare claims (identified by billing codes 
presented in Table 13) and SEER data. Qualifying surgical procedures in SEER data 
were the following: radical prostatectomy not otherwise specified (NOS), total 
prostatectomy NOS, prostatectomy with resection in continuity with other organs, and 
prostatectomy NOS. 
The sample was further refined to include only those men who met the inclusion 
criteria for the three clinical trials evaluating ART.6-8 That is, they had one of the following 
adverse pathologic features: positive margins, seminal vesicle invasion, or extracapsular 
extension. One trial further limited inclusion to men who achieved an undetectable PSA 
level following radical prostatectomy,6 but this cannot be captured in the SEER-Medicare 
data. Final sample size was 3,993 men. 
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Table 13. Billing Codes Used to Identify Relevant Procedures  
  ICD-9 CPT/HCPCS 
Radical prostatectomy 60.4, 60.5, 60.6x 
55810, 55812, 55815, 55840, 55842, 
55845, 00865, 55866 
External beam 
radiation therapy* 92.24, 92.26  
77301, 77305, 77310, 77315, 77321, 
77371-77373, 77380, 77381, 77401, 
77403-77409, 77411-77414, 77416, 
77418, 77422, 77423, 77520, 77522, 
77523, 77525, 77526, 0073T, G0178 
*These codes capture both adjuvant and salvage/palliative radiation therapy; the distinction is 
made by examining treatment timing relative to radical prostatectomy.  
 
Note: ICD-9: International Classification of Diseases, 9th Revision; CPT: Current Procedural 
Terminology; HCPCS: Healthcare Common Procedure Coding System 
 
5.2.3. Construction of Agreement Variable 
SEER data contain a radiation therapy variable describing the type of radiation 
therapy administered as a first course of treatment.130 Radiation therapy delivered after 
disease progression is not captured by SEER as disease progression marks the end of 
initial therapy. Radiation therapy is coded as none, received (by type of radiation 
therapy), refused, recommended, or unknown. The possible types of radiation therapy 
are beam radiation, radioactive implants, radioisotopes, a combination of beam and 
other radiation therapy, and radiation therapy NOS. This radiation therapy variable was 
used to create an indicator of external beam radiation therapy (beam radiation) receipt in 
SEER records. Men with combination therapy and radiation therapy NOS were 
considered to have received beam radiation; men for whom radiation therapy was 
recommended (but receipt was unknown) and men who refused were considered not to 
have received radiation. Radioactive implants and radioisotopes were not considered as 
a form of ART as these modalities are not recommended adjuvant to radical 
prostatectomy.22 The 29 men with unknown radiation therapy receipt were excluded.  
ART was identified in Medicare claims as radiation therapy initiated within 180 
days of radical prostatectomy using the billing codes in Table 13. These codes were 
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compiled from journal articles,123,124 SEER-Medicare training information,125 International 
Classification of Diseases, 9th revision (ICD-9) codebooks,126,127 a Current Procedural 
Terminology (CPT) codebook,128 and online Healthcare Common Procedure Coding 
System (HCPCS) documentation.129 Radiation therapy delivered outside of the 180-day 
window following surgery was also captured in Medicare claims. Radiation therapy in 
this setting was considered to be salvage (delivered with curative intent in response to 
disease recurrence) or palliative (delivered in response to symptoms of metastatic 
disease), but it is not the intent of this study to distinguish between the two. The binary 
agreement variable was constructed to indicate whether or not there was a match in the 
receipt of ART across SEER and Medicare records for each individual. There were two 
ways in which records could not agree: either by having documentation of ART in SEER 
but not Medicare, or by having documentation of ART in Medicare but not SEER.  
A secondary measure of agreement was constructed to test the sensitivity of 
results to the classification of men for whom radiation was recommended but receipt was 
unknown. There are two “unknown” categories within the SEER radiation therapy 
variable. One category is composed of men for whom radiation receipt is unknown (n = 
29). These men were excluded from all analyses. The second category is men for whom 
radiation was recommended but it was not known whether the radiation therapy was 
administered (n = 41). A secondary measure of agreement was calculated after 
reclassifying these 41 men as having received ART.  
5.2.4. Key Independent and Control Variables 
Variables related to the timing of initiation of radiation therapy were hypothesized 
to affect the likelihood that SEER and Medicare records would match. The decision to 
initiate ART may not be made until after examination of the surgical specimen, so tumor 
and disease characteristics, specifically combined Gleason score and pathologic 
disease stage were examined in the analysis to identify individuals with adverse disease 
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features. An indicator of tumor differentiation (well/moderately differentiated versus 
poorly differentiated) based on collapsed Gleason categories was available for all years 
of data. Previous validation studies in the breast cancer literature have found differences 
in the likelihood of a registry-claims match by age at diagnosis,94,96 but there is little 
evidence that other demographic and socioeconomic characteristics affect the likelihood 
that registry and claims records would agree on ART receipt. However, these 
characteristics may be related to disease severity as well as the type of treatment 
received,68,139,140 so age at diagnosis, race/ethnicity, and marital status were included as 
control variables. 
SEER region at diagnosis was included to control for potential differences in how 
well different registries capture treatment information. Surgical facility characteristics, 
particularly bed size and National Cancer Institute (NCI) affiliation (defined as being a 
clinical or comprehensive designated cancer center) were also hypothesized to affect 
the documentation and reporting of treatments.96 Surgical facility characteristics were 
used instead of diagnosing facility characteristics as the surgical findings play a large 
role in the decision to initiate or recommend ART. NCI affiliation information was 
available only for 2002 and 2005. Assuming that affiliation status was stable, the 2002 
affiliation was used for diagnoses between 2000 and 2003 and the 2005 affiliation was 
used for diagnoses between 2004 and 2007. Other surgical facility characteristics 
examined in bivariate statistical tests were medical school affiliation and the whether the 
facility provided therapeutic radiology services or not. A facility was classified as 
affiliated with a medical school if affiliation was major, limited, or graduate-level only. 
Other than NCI affiliation, all facility level variables were available for 2000-2007.  
5.2.5. Statistical Methods 
Initial descriptive analysis examined the percentage of men for whom SEER and 
Medicare data agree on receipt of ART as part of the initial course of treatment. These 
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percentages were calculated by year, SEER reporting area, patient characteristics, and 
surgical facility characteristics. I performed bivariate statistical tests, specifically t-tests 
and chi-squared tests,154 to examine potential differences in agreement across patient 
characteristics.  
The main analysis consisted of a person-level logistic regression in which the 
dependent variable was an indicator of agreement between SEER and Medicare on 
patient receipt of ART. I modeled this agreement as a function of a person’s tumor, 
demographic, and surgical facility characteristics. I also estimated a second logistic 
regression to examine the sensitivity of results to the classification of men for whom 
radiation therapy was recommended but were not known to have received it. This model 
used the same dependent and independent variables as the primary model; agreement 
status differed for some men. All models were estimated with robust standard errors 
clustered at the surgical facility.154 Final model specification was determined by 
examining each model’s reported log-likelihood and Akaike Information Criterion score 
and individual coefficient z-statistics.154 Results are reported in terms of odds ratios (OR) 
and 95% confidence intervals (CI), and statistical significance was assessed using an 
alpha of 0.05. I compiled data both in SAS, version 9.1 (SAS, Cary, NC) and Stata, 
version 10 (StataCorp, College Station, TX). I performed all data analysis in Stata. This 
research was approved by the Public Health-Nursing Institutional Review Board at the 
University of North Carolina at Chapel Hill.  
5.3. Results 
5.3.1. Descriptive Statistics 
The average age at diagnosis for men in the sample was 69.8 years (standard 
deviation [SD] = 3.3) (Table 14). The sample was primarily non-Hispanic White (82.3%), 
with an additional 5.9% non-Hispanic Black, 6.8% Hispanic, and 4.5% of other/unknown 
race. Thirty-six percent of the men were diagnosed with pT2 disease (as opposed to 
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pT3), and most men (69.4%) had well/moderately differentiated disease, defined by a 
combined Gleason score of 7 or less. Approximately half of the men received surgery at 
a medical school-affiliated facility (54.5%), 13.4% of men received surgery at an NCI-
affiliated facility, and 84.9% of men received surgery at a facility that provided radiation 
(although men did not necessarily receive radiation at the same facility where they 
received surgery).  
Table 14. Sample Characteristics by Whether or Not Individual Received ART According 
to SEER Documentation, continued on next page 
 % or mean (SD)  
Overall 
Received 
ART No ART p-value† 
Number of observations 3,993 387 3,606  
Age at diagnosis (years) 69.8 (3.3) 69.5 (3.3) 69.9 (3.3) .0273 
Age categories %    .2025 
65-69 53.8 58.1 53.4  
70-74 36.6 33.3 36.9  
75+ 9.6 8.5 9.7  
Married at diagnosis % 82.7 83.7 82.6 .5574 
State buy-in at diagnosis % 7.8 7.8 7.8 .9466 
Tumor Histology %   < .0001 
Well/Moderately 
differentiated 69.4 47.9 71.7  
Poorly differentiated 30.6 52.1 28.3  
Tumor pathologic stage %    < .0001 
Stage pT2 36.1 25.3 37.3  
Stage pT3 63.9 74.7 62.7  
Race/ethnicity %    .4516 
Non-Hispanic White 82.3 79.6 82.6  
Non-Hispanic Black 5.9 7.0 5.8  
Hispanic 6.8 7.2 6.7  
Other/Unknown 4.5 6.2 4.8  
*Only available for those diagnosed from 2004-2007, ** Connecticut, New Mexico, Rural Georgia, 
San Jose, and Atlanta registries not presented due to small cell size, † p-values obtained using t-
tests and chi-square tests and apply to differences in percentages or means across columns 3 
and 4. 
 
Note: ART: Adjuvant radiation therapy; SD: Standard deviation; SEER: Surveillance, 
Epidemiology, and End Results; NCI: National Cancer Institute; PSA: Prostate-specific antigen; 
HMO: Health maintenance organization 
 
 
97 
 
Table 14. Sample Characteristics by Whether or Not Individual Received ART According 
to SEER Documentation, continued from previous page, continued on next page 
 % or mean (SD)  
Overall 
Received 
ART No ART p-value† 
Total Gleason score* %   < .0001 
< 7 15.3 5.5 16.3  
7 61.5 45.5 63.2  
8 11.6 17.3 11.0  
> 8 11.7 31.8 9.5  
PSA value at diagnosis* 9.2 (10.0) 10.5 (11.1) 9.1 (9.9) .0676 
NCI Comorbidity Index at 
diagnosis 0.11 (0.26) 0.09 (0.21) 0.11 (0.26) .0588 
NCI Comorbidity categories %   .1486 
0 76.6 79.6 76.3  
> 0 23.4 20.4 23.7  
Registry at diagnosis** %   .0010 
San Francisco 3.3 2.8 3.3  
Detroit 7.5 8.3 7.4  
Hawaii 1.3 3.6 1.1  
Iowa 7.4 4.1 7.8  
Seattle 10.2 11.6 10.0  
Utah 7.0 7.0 7.0  
Los Angeles 12.3 14.5 12.1  
Greater California 26.3 24.8 26.4  
Kentucky 4.0 3.9 4.0  
Louisiana 5.8 7.8 5.6  
New Jersey 4.9 5.2 4.9  
Year of diagnosis %   .0374 
2000 8.3 10.9 8.4  
2001 10.2 10.6 10.1  
2002 11.8 12.9 11.7  
2003 12.8 8.8 13.3  
2004 13.6 15.8 13.4  
2005 13.3 11.9 13.4  
2006 13.5 15.5 13.2  
2007 16.6 13.7 16.9  
*Only available for those diagnosed from 2004-2007, ** Connecticut, New Mexico, Rural Georgia, 
San Jose, and Atlanta registries not presented due to small cell size, † p-values obtained using t-
tests and chi-square tests and apply to differences in percentages or means across columns 3 
and 4. 
 
Note: ART: Adjuvant radiation therapy; SD: Standard deviation; SEER: Surveillance, 
Epidemiology, and End Results; NCI: National Cancer Institute; PSA: Prostate-specific antigen; 
HMO: Health maintenance organization 
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Table 14. Sample Characteristics by Whether or Not Individual Received ART According 
to SEER Documentation, continued from previous page 
 % or mean (SD)  
Overall 
Received 
ART No ART p-value† 
Medicare HMO penetration 
rate 17.1 (15.2) 18.7 (14.9) 16.9 (15.2) .0329 
Surgical facility medical 
school-affiliated % 54.5 57.2 54.3 .2738 
Surgical facility bed size 421 (291) 391 (263) 424 (294) .0186 
Surgical facility NCI-
affiliated% 13.4 15.9 13.1 .1533 
Surgical facility provides 
radiation % 84.9 83.6 85.1 .4448 
*Only available for those diagnosed from 2004-2007, ** Connecticut, New Mexico, Rural Georgia, 
San Jose, and Atlanta registries not presented due to small cell size, † p-values obtained using t-
tests and chi-square tests and apply to differences in percentages or means across columns 3 
and 4. 
 
Note: ART: Adjuvant radiation therapy; SD: Standard deviation; SEER: Surveillance, 
Epidemiology, and End Results; NCI: National Cancer Institute; PSA: Prostate-specific antigen; 
HMO: Health maintenance organization 
 
Under the SEER definition of radiation receipt, only a small percentage of the 
sample received ART (9.7%). Using the Medicare definition of ART receipt increased 
this figure slightly (10.9%). Compared to men who did not receive ART, men who 
received ART more often had poorly differentiated disease (p < .0001), pT3 tumors (p < 
.0001), were slightly younger at diagnosis (69.5 years old versus 69.9, p = .0273), and 
lived in counties with higher Medicare HMO penetration (18.7% versus 16.9%, p = 
.0329). There were no significant differences across men who did and did not receive 
ART by surgical facility characteristics (with the exception of facility size), age at 
diagnosis, marital status, state buy-in, and race. Men who received ART more often 
received surgery in smaller hospitals than men who did not receive ART (p = .0186).  
Overall agreement on ART receipt across the two sources was 94.8%. Across 
the 6 registries with reportable cell sizes, agreement was highest in the Greater 
California registry (95.0%) and lowest in New Jersey (92.4%). Detailed agreement by 
registry is not presented as the data use agreement with NCI precludes presenting data 
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for cell-sizes smaller than 10. Across the 15 registries with at least some variation in 
agreement, agreement rates ranged from 84.9% to 98.3%. Among men whose records 
did not agree, 53.4% had poorly differentiated tumors, compared to 29.4% of men who 
had agreement in their records (p < .0001). Men whose records did not agree were also 
less likely to have pT2 tumors than men whose records agreed (26.3% versus 36.7%, p 
= .0012).  
Compared to men with documentation of ART in SEER but not Medicare, men 
with documentation of ART in Medicare but not SEER more often had poorly 
differentiated tumors (p =.0404) (Table 15). There were no other differences in the 
demographic, tumor, or surgical facility characteristics of men who had ART documented 
in one source but not the other. Men with ART documentation in Medicare only were 
less likely to have received surgery at an NCI-affiliated facility (p = .0124) than men with 
documentation in both sources. Men who had documentation in SEER only were less 
likely to be married than men with documentation in both sources (p = .0114). 
All but 3 of the 387 men with documentation of ART receipt in SEER had 
documentation of radiation therapy in Medicare claims at some point beyond surgery. Of 
the 306 men with documentation of ART receipt in SEER and Medicare, the average 
time in days from surgery to first radiation therapy treatment was 106 (SD = 37, range 
18-180). Of the 78 men with documentation of ART receipt in SEER and Medicare 
claims for radiation therapy more than 180 days after surgery (which could be either 
salvage or palliative rather than adjuvant), average time in days from surgery to first 
radiation therapy treatment was 370 (SD = 375, range 182-2,397). There were no 
differences in individual, tumor, or surgical facility characteristics across the two groups 
of men who received ART according to SEER but initiated radiation therapy according to 
Medicare claims either within 180 days or more than 180 days following surgery.  
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Table 15. Characteristics of Individuals with Record of ART in SEER Data, Medicare 
Data, or Both Sources, continued on next page 
 % or mean (SD)  
ART in 
both 
SEER and 
Medicare 
ART in 
Medicare, 
not SEER 
ART in 
SEER, not 
Medicare p-value† 
Number of observations 306 128 81  
Age at diagnosis (years) 69.5 (3.3) 69.6 (3.4) 69.3 (3.3) .5243 
Age categories** %     
65-69 58.8 58.6 55.6 .8095 
70+ 41.2 41.4 44.4  
Married at diagnosis % 86.6 82.8 72.8 .0983 
State buy-in at diagnosis % 7.8 9.4 7.4 .6151 
Tumor Histology %     
Well/Moderately 
differentiated 45.9 40.9 55.6  
Poorly differentiated 54.1 59.1 44.4 .0404 
Tumor pathologic stage %     
Stage pT2 24.2 24.2 29.6 .3965 
Stage pT3 75.8 75.8 70.4  
Race/ethnicity** %    .9424 
Non-Hispanic White 78.8 80.5 82.7  
Other/Unknown 21.2 19.5 17.3  
PSA value at diagnosis* 10.7 (11.8) 14.0 (18.6) 9.8 (7.0) .1264 
NCI Comorbidity categories %    .2347 
0 78.8 75.8 82.7  
> 0 21.2 24.2 17.3  
NCI Comorbidity Index at 
diagnosis 0.09 (0.21) 0.12 (0.30) 0.08 (0.23) .2747 
*Only available for those diagnosed from 2004-2007, **Categories collapsed due to small cell-
size. Gleason score and registry at diagnosis not presented due to small cell size. † p-values 
obtained using t-tests and chi-square tests and apply to differences in percentages or means 
across columns 3 and 4. 
 
Note: ART: Adjuvant radiation therapy; SD: Standard deviation; SEER: Surveillance, 
Epidemiology, and End Results; NCI: National Cancer Institute; PSA: Prostate-specific antigen; 
HMO: Health maintenance organization 
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Table 15. Characteristics of Individuals with Record of ART in SEER Data, Medicare 
Data, or Both Sources, continued from previous page 
 % or mean (SD)  
ART in 
both 
SEER and 
Medicare 
ART in 
Medicare, 
not SEER 
ART in 
SEER, not 
Medicare p-value† 
Year of diagnosis** %    .7464 
2000 or 2001 22.1 23.4 18.4  
2002 12.8 10.9 13.6  
2003 7.5 8.6 13.6  
2004 16.0 11.7 14.8  
2005 11.8 9.4 12.4  
2006 15.4 18.8 16.1  
2007 14.4 17.2 11.1  
Medicare HMO penetration 
rate 18.4 (14.9) 19.4 (15.0) 19.7 (15.1) .8850 
Surgical facility medical 
school-affiliated % 58.3 54.4 53.1 .8545 
Surgical facility bed size 395 (264) 404 (228) 375 (260) .4019 
Surgical facility NCI-
affiliated% 17.2 8.8 11.1 .5949 
Surgical facility provides 
radiation % 84.4 86.4 80.2 .2573 
*Only available for those diagnosed from 2004-2007, **Categories collapsed due to small cell-
size. Gleason score and registry at diagnosis not presented due to small cell size. † p-values 
obtained using t-tests and chi-square tests and apply to differences in percentages or means 
across columns 3 and 4. 
 
Note: ART: Adjuvant radiation therapy; SD: Standard deviation; SEER: Surveillance, 
Epidemiology, and End Results; NCI: National Cancer Institute; PSA: Prostate-specific antigen; 
HMO: Health maintenance organization 
 
5.3.2. Multivariate Logistic Regression Analysis 
The relationship between SEER and Medicare record agreement and tumor, 
individual, and surgical facility characteristics was more fully explored in a logistic 
regression model. The final model specification did not variables indicating whether the 
surgical facility was affiliated with a medical school or provided radiation therapy as 
these variables were not shown to affect agreement in the bivariate analyses and their 
inclusion did not improve model fit. Year of diagnosis was included as a continuous 
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variable to detect a potential trend in agreement over time and to preserve degrees of 
freedom.  
Men with poorly differentiated tumors had lower odds of agreement than men 
with well- or moderately-differentiated tumors (OR = 0.38, 95% CI = 0.28-0.52), but 
pathologic stage did not have a significant effect on the odds of record agreement (Table 
16). As a group, registry at diagnosis had a significant effect on the odds of agreement 
(χ2 = 41.22, p = .0002), and individual registries varied in whether they had higher or 
lower odds of agreement than the reference category (Greater California). Significantly, 
men diagnosed in Utah had higher odds of agreement (OR = 2.72, 95% CI = 1.06-6.90). 
Men diagnosed in Hawaii registry area had lower odds of agreement (OR = 0.26, 95% CI 
= 0.13-0.53), as did men diagnosed in the Los Angeles registry area (OR = 0.54, 95% CI 
= 0.32-0.91). Receiving surgery at an NCI-affiliated facility was associated with higher 
odds of agreement (OR = 1.85, 95% CI = 1.02-3.37).  
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Table 16. Logistic Regression Results for Agreement Between SEER and Medicare 
Regression Results 
OR 95% CI 
Age at diagnosis 1.05* 1.00-1.10 
Race (non-Hispanic White is reference)  
Non-Hispanic Black 1.26 0.64-2.48 
Hispanic 0.95 0.54-1.66 
Other/Unknown 1.90 0.98-3.68 
Pathologic stage T2 1.28 0.90-1.83 
Tumor poorly differentiated 0.38** 0.28-0.52 
Registry at diagnosis (Greater California is 
reference)†  
San Francisco 0.96 0.42-2.14 
Connecticut 1.03 0.47-2.23 
Detroit 0.74 0.37-1.49 
Hawaii 0.24** 0.13-0.47 
Iowa 2.63 0.80-8.58 
New Mexico 0.82 0.63-1.84 
Seattle 0.98 0.56-1.71 
Utah 2.72* 1.07-6.90 
Atlanta 0.69 0.16-2.99 
San Jose 0.88 0.49-1.59 
Los Angeles 0.54* 0.32-0.91 
Kentucky 0.62 0.24-1.63 
Louisiana 1.58 0.67-3.75 
New Jersey 0.58 0.31-1.08 
HMO penetration rate 0.64 0.19-2.16 
Bed size 1.06 0.99-1.13 
NCI affiliation 1.85* 1.02-3.37 
Year of diagnosis 0.98 0.91-1.05 
Observations 3,929  
Log pseudolikelihood -754.03  
AIC 1558.07  
* significant at 5%, ** significant at 1%, †Rural Georgia registry area dropped due to perfect 
prediction, standard errors clustered by surgical facility 
 
Note: SEER: Surveillance, Epidemiology, and End Results; NCI: National Cancer Institute; OR: 
odds ratio; CI: confidence interval; AIC: Akaike Information Criterion 
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Table 17. Logistic Regression Results for Agreement Between SEER and Medicare, 
Alternate SEER Radiation Definition 
Regression Results 
OR 95% CI 
Age at diagnosis 1.05* 1.00-1.10 
Race (non-Hispanic White is reference)  
Non-Hispanic Black 1.08 0.61-1.89 
Hispanic 1.06 0.62-1.82 
Other/Unknown 2.18* 1.12-4.24 
Pathologic stage T2 1.27 0.92-1.75 
Tumor poorly differentiated 0.39** 0.29-0.51 
Registry at diagnosis (Greater California is 
reference)†  
San Francisco 1.08 0.50-2.37 
Connecticut 0.88 0.44-1.75 
Detroit 0.77 0.41-1.45 
Hawaii 0.26** 0.14-0.50 
Iowa 2.89* 1.00-8.30 
New Mexico 0.93 0.42-2.08 
Seattle 0.97 0.60-1.56 
Utah 3.22* 1.30-7.95 
Atlanta 0.89 0.20-3.99 
San Jose 0.87 0.46-1.64 
Los Angeles 0.59* 0.37-0.93 
Kentucky 0.95 0.42-2.17 
Louisiana 2.09 0.91-4.80 
New Jersey 0.80 0.44-1.46 
HMO penetration rate 0.76 0.23-2.48 
Bed size 1.02 0.97-1.08 
NCI affiliation 1.33 0.88-2.02 
Year of diagnosis 0.97 0.91-1.04 
Observations 3,929  
Log pseudolikelihood -831.95  
AIC 1713.91  
* significant at 5%, ** significant at 1%, †Rural Georgia registry area dropped due to perfect 
prediction, standard errors clustered by surgical facility 
 
Note: SEER: Surveillance, Epidemiology, and End Results; NCI: National Cancer Institute; OR: 
odds ratio; CI: confidence interval; AIC: Akaike Information Criterion 
 
To test the sensitivity of the results to the specification of the SEER radiation 
variable, an alternate measure of ART receipt in SEER data was examined. An 
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additional logistic model was estimated to test the sensitivity of the results to the 
assumption that the 41 men for whom radiation therapy was recommended did not 
receive ART (Table 17). In the model presented in Table 16, these men were considered 
not to have documentation of radiation therapy in SEER. In the model presented in 
Table 17, these 41 men were considered to have received ART according to SEER data 
(following the example of an earlier examination of ART receipt in SEER data86). 
The magnitudes of the estimated ORs in the models presented in Table 16 and 
Table 17 are similar, but there are some differences in which variables have a significant 
effect on the odds of agreement. Specifically, the odds ratio associated with receiving 
surgery at an NCI-affiliated facility was no longer significant, but men of other/unknown 
race had higher odds of agreement (OR = 2.17, 95% CI = 1.12-4.24). Of the 41 men with 
recommended but unknown radiation receipt in SEER, 20 had no Medicare claim for 
radiation therapy at any point in time. The remaining 21 men had Medicare claims for 
radiation therapy, with average time from surgery to initiation of radiation therapy of 540 
days (SD = 478, range = 73-1,533). 
5.4. Discussion 
Agreement between SEER and Medicare with regards to ART receipt was found 
to be high, at 94.8%. This is slightly higher than the 93% agreement among prostate 
cancer patients reported by Virnig et al. in their 2002 study.34 These rates cannot be 
directly compared, however, as the first study sought to document agreement for all 
prostate cancer patients and all types of radiation and the present study examined the 
subset of men who received a radical prostatectomy and external beam radiation 
therapy adjuvant to radical prostatectomy. The differences in samples across the two 
studies make it impossible to say with certainty whether there has been an improvement 
in SEER radiation documentation since the mid-1990s.  
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Overall, 434 men had documentation of ART receipt in Medicare (10.9%), and 
387 men had documentation of ART receipt in SEER (9.7%). These percentages are 
comparable to the 13.5% of men with qualifying disease characteristics for whom 
radiation therapy was recommended reported in an earlier study of ART receipt in 
SEER.86 The rates of ART found in this study are, however, lower than the 18.2% 
reported in a second study of ART receipt in SEER.87 These previous studies used the 
entire SEER population rather than only those men participating in Medicare plans, so 
differences in sample characteristics may help explain some of the difference in reported 
receipt of ART.  
Among men with documentation of ART in SEER but not Medicare, almost all of 
the disagreement is driven by the timing of radiation therapy. In recent clinical trials, ART 
was delivered within 16 weeks of surgery,7,9 and the 180-day (i.e. 6-month) period used 
in this study was designed as an upper bound on the window of time in which radiation 
could be considered adjuvant to surgery (as opposed to salvage or palliative). Since 
almost all men with documentation of ART in SEER also have documentation of 
radiation in Medicare at some point after surgery, the rate of agreement in receipt of 
ART is almost entirely dependent on the time interval used to differentiate adjuvant and 
salvage or palliative radiation. The use of SEER records alone to measure ART would 
result in erroneously classifying men who received salvage or palliative radiation therapy 
as receiving ART. On the other hand, use of Medicare records alone could result in 
erroneously classifying men who received salvage radiation therapy as receiving ART. In 
some men, radiation therapy delivered within 180 days of radical prostatectomy could be 
initiated in response to rising PSA levels following surgery. Radiation therapy for these 
men would be considered salvage, not adjuvant, but there is no way to capture this in 
Medicare claims data.  
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The results from both regression models suggest that Medicare and SEER are 
less likely to agree on receipt of ART for men with more severe disease. In bivariate 
analyses, men with pT3 tumors and poorly-differentiated tumors are less likely to have 
agreement in SEER and Medicare on whether or not they received ART, but only tumor 
differentiation significantly affected agreement in multivariate regression analyses. This 
suggests that SEER records alone are insufficient for classifying men according to 
receipt of ART, particularly when the sample of interest is men for whom ART is most 
likely to be recommended and initiated. 
I also found evidence of differences across registries in agreement on ART 
receipt. In both regressions, the registry construct had an overall significant effect on 
agreement, and the individual registry results were robust across ART receipt 
specifications. Specifically, the men living in the Utah registry area had higher odds of 
record agreement compared to men in the Greater California registry area, and men 
living in the Hawaii and Los Angeles registry areas had lower odds of record agreement. 
Utah and Hawaii entered the SEER program in 1973, and Los Angeles entered the 
SEER program in 1992,119 so the difference in agreement does not appear to be related 
to how long the registry has been established.  
The findings from this study are applicable to only a portion of prostate cancer 
patients, those who were continuously enrolled in traditional FFS Medicare throughout 
the study period. The use of Medicare claims, though essential to fulfilling the aim of this 
study, limits the generalizability of the results beyond the study population. Because 
private insurance plans used by traditional FFS and Medicare HMO enrollees may differ 
in their documentation and reimbursement policies, these differences could affect the 
rate of ART receipt observed in different insurance group populations. That is, it is 
unclear whether the findings from this study would extend to patient populations without 
Medicare coverage or with Medicare HMO coverage. Also, enrollment in Medicare 
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managed care plans is elective, so there is the possibility of selection bias in the study 
population. The county-level proportion of Medicare eligible enrolled in HMO plans was 
included in models to attempt to control for possible selection bias.  
Increasing focus on the added survival benefit conferred by ART for some men 
has already created interest in examining the receipt of ART in the SEER population.86,87 
This study suggests that the rates of receipt reported in examinations of the SEER 
population may be slight overestimates, as there were more men receiving salvage or 
palliative radiation therapy classified as ART in SEER than there were men with ART 
Medicare claims but no documentation of ART in SEER. However, agreement between 
the two sources was very high overall, which confirms a previous comparison of 
radiation receipt in prostate cancer patients.34 This high agreement, combined with the 
low rates of ART observed in the sample, suggests that the low rates of ART reported by 
previous studies of SEER data are unlikely due to underreporting of radiation therapy in 
SEER. Rather, the prior findings are likely due to lack of adoption of ART in response to 
recently reported clinical trial results. High agreement notwithstanding, neither Medicare 
nor SEER alone can be considered the gold standard in studying treatment, and this 
study calls attention to potential sources of bias in the use of SEER data to examine 
ART receipt, particularly in the sample of men for whom ART is most likely to be 
recommended. 
  
 
CHAPTER 6. THE COST-UTILITY OF ADJUVANT RADIATION THERAPY 
FOLLOWING RADICAL PROSTATECTOMY 
 
6.1. Introduction 
Of prostate cancer patients presenting with pathological stage T3 (pT3) disease, 
10% to 50% may not achieve disease control with radical prostatectomy alone.75 In 
2005, the initial publication of results from the first of three major clinical trials evaluating 
the use of adjuvant radiation therapy (ART) after prostatectomy provided evidence of the 
benefit of ART for certain high-risk prostate cancer patients.7 The other two trials 
published similar results in 2006 and 2009.6,8 In all three trials, ART was compared to a 
wait and see approach in which salvage radiation therapy (SRT) was initiated in 
response to disease recurrence, as indicated by increasing prostate-specific antigen 
(PSA) levels or detected through biopsy. This time period also saw the publication of a 
large retrospective study reporting durable disease response to SRT following 
prostatectomy.76  
The clinical trial results suggest benefits associated with ART in terms of time to 
PSA recurrence, but the associated harms are unclear. On one hand, treating all 
qualifying patients with ART would result in treating individuals who would have lived 
recurrence-free without additional treatment. As the side effects of radiation therapy can 
have serious quality of life implications,10-13 the impact of radiation therapy on these 
patients and the associated costs should be carefully considered. On the other hand, the 
success of the wait and see approach is predicated upon frequent PSA testing and 
appropriate follow-up care in the event of a detectable and rising PSA. The analysis in 
Chapter 4 demonstrates that PSA surveillance rates decrease over time and are lower in 
110 
 
minority populations, which indicates that some men may be at risk of delayed detection 
of disease recurrence.  
Only one of the three trials has reported improved overall survival associated 
with ART compared to the wait and see approach (13.3 versus 15.2 years),9 however, 
this study enrolled patients prior to widespread PSA screening and questions have been 
raised with respect to the generalizability of this study cohort to contemporary men with 
screen-detected disease.81 However, even if the evidence supporting one approach over 
the other is clear in terms of survival, it is important to consider quality of life associated 
with each approach to radiation therapy. The Institute of Medicine states that the late 
effects on quality of life of both treatment for local disease and living with recurrent 
disease are of central importance to prostate cancer survivors.47 As the combination of 
surgery and radiation therapy, administered as either adjuvant or salvage therapy, may 
result in additional decrements in health-related quality of life beyond those associated 
with a single treatment,168 patients and physicians must weigh changes in quality of life 
against the potential for improved survival. As the findings presented in Chapter 4 
indicate, PSA surveillance rates are high in the year immediately following radical 
prostatectomy, but surveillance drops off over time. Additionally, minority racial groups 
are at greater risk for not receiving surveillance in concordance with established 
guidelines. Low surveillance rates could be associated with decreased detection of 
disease recurrence, which could be a mechanism to help explain observed racial 
disparities in prostate cancer outcomes.  
 The present model extends and improves upon a recent decision analysis 
comparing the quality of life benefits of ART to a wait and see approach to radiation 
therapy after radical prostatectomy.118 The authors found that the wait and see approach 
resulted in 6.8 quality-adjusted life-years (QALYs) during a 10-year period compared to 
6.13 QALYs for ART. However, ART was found to be more effective than the wait and 
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see approach in terms of 10-year PSA recurrence-free survival, metastasis-free survival, 
and overall survival. The present model improves upon this existing model by evaluating 
the lifetime costs and effects of the two approaches, evaluating results using a full 
probabilistic sensitivity analysis, discounting future costs and time, and more precisely 
specifying possible transitions within each period.  
The long natural history of prostate cancer, combined with advances in detection 
and treatment, make it difficult to evaluate long-term outcomes using prospective 
studies. Cost-utility and cost-effectiveness models provide one way to estimate and to 
simulate how changing practice patterns and treatment recommendations could affect a 
range of outcomes, including survival and quality of life. This approach is ideal for 
evaluating outcomes associated with post-operative radiation therapy in prostate cancer, 
as factors that may influence the effectiveness of one approach over another (such as 
intensity of post-surgical PSA surveillance) were not considered in clinical trial evaluation 
of treatment efficacy.  
6.2. Methods 
6.2.1. Model Construction 
A Markov model was constructed to estimate the cost-utility of the current wait 
and see approach to SRT compared to an alternative policy of ART within four months of 
prostatectomy for a cohort of patients. The hypothetical model cohort was composed of 
men 65 years old treated with radical prostatectomy for high-risk prostate cancer within 
180 days of biopsy-proven diagnosis. Following the inclusion criteria of the clinical trials, 
high-risk disease was defined as a pathological T3 tumor or a pathological T2 tumor with 
positive surgical margins. All men were assumed to have achieved an undetectable PSA 
level following surgery ( < 0.1 ng/ml).  
Figure 10 shows the Markov model structure depicting the approach of ART for 
all qualifying patients. See Figures 11 and 12 for the complete model. In each cycle of 
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the model, defined as three months, individuals may move from their current disease 
state to a new one or remain in their current disease state. For example, in Figure 10, all 
individuals enter the model in period one in the state “NED (no evidence of disease) 
after RT.” At the end of 3 months, they either remain in this state or experience a PSA 
recurrence without metastatic disease (“PSA Recur after RT”). In this way, all individuals 
move through the model until they end in an absorbing state, that is, one that does not 
allow outward movement. In this model, absorbing states include death from prostate 
cancer (“Death, CaP”) or death from other causes (“Death, other cause”). Individuals 
may transition into death from other causes from any state in the model (other than 
death from prostate cancer) at any time, whereas individuals may transition to death 
from prostate cancer only after having developed metastatic disease. This model 
contains two states of metastatic disease: metastatic disease responsive to hormonal 
therapy and metastatic disease resistant to hormonal therapy (hormone-refractory 
disease). Men in these two states of metastatic disease receive different treatments, and 
hormone-refractory disease is associated with greatly reduced quality of life compared to 
metastatic disease that is responsive to hormonal therapy.  
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Figure 10. Markov Cohort Model for Adjuvant Radiation Therapy Treatment Arm 
 
 
Note: NED: No evidence of disease; PSA: Prostate-specific antigen; CaP: Prostate cancer; RT: 
Radiation therapy 
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Figure 11. Wait and See Arm of Markov Model 
 
Note: PSA: prostate-specific antigen; Chemo; chemotherapy (bicalutamide)SRT: salvage 
radiation therapy; RP: radical prostatectomy; NED: no evidence of disease; CaP: prostate cancer; 
ADT: androgen deprivation therapy (leuprolide); RT: radiation therapy; Mets: metastatic disease 
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Figure 12. Adjuvant Radiation Therapy Arm of Markov Model 
 
Note: PSA: prostate-specific antigen; Chemo; chemotherapy (bicalutamide)SRT: salvage 
radiation therapy; RP: radical prostatectomy; NED: no evidence of disease; CaP: prostate cancer; 
ADT: androgen deprivation therapy (leuprolide); RT: radiation therapy; Mets: metastatic disease; 
Clone 1 and 2 - refer to Figure 11. 
6.2.2. Probabilities 
Cost-utility, cost-effectiveness, and comparative effectiveness studies, along with 
results from clinical trials and retrospective series were used to derive transition 
probabilities for the model (Table 18). A PubMed search was conducted using the 
following terms alone and in combination: prostate cancer, cancer, quality of life, utility, 
cost-effectiveness, cost-utility, QALY, willingness to pay, quality of life, comparative 
effectiveness, and health-related quality of life. This search process began in May 2011, 
and was periodically repeated between May and December 2011 to capture any new 
publications. I reviewed reference lists from relevant articles to identify additional 
sources of input data.  
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Table 18. Probabilities, Utilities, and Costs Used in Base-case and One-way Sensitivity Analysis, continued on next page  
Probabilities 
Base-case 
value SD 
Lower 
95% CI 
Upper 
95% CI Distribution  
Adverse effects of treatment112    
Short term    
Radical prostatectomy    
Sexual 0.768 0.054 0.662 0.874 Beta  
Urinary 0.467 0.110 0.251 0.683 Beta  
Radiation therapy    
Urinary 0.300 0.086 0.134 0.469 Beta  
Bowel 0.184 0.052 0.082 0.286 Beta  
Long term    
Radical prostatectomy    
Sexual 0.453 0.034 0.386 0.520 Beta  
Urinary 0.127 0.016 0.096 0.158 Beta  
Radiation therapy    
Urinary 0.134 0.030 0.075 0.193 Beta  
Bowel 0.066 0.014 0.039 0.093 Beta  
Sexual 0.485 0.048 0.391 0.579 Beta  
Progression-related    
Progression following RP6 0.46 0.046 0.370 0.550 Beta  
Receipt of SRT after recurrence 0.75 0 1 NA  
Progression following SRT5 0.45 0.11 0.234 0.667 Beta  
Progression following ART6 0.28 0.209 0.351  Beta  
Metastases following progression4 0.37 0.299 0.441  Beta  
Development of metastatic disease no 
longer responsive to hormonal 
therapy143 0.35 0.049 0.254 0.446 Beta  
Death from prostate cancer144 0.39 0.059 0.274 0.506 Beta  
Death from other causes145 Varied   NA  
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Cost (in 2011 US$) 
Base-case 
value SD 
Lower 
95% CI 
Upper 
95% CI Distribution Units 
Bone Scan141 261 71.14 122 400 Log Normal 1 
IMRT141    
IMRT Visit 183 35.24 114 252 Log Normal 2 
CT Scan 198 57.16 86 310 Log Normal 1 
IMRT Planning 2,150 218.41 1,721 2,578 Gamma 1 
IMRT Delivery 537 61.51 416 657 Gamma 37 
Leuprolide142 314 49.30 217 411 Gamma 2 per month 
Bicalutamide142 1,881 66.57 1,751 2,011 Gamma 
per 100 
days 
Utilities148 
Base-case 
value SD 
Lower 
95% CI 
Upper 
95% CI Distribution  
Impotence 0.89 0.16 0.576 1 Beta  
Urinary incontinence 0.83 0.21 0.418 1 Beta  
Bowel problems 0.71 0.26 0.200 1 Beta  
Impotence and urinary incontinence 0.79 0.23 0.339 1 Beta  
Urinary incontinence and bowel 
problems 0.7 0.26 0.190 1 Beta  
Impotence and bowel problems 0.57 0.26 0.060 1 Beta  
Impotence, urinary incontinence, and 
bowel problems 0.45 0.31 0.050 1 Beta  
Metastatic disease responsive to 
leuprolide149,150 0.47 0.3 0.050 1 Beta  
Metastatic disease not responsive to 
leuprolide 0.25 0.11 0.034 0.466 Beta  
Note: SD: standard deviation; IMRT: intensity-modulated radiation therapy, CT: computed tomography; RP: radical prostatectomy; SRT: salvage 
radiation therapy; ART: adjuvant radiation therapy; NA: not applicable; CI: confidence interval 
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Probabilities associated with biochemical recurrence following radical 
prostatectomy and biochemical recurrence following ART came from two recent clinical 
trials.6,78 Probabilities for progression from disease recurrence to metastatic disease and 
progression from hormonally responsive metastatic disease to hormone-refractory 
disease came from retrospective studies,4,5,83,143 and biochemical recurrence following 
SRT and survival following hormone-refractory disease were calculated using peer-
reviewed risk prediction nomograms.5,144 When available, event counts were used to 
create beta distributions around the base-case probability. If event counts were not 
presented in the source article, a beta distribution was approximated from a mean and 
standard deviation.100 All probabilities were converted from annual or multiple year 
probabilities to quarterly probabilities.100 Annual probability of death from background 
causes was obtained from the 2007 U.S. life tables for men.145 
In the base-case, 5-year probability of progression-free survival following radical 
prostatectomy in the wait and see arm was 0.54.6 This probability is equivalent to an 
annual progression probability of 0.116. Following progression, 75% of men were 
assumed to receive SRT.118 The probability of disease progression following SRT was 
calculated using a peer-reviewed risk prediction nomogram5 populated with disease 
characteristics of men in the clinical trial conducted by the German Cancer Society 
(referred to hereafter as ARO) and two retrospective studies of SRT.5,6,83 In contrast to 
the clinical trial results, which were presented in terms of the 5-year probability of 
progression-free survival, the nomogram output is the 6-year probability of progression-
free survival. Specifically, the 6-year progression-free probability for a man with a pre-
prostatectomy PSA of 10 ng/ml, a primary Gleason score of 3 with a secondary Gleason 
score of 4, positive surgical margins, extracapsular extension, PSA recurrence 12 
months after prostatectomy, and a PSA doubling time of 5 months who received a 
radiation dose of 66 gray (Gy) at a PSA level of 0.5 ng/ml was estimated at 0.55, which 
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is equivalent to an annual progression probability of 0.095. A standard deviation of 0.11 
(20% of the 6-year estimate) was assumed and used to create a beta distribution. The 
probability of progression varies based on the PSA level at initiation of SRT, and the 
nomogram was repopulated for cohorts of men receiving SRT at different PSA levels. 
These progression probabilities were used in scenario analyses. Additional distributions 
were created around the nomogram-calculated probability of progression when SRT was 
initiated at PSA levels of 0.1 ng/ml, 1 ng/ml, 1.5 ng/ml, and 3 ng/ml.5  
The 5-year probability of progression-free survival in the ART arm was 0.72 (95% 
CI 0.65-0.81),6 equivalent to an annual progression probability of 0.064. Once 
biochemical recurrence occurred following radiation therapy, whether adjuvant or 
salvage, the annual probability of progressing to metastatic disease was 0.088.4 This 
probability also was used for men who progressed after radical prostatectomy but did not 
receive SRT. 
Additional probabilities of disease progression following radical prostatectomy, 
ART, and SRT were derived for subgroups of men with and without positive surgical 
margins and with and without seminal vesicle invasion. These subgroup probabilities are 
presented in Table 19. 
The probabilities for developing short- and long-term urinary, sexual, and 
gastrointestinal adverse effects following radical prostatectomy and radiation therapy 
came from a random-effects meta-analysis conducted by Hayes et al.112 Short-term 
adverse events resolved within 3 months of treatment, whereas long-term adverse 
events persisted from 3 months until death. Following the methods of Elliot et al.,118 the 
probabilities of developing adverse events were considered to be the probability of 
developing the given adverse event alone and in combination with other adverse events.  
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Table 19. Probabilities of PSA Recurrence by Tumor Characteristics 
 
ART WS SRT 
Patients 
with PSA 
Recurrence 
Total 
Patients 
Equivalent 
5-Year 
Probability 
of 
Recurrence 
Patients 
with PSA 
Recurrence 
Total 
Patients 
Equivalent 
5-Year 
Probability 
of 
Recurrence 
6-Year Probability 
of Recurrence5 
Surgical Margins6        
Negative 13 48 0.27 19 61 0.31 0.64 
Positive 25 100 0.25 47 97 0.49 0.50 
Seminal Vesicle 
Invasion6        
No 14 99 0.14 36 101 0.36 0.50 
Yes 19 40 0.48 24 43 0.56 0.58 
Note: ART: adjuvant radiation therapy; WS: wait and see; SRT: salvage radiation therapy; PSA: prostate-specific antigen 
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6.2.3. Utilities 
Substantial research exists on prostate cancer-related quality of life and health 
states.146 Titles and abstracts located through the PubMed searches were reviewed to 
identify articles that reported utility values rather than quality of life or functioning scores. 
Although many instruments are used to evaluate quality of life in prostate cancer 
patients,147 few of these instruments generate utility measures. Many of the articles 
identified in the initial search were cost-effectiveness or cost-utility studies that 
referenced utility values from a previous study, so reference lists of relevant articles 
were reviewed to identify any additional publications.  
Thirty studies were used to create a database of prostate cancer-specific utility 
values containing 289 utility values. Values were categorized as describing a treatment 
state, adverse event, short-term effect, and/or long-term effect. The quality of each 
measure and its relevance to the current study were evaluated by examining the 
population from which the value was elicited, the elicitation technique, the sample size, 
and the utility scale endpoints. Utilities from scales using anchors other than death and 
perfect health were excluded. Utility values derived from expert opinion also were 
excluded unless they were the only ones representing a specific health state. To ensure 
the consistency of the evaluated outcomes, studies were excluded if cancer patients 
were asked to evaluate the utility of their current health state rather than a standard 
health state description. 
Seventeen of the studies presenting prostate cancer-related utilities involved 
utilities related to metastatic disease. Of these 17 studies, seven met the inclusion 
criteria described above, however 3 studies appeared to use the same data set, bringing 
the total number of studies with useful utility data to 5.113,115,148-150 Two of these 5 studies 
reported more than one utility measure.149,150 Since the model had two metastatic 
disease states, utilities were separated by whether or not the disease was responsive to 
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hormonal therapy (specifically, leuprolide). In cases where the authors did not 
specifically state the level of disease advancement, the disease description used in the 
utility exercise was used to properly categorize the utility. This process resulted in a final 
group of 4 estimates from 2 studies for the utility of living with metastatic prostate cancer 
responsive to hormonal therapy149,150 and 7 utility estimates from 5 studies for the utility 
of living with metastatic prostate cancer that is no longer hormonally responsive.113,115,148-
150
 For hormonally responsive disease, the utility value mean and standard deviation 
were determined by examining the means, standard deviations (where available), and 
interquartile ranges (where available) to derive a single mean and standard deviation 
reflective of the ranges reported in the two studies. For metastatic disease no longer 
responsive to hormonal therapy, the base-case utility value mean and standard deviation 
were taken from Stewart et al.148 as this study focused specifically on the preferences of 
men aged 60 and older, used the standard gamble technique (which, all else equal, is 
preferred to the time trade off technique for preference elicitation102), and falls in the 
middle of the range of utilities reported in the five studies.  
The utilities associated with living with adverse events related to treatment were 
taken from Stewart et al.148 In contrast to other utility studies that examine the utilities of 
adverse events separately, Stewart et al. elicited utilities for adverse events singularly 
and in combination. These combinations are essential for evaluating health states 
following prostate cancer treatment, as individuals may experience multiple treatment-
related adverse events, and no model exists to accurately predict joint health state 
utilities from the component single health state utilities.151 Table 18 presents all utility 
values used in the analysis.  
6.2.4. Costs 
With the exception of drug costs, all cost data for the analysis were derived from 
established Medicare fee schedules (Table 18). Costs were from the calendar year 2011 
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fee schedule,141 which is based on Healthcare Common Procedure Coding System 
(HCPCS) codes. As the difference in salvage and adjuvant radiation therapy is only in 
the timing of the treatment rather than the dosage or administration, both arms of the 
model incorporate essentially the same costs. The model did not include costs 
associated with radical prostatectomy or surgical follow-up, as all individuals 
experienced this procedure prior to the beginning of the model. Included costs are those 
costs associated with radiation therapy administration and follow-up and management of 
metastatic disease.  
Metastatic disease was assumed to be initially treated with gonadotropin-
releasing hormone agonist (leuprolide) rather than orchiectomy, and hormone-refractory 
disease was assumed to be treated with bicalutamide. Drug prices were obtained from 
the 2010 edition of the Red Book142 and adjusted to 2011 dollars using the medical care-
specific Consumer Price Index.99,152 All individuals were assumed to receive semi-annual 
PSA tests regardless of timing of radiation receipt based the analysis presented in 
Chapter 4, so this cost excluded. As the adverse events included in the model were 
considered to be minor rather than requiring substantial medical intervention, there were 
no additional direct healthcare costs associated with adverse events.  
The Centers for Medicare and Medicaid Services provides information on both 
the national payment amount and Part B carrier-specific payment amounts. The national 
payment amount was used in the base-case analysis, and the carrier-specific amounts 
were used to create a distribution for probabilistic analysis. Input Analyzer (Arena 
Version 13.9, Rockwell Automation, Inc., Wexford, PA) was used to analyze the entire 
set of payment amounts and create distributions to best fit the data.  
All costs and outcomes occurring in the future were discounted at 3% per year to 
account for the time value of money and utility.102,156 All results are presented from the 
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payer perspective (in this case, Medicare) over the time horizon from prostatectomy to 
death, which, on average, occurred approximately 15 years after radical prostatectomy.  
6.2.5. Analysis 
The model was used to calculate the total cost and the total utility associated with 
the ART approach and the total cost and the total utility associated with the wait and see 
approach. In addition, the proportion of the cohort experiencing disease recurrence, 
receiving radiation therapy, developing metastatic disease, and dying from prostate 
cancer were calculated for each alternative. The total cost and total utility totals were 
used to calculate the incremental cost-effectiveness ratio: 
ICER = (Cost(adjuvant) – Cost(wait and see))/(Benefit(adjuvant) – Benefit(wait and see)) 
The ICER either will be positive or negative, and the interpretation of the ICER 
can most easily be seen by plotting the incremental costs (y-axis) and benefits (x-axis) 
on an x-y axis (called the incremental cost-effectiveness plane). The ICER is the slope of 
the line from the origin to the point. When the point estimate ICER falls in northwest or 
southeast quadrants, one alternative is clearly superior to the other.102 Points (and 
therefore ICER values) falling in northeast or southwest quadrants represent alternatives 
with a trade-off between cost and effectiveness. The standard practice is to establish a 
threshold for the maximum willingness to pay (WTP) per QALY.102 The slope of a line 
running through the origin of the x-y axis represents this WTP threshold. An ICER above 
the threshold indicates the superiority of the wait and see approach to salvage radiation 
therapy, whereas an ICER below the threshold indicates the superiority of ART. 
Generally, in the U.S., an intervention or program is considered cost-effective if the ICER 
is less than $50,000 per QALY.103  
Clearly, a single estimate of the ICER is insufficient for drawing conclusions 
about the relative costs and benefits of the two approaches to radiation therapy. 
Although a single estimate for each parameter was chosen for the base-case scenario, 
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one-way and probabilistic sensitivity analyses were used to test the sensitivity of the 
results to uncertainty in each parameter.102 
In one-way sensitivity analyses, one parameter at a time was varied over its 
range of plausible values (Table 18) to determine how much influence that single 
parameter had on the ICER.102 Parameters that have a large influence on the ICER, 
particularly ones that cause the ICER to move from one quadrant to another, indicate 
areas in which more information would be most valuable. That is, narrowing down the 
range of values that parameter might take would lead to a more concise estimate of 
each alternative’s relative value.102  
In the probabilistic sensitivity analysis, all parameters are varied 
simultaneously.102 Whereas the one-way sensitivity analysis requires only a range for 
each parameter, the probabilistic sensitivity analysis requires both a range and a defined 
distribution.102 The distributions associated with each variable are given in Table 18. All 
probabilities are estimated from a binomial proportion, thus beta distributions are 
assumed.100 The distributions for the Medicare cost parameters were created from the 
source data,141 which indicated that the lognormal and gamma distributions were the 
best fit. The use of these distributions is supported by the skewed nature of cost data.100 
The 2010 Red Book provided 8 prices for bicalutamide and 4 prices for leuprolide,142 
which were used to calculate means and standard deviations. The method of moments 
approach was then used to create gamma distributions from the means and standard 
deviations.100  
The probabilistic sensitivity analysis used a Monte Carlo simulation of 1,000 
iterations which selected the values of parameters from the assigned distributions for a 
cohort moving through the model. The output of the probabilistic sensitivity analysis is 
1,000 ICERs, which can be interpreted as the range of potential outcomes that could be 
expected given the range of input parameters assumed.102 
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The resulting ICERs are plotted on the x-y axis and interpreted as described 
above. Multiple ICERs allow for the calculation of the percentage of ICERs falling in 
each quadrant. If all ICERs fall in a single quadrant, then it can be said with some 
certainty that the true value lies in that quadrant, provided the model is comprehensive 
and correctly constructed. It is more likely that the ICERs fall in multiple quadrants, or 
that they fall in the northeast or southwest quadrants, where the determination of the 
superior treatment depends on how much the payer, in this case, Medicare, is willing to 
pay per QALY gained.  
Results from the probabilistic sensitivity analysis results also were used to plot a 
cost-effectiveness acceptability curve (CEAC). The CEAC shows the probability that one 
intervention is more cost-effective than its comparator over a range of WTP value per 
QALY thresholds.102 For a given WTP value, the CEAC indicates the probability that 
implementing the intervention would be the “right” choice, that is, that the cost per QALY 
gained would be equal to or below the WTP per QALY gained. The inverse of this 
probability is the likelihood that the intervention would be the wrong choice.102 Plotting 
the CEAC requires the calculation of the incremental net benefit (INB) for each iteration 
of the Monte Carlo simulation, where the INB is defined as:  
INB = λ*(Benefit(adjuvant) – Benefit(wait and see)) - (Cost(adjuvant) – Cost(wait and see)) 
and λ is the societal WTP for a QALY.157 If the INB is positive, the ART approach offers a 
greater net benefit. If the INB is negative, the wait and see approach offers a greater net 
benefit. For a range of λ values, the CEAC represents the proportion of iterations in 
which the INB is positive.100  
In scenario analyses, cohort characteristics were changed to evaluate outcomes 
for men with different disease characteristics than those men represented by the base-
case (Figure 13). To reflect the findings presented in Chapter 4 that men do not receive 
consistent follow-up surveillance over time, the probability of receiving SRT upon 
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disease recurrence following radical prostatectomy was assumed to be 0.75 for 
recurrences in the first two years following surgery, 0.50 for recurrences in years 3-4, 
and 0.25 thereafter. In an additional scenario to evaluate the effect of increasing PSA 
values over time since radical prostatectomy, PSA level at initiation of SRT was 0.5 
ng/ml for recurrences in the first two years following surgery, 1 ng/ml in years 3-4, and 
1.5 ng/ml in year 5 and beyond. Scenario analyses also evaluated outcomes for four 
groups: men with and without positive surgical margins and with and without seminal 
vesicle invasion.  
All analyses were conducted in 
TreeAge Pro 2011 (Williamstown, MA) and 
followed the guidelines set forth by the 
International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) Modeling 
Good Research Practices Task Force.169 This 
research was approved by the Public Health 
and Nursing Institutional Review Board of the 
University of North Carolina at Chapel Hill. 
6.3. Results 
6.3.1. Base-case Scenario 
In the base-case scenario, treating all 
men with adjuvant radiation following radical prostatectomy resulted in a cost of $31,021 
with a benefit of 10.45 QALYs per person (Table 20). In comparison, waiting until PSA 
recurrence to initiate SRT would be expected to result in $12,726 lower cost and 
increase quality-adjusted survival by 6 months. That is, the wait and see approach to 
radiation is both less costly and results in better outcomes in terms of QALYs (i.e., the 
wait and see approach dominates ART). Although the wait and see approach results in 
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more instances of recurrence overall (79.4% of men experience disease recurrence in 
the wait and see arm compared to 61.9% of men in the ART arm), fewer men develop 
metastatic disease or die from prostate cancer. Under the wait and see approach, 32.4% 
of men are expected to develop metastatic disease, and 19.1% of men will die from 
prostate cancer. Treating all men with adjuvant radiation results in 36.7% of the cohort 
developing metastatic disease and 22.7% of men dying from prostate cancer. All of the 
men treated with the ART approach received radiation therapy, compared to 59.1% of 
the men treated with the wait and see approach.  
Table 20. Base-case Results for Adjuvant Radiation Therapy versus the Wait and See 
Approach to Radiation Therapy 
Adjuvant Wait and See 
Cost (in 2011$) $31,021 $18,295 
Effect (QALYs) 10.45 10.95 
% Experiencing 
recurrence 61.9 79.4 
% Experiencing 
metastatic disease 36.7 32.4 
% of Deaths due to 
prostate cancer 22.7 19.1 
% Receiving SRT 59.1 
Note: CI: confidence interval; QALY: quality-adjusted life-year; SRT: salvage radiation therapy 
 
6.3.2. One-way Sensitivity Analysis 
All model outcomes were calculated using both the high and low values for all 
model inputs listed in Table 18. For all one-way sensitivity analyses, the cost associated 
with ART was greater than the cost associated with the wait and see approach. One 
extreme input value resulted in an ICER in which ART was not dominated by the wait 
and see approach. When the proportion of men who receive SRT after recurrence was 
set to zero, the ICER was $41,762 per QALY. Using a WTP per QALY value of $50,000, 
the difference in INB between the high and low parameter values was greatest for the 
proportion of men who receive SRT after recurrence ($55,123), followed by the 
probability of progression-free survival following ART ($36,789), the probability of 
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progression-free survival following SRT ($32,048), and the probability of progression-
free survival following radical prostatectomy ($25,397).  
In order to further investigate the sensitivity of results to the proportion of men 
receiving SRT after recurrence, outcomes were calculated for a range of proportion 
values (Table 21). For all possible values of the proportion of men receiving SRT after 
recurrence, ART is always the more costly alternative and the wait and see approach 
always results in more instances of disease recurrence. The two alternatives are 
equivalent in terms of QALYs when 36% of men experiencing recurrence receive SRT, 
and ART becomes cost-effective when 6.9% of men experiencing recurrence receive 
SRT (using a $50,000 per QALY WTP threshold). ART and the wait and see approach 
are equivalent in terms of the proportion of men developing metastatic disease and the 
proportion of deaths due to prostate cancer when approximately 55% of men with 
recurrence receive SRT. 
6.3.3. Probabilistic Sensitivity Analysis 
In the probabilistic sensitivity analysis, 75% of men experiencing recurrence were 
assumed to receive SRT. All other parameters values were drawn from their associated 
distributions. Across 1,000 iterations, the average cost associated with the wait and see 
approach was $17,779, compared to $30,927 under the ART approach (Table 22). The 
wait and see approach resulted in 0.51 more QALYs on average, associated with a 
quality-adjusted survival difference of 186 days. As in the base-case, more individuals 
experienced disease recurrence with the wait and see approach (77.3% compared to 
59.4%), but the wait and see approach was associated with a lower proportion of men 
developing metastatic disease (31.2% compared to 35.3%) and a lower proportion of 
men dying of prostate cancer (18.4% compared to 21.9%). 
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Table 21. Results by Proportion of Men Experiencing Biochemical Recurrence who Receive Salvage Radiation Therapy 
 
ART 0% SRT 25% SRT 50% SRT 75% SRT 100% SRT 
Cost (in 2011$) $31,021 $11,773 $13,947 $16,121 $18,295 $20,470 
Effect 10.45 9.99 10.31 10.63 10.95 11.27 
ICER (compared to ART) -- $41,762 $120,412 Dominated Dominated Dominated 
% Experiencing recurrence 61.9 79.4 79.4 79.4 79.4 79.4 
% Experiencing metastatic disease 36.7 48.9 43.4 39.4 32.4 26.9 
% of Deaths due to prostate cancer 22.7 31.3 27.2 23.2 19.1 15.0 
% Recurring and receiving SRT 0 19.1 37.9 59.1 78.8 
*ICER = incremental cost-effectiveness ratio (in 2011$/QALY gained) of ART compared to SRT, **Dominated—SRT dominates ART (i.e., SRT 
costs less and results in better outcomes as measured in QALYs gained compared to ART) 
 
Note: SRT: salvage radiation therapy; ART: adjuvant radiation therapy; QALY: quality-adjusted life year 
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Table 22. Probabilistic Sensitivity Analysis Results 
Adjuvant Wait and See 
Estimate 95% CI Estimate 95% CI 
Cost (in 2011$) $30,927 23,122-41,226 $17,779 9,277-25,718 
Effect (QALYs) 10.45 8.83-12.20 10.96 9.79-12.24 
% Experiencing 
recurrence 59.4 24.4-90.6 77.3 47.8-95.6 
% Experiencing 
metastatic disease 35.3 12.9-55.4 31.2 17.2-44.8 
% of Deaths due to 
prostate cancer 21.9 7.2-41.5 18.4 9.3-35.1 
% Receiving SRT  57.5 35.4-71.3 
Note: CI: confidence interval; QALY: quality-adjusted life-year; SRT: salvage radiation therapy 
 
The range of ICERs, when plotted on the ICER plane, spread across the 
northwest and northeast quadrants (Figure 14). Using a WTP per QALY threshold of 
$50,000, the wait and see is more cost-effective than the ART approach 84.3% of the 
time. That is, the point estimates from 84.3% of the 1,000 iterations fall to the left of the 
threshold line as depicted in Figure 13. In all but 2 model iterations, ART was more 
expensive than wait and see. In 75.6% of the iterations, ART was also less effective in 
terms of QALYs. These iterations are represented by the points in the northwest 
quadrant of the ICER plane in Figure 14. This means that no matter how much society 
was willing to pay for an additional QALY, the wait and see approach would result in the 
greatest net benefit 75.6% of the time. In 8.7% of the iterations the ICER fell to the left of 
the vertical axis, indicating that ART was more effective, but right of the WTP threshold, 
indicating that the cost per QALY gained was higher than society’s WTP.  
6.3.4. Scenario Analyses 
In the base-case and probabilistic sensitivity analysis presented above, the 
proportion of men receiving salvage radiation therapy in response to disease recurrence 
remained constant over time at 75%. This proportion is likely not constant over time, as 
initiation of salvage radiation is dependent on detection of PSA recurrence through PSA 
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surveillance, which, as shown in Chapter 4, declines over time. In a scenario analysis, 
the probability of receiving SRT upon disease recurrence following radical prostatectomy 
was assumed to be 0.75 for recurrences in the first two years following surgery, 0.50 for 
recurrences in years 3-4, and 0.25 thereafter. All other model parameters were drawn 
from their associated distributions, and 1,000 model iterations were run.  
Figure 14. Incremental Cost-effectiveness Ratio Plane Comparing Adjuvant Radiation 
Therapy Versus Wait and See 
 
*Each point represents the incremental cost and incremental effect of adjuvant radiation therapy 
compared to the wait and see approach for a single iteration of the model. The x-axis is quality-
adjusted life years and the y-axis is cost in 2011 US$. All points in the northwest quadrant of the 
graph represent model iterations in which adjuvant radiation therapy was more expensive and 
less effective than the wait and see approach (75.6%). The diagonal line represents a willingness 
to pay threshold of $50,000 per QALY. All points to the right of the threshold represent model 
iterations in which adjuvant radiation therapy was cost-effective compared to a wait and see 
approach (15.7% of points). The remaining 8.7% of points that fall between the y-axis and the 
threshold represent model iterations in which adjuvant radiation therapy was more costly and 
more effective than the wait and see approach but the cost per QALY gained was greater than 
$50,000. 
 
Note: QALY: quality-adjusted life year. Willingness to pay threshold of $50,000 per quality-
adjusted life-year 
 
When the proportion of men who receive SRT following disease recurrence 
decreases over time, the wait and see approach remains superior to ART. Using a WTP 
threshold of $50,000 per QALY, the wait and see approach was the more cost-effective 
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option in 74.5% of model iterations. Compared to a scenario in which 75% of men with 
recurrence receive SRT no matter when recurrence is experienced, the time-varying 
SRT rate is associated with more men developing metastatic disease (37.3% when the 
SRT rate varies over time versus 31.2% when 75% of recurrences receive SRT) and 
more deaths due to prostate cancer (22.4% when the SRT rate varies over time versus 
18.5% when 75% of recurrences receive SRT).  
I also modeled four cohorts of men who received SRT at different PSA levels. In 
the Southwest Oncology Group (SWOG) clinical trial, among the 65 patients in the wait 
and see group received radiation therapy with known treatment initiation dates, 45.1% 
initiated radiation therapy after PSA relapse and objective recurrence (for example, 
biopsy-proven local recurrence).8 Among these men, the median PSA level at the time of 
initiation of SRT was 0.75 ng/ml,9 compared to the 0.50 ng/ml used in the base-case 
analysis. Four additional cohorts of men were created based on PSA level at SRT 
initiation and faced a different probability of progression following SRT. Each probability 
was drawn from its associated distribution (Table 23). Separate probabilistic sensitivity 
analyses were conducted for cohorts of men that initiated SRT at PSA level of 0.1 ng/ml, 
0.75 ng/ml, 1.5 ng/ml, and 3 ng/ml. Base-case results are presented in Table 24. 
Table 23. Probabilities Associated with Disease Recurrence Following Salvage 
Radiation Therapy, by PSA Level at Initiation 
Probabilities 
Base-case 
value SD 
Lower 
95% CI 
Upper 
95% CI 
Progression following SRT*5    
PSA = 0.1 ng/ml 0.37 0.07 0.225 0.515 
PSA = 0.5 ng/ml 0.45 0.11 0.234 0.667 
PSA = 0.75 ng/ml 0.50 0.20 0.108 0.892 
PSA = 1.5 ng/ml 0.65 0.13 0.395 0.905 
PSA = 3 ng/ml 0.80 0.16 0.486 0.999 
*Time period for all probabilities is 6 years, beta distributions used for all probabilities. 
 
Note: PSA: prostate-specific antigen; SD: standard deviation; CI: confidence interval; SRT: 
salvage radiation therapy; ng/ml: nanograms/milliliter 
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When SRT is initiated at 0.1 ng/ml, the wait and see approach dominates ART in 
13.9% of iterations (assuming a WTP per QALY of $50,000). When SRT is initiated at 3 
ng/ml, ART is the more cost-effective approach in 40% of iterations. Figure 15 presents 
the CEACs associated with ART for each of the 5 cohorts of men. For all WTP 
thresholds over the range $0 to $150,000 per QALY, the ART approach is cost-effective 
less than half of the time. There is a greater probability that the wait and see approach 
will be cost-effective, regardless of the PSA level at SRT initiation. The probability that 
ART is cost-effective compared to the wait and see approach is lowest for men who 
initiate SRT at low PSA levels and highest for men who initiate SRT at higher PSA 
levels.  
Figure 15. Cost-effectiveness Acceptability Curves, by PSA Level at SRT Initiation 
 
*Each curve represents the probability that ART will be cost-effective compared to the wait and 
see approach to radiation therapy over a range of willingness to pay values. The willingness to 
pay values represent the maximum value society is willing to pay for an additional quality-
adjusted life year. The threshold values are shown on the x-axis and the probability that ART is 
cost-effective is shown on the y-axis. Each curve represents the relationship between the 
willingness to pay threshold and the probability for a different PSA value at initiation of SRT. The 
curve associated with a PSA level of 0.5 ng/ml at SRT initiation represents the base-case.  
 
Note: PSA: prostate-specific antigen, ART: adjuvant radiation therapy, QALY: quality-adjusted life 
year; SRT: salvage radiation therapy  
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Table 24. Results by PSA Level at Initiation of Salvage Radiation Therapy 
 
ART 
SRT at 0.1 
ng/ml 
SRT at 0.5 
ng/ml 
SRT at 
0.75 ng/ml 
SRT at 1.5 
ng/ml 
SRT at 3 
ng/ml 
Cost $31,021 $17,703 $18,295 $18,645 $19,617 $20,520 
Effect 10.45 11.06 10.95 10.88 10.70 10.51 
ICER (compared to ART) -- Dominated** Dominated Dominated Dominated Dominated 
% Experiencing recurrence 61.9 79.4 79.4 79.4 79.4 79.4 
% Experiencing metastatic disease 36.7 29.7 32.4 33.9 37.9 41.2 
% of Deaths due to prostate cancer 22.7 17.4 19.1 20.0 22.6 25.0 
% Recurring and receiving SRT 59.1 59.1 59.1 59.1 59.1 
*ICER = incremental cost-effectiveness ratio (in 2011$/QALY gained) of ART compared to SRT. **Dominated—SRT dominates ART (i.e., SRT 
costs less and results in better outcomes as measured in QALYs gained than ART) 
 
Note: SRT: salvage radiation therapy; ART: adjuvant radiation therapy; PSA: prostate-specific antigen 
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Table 25. Results by Tumor Characteristics 
 
 Positive SM Negative SM 
ART WS ART WS 
Cost (in 2011$) $30,303 $18,861 $30,805 $14,883 
Effect 10.60 10.89 10.50 11.20 
ICER Dominated  Dominated  
% Experiencing recurrence 57.7 81.1 60.7 65.8 
% Experiencing metastatic disease 33.9 33.4 35.8 28.1 
% of Deaths due to prostate cancer 20.8 19.8 22.1 16.2 
% Recurring and receiving SRT  60.3  48.9 
 
 SV Invasion No SV Invasion 
ART WS ART WS 
Cost (in 2011$) $34,896 $20,886 $27,367 $15,586 
Effect 9.63 10.65 11.17 11.21 
ICER Dominated  Dominated  
% Experiencing recurrence 80.4 85.2 38.5 70.7 
% Experiencing metastatic disease 50.4 38.1 21.7 27.6 
% of Deaths due to prostate cancer 32.6 22.9 13.0 15.9 
% Recurring and receiving SRT  63.5  52.6 
*ICER = incremental cost-effectiveness ratio (in 2011$/QALY gained) of ART compared to SRT. **Dominated - SRT dominates ART (i.e., SRT 
costs less and results in better outcomes as measured in QALYs gained than ART) 
 
Note: SRT: salvage radiation therapy; ART: adjuvant radiation therapy; SM: surgical margins; SV: seminal vesicle 
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If, as has been suggested by the research presented in Chapter 4, men receive 
less intensive PSA surveillance as time from surgery increases, it is possible that the 
average PSA at SRT initiation increases as well. PSA level at initiation of SRT was 0.5 
ng/ml for recurrences in the first two years following surgery, 1 ng/ml in years 3-4, and 
1.5 ng/ml in year 5 and beyond. This led to the creation of a scenario in which 75% of 
PSA recurrences within the first two years after surgery are treated with SRT at a PSA 
level of 0.5 ng/ml, 50% of PSA recurrences in years 3 and 4 were treated with SRT at a 
PSA level of 1 ng/ml, and 25% of PSA recurrences in year 5 and beyond were treated 
with SRT at a PSA level of 3 ng/ml.  
In a probabilistic sensitivity analysis of a scenario in which rates of SRT receipt 
and PSA levels at SRT initiation varied over time, average cost of the wait and see 
approach was $16,299 (compared to $30,598 for ART) and the wait and see approach 
only resulted in an increase of approximately 4 days of quality-adjusted survival 
compared to ART. Compared to ART, the wait and see approach resulted in an increase 
in the proportion of men developing metastatic disease (41.8% versus 35.2%) and dying 
of prostate cancer (25.4% versus 21.9%). With a WTP threshold of $50,000 per QALY, 
ART was cost-effective in 36.7% of model iterations. 
For the cohort of individuals without seminal vesicle invasion, the adjuvant 
approach to radiation therapy results in higher costs and lower QALYs compared to the 
wait and see approach (Table 25). The wait and see approach is associated with more 
cases of recurrence, more cases of metastatic disease, and more deaths due to prostate 
cancer. The outcome in terms of costs and QALYs is the same in the cohort of 
individuals with seminal vesicle invasion, but for these individuals the wait and see 
approach is associated with higher recurrence rates but fewer cases of metastatic 
disease and fewer prostate cancer deaths. At a WTP threshold of $50,000 per QALY, 
the ART approach is cost-effective 19% of the time for individuals without seminal 
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vesicle invasion, compared to less than 1% of the time for individuals with seminal 
vesicle invasion.  
Regardless of surgical margin status, ART results in higher costs and lower 
QALYs than using the wait and see approach to radiation therapy. For the cohorts of 
men with positive and negative surgical margins, ART is associated with a lower 
recurrence rate but a higher rate of metastatic disease and higher proportion of prostate 
cancer deaths. For individuals with negative surgical margins, ART is the more cost-
effective option 2% of the time (using a WTP threshold of $50,000 per QALY). For 
individuals with positive surgical margins, ART is the more cost-effective option 8% of 
the time.  
6.4. Discussion 
Overall, the wait and see approach to radiation therapy resulted in lower costs 
and better quality-adjusted life expectancy than ART. Whereas cost was always higher 
under the adjuvant radiation approach, the preferred alternative determined by other 
outcomes was sensitive to the proportion of men experiencing disease recurrence 
following radical prostatectomy who received SRT and PSA level at time of salvage 
therapy initiation.  
The true proportion of men who receive SRT after disease recurrence is 
unknown, and likely would vary by patient characteristics, surveillance intensity, and 
local practice patterns. In the SWOG study, 111 men in the wait and see group 
experienced recurrence or died during the study period. Of these 111 men, 70 received 
radiation therapy (63%).8 The actual proportion of men receiving SRT could have been 
higher, depending on when deaths in this group occurred. However, of these 70 men 
many did not initiate radiation therapy until an objective recurrence as defined by biopsy-
detected local disease (which is more advanced than a recurrence detectable only by 
rising PSA levels). The probabilities associated with the risk of recurrence following SRT 
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assume that SRT is initiated upon PSA-only recurrence and that radiation therapy is 
administered before objective recurrence. By this definition, only 55.4% of the sample in 
the SWOG trial would have been considered to have received SRT.8 Based on the 
patterns observed in the SWOG study, the 75% salvage administration rate used in this 
model may be on the upper end of the range of plausible values.  
The results from this model do not reflect the improved metastases-free survival 
associated with ART observed in the SWOG study. One reason for this difference is the 
probability of SRT initiation, as discussed above. Additionally, the entire cohort of men 
modeled was assumed to achieved an undetectable PSA level after prostatectomy, 
compared to 66% of men in the SWOG study.8 The presence of elevated PSA following 
surgery is associated with shorter disease-free time following salvage radiation,5 so the 
results observed in the SWOG study are likely not applicable to a cohort of men with 
undetectable PSA following surgery (< 0.1 ng/ml). Additionally, the men in the SWOG 
study, as clinical trial participants, may not be representative of the Medicare population, 
which limits the generalizability of trial results.14  
The results by tumor characteristics suggested that men with positive surgical 
margins and seminal vesicle invasion may benefit from the wait and see approach to 
radiation therapy. Although in all scenarios adjuvant radiation was associated with a 
lower proportion of men who experienced biochemical recurrence, men who 
experienced biochemical recurrence after ART were more likely to go on to experience 
metastatic disease. This observation is in contrast to men who experienced biochemical 
recurrence after radical prostatectomy and received SRT, which essentially bought them 
additional time until progression to metastatic disease. These results should be 
interpreted with caution, however, as they are based on progression probabilities 
observed in an unplanned subgroup analysis from the ARO trial and sample sizes are 
relatively small.6  
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As shown by the change in results when considering SRT administered at a PSA 
level of 0.1 ng/ml compared to 3 ng/ml, the model is sensitive to changes in the 
probability of progression following SRT. SRT was most effective when initiated in all 
patients with a biochemical recurrence following radical prostatectomy and at lower PSA 
levels. No published clinical trials evaluate the ideal timing of SRT initiation, but research 
suggests that a PSA increase from an undetectable level to 0.1 ng/ml may be large 
enough to consider SRT initiation.81 Initiating SRT this early greatly affects the 
probability of progression following SRT and swings the results from this model even 
more in favor of the wait and see approach.  
As with all simulation models, the results are only as valid as the model 
construction and input values. This model was constructed based on previous models of 
prostate cancer progression112,118 and with input from specialists in urology and 
oncology. When at all possible, input values were representative of the population of 
men for whom ART would be appropriate. This approach was not possible in all cases, 
particularly with regards to utility values and probabilities associated with progression 
from biochemical recurrence to metastatic disease. That is, these input values came 
from studies where the sample was not restricted to men with intermediate- or high-risk 
disease. Men who are initially diagnosed with low-risk disease may have lower 
progression-related probabilities, which may mean that the probabilities used in this 
model are biased in the downward direction. The results from this model are roughly 
similar to those reported in previous decision analyses related to radiation therapy in 
prostate cancer although it is not appropriate to directly compare the results due to 
differences in model construction, patient population, and outcomes of interest.118,170  
Of the three clinical trials to compare ART to a wait and see approach, only one 
trial has demonstrated improved metastases-free and overall survival associated with 
ART.9 The results from this model suggest, however, that although the ART approach 
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reduces the proportion of men who experience disease recurrence, the wait and see 
approach may be more effective in reducing the proportion of men who develop 
metastatic disease and the proportion of men who die from prostate cancer. Essentially, 
SRT increases the time from initial recurrence to progression to metastatic disease, 
which creates a survival advantage associated with this approach. The success of the 
wait and see approach in terms of quality-adjusted life expectancy, metastases, and 
prostate cancer deaths depends in part upon two factors that are unknown at the time of 
surgery: the proportion of men experiencing biochemical recurrence who receive SRT 
and PSA level at SRT initiation.  
Post-operative surveillance through frequent PSA testing can increase the 
likelihood of detecting rising PSA levels and help inform the decision to initiate SRT. This 
surveillance is essential if the benefits associated with the wait and see approach 
compared to ART are to be realized. The analysis in Chapter 4 suggests that PSA 
surveillance decreases over time and that minority groups have lower odds of receiving 
a PSA test in any given year past radical prostatectomy compared to non-Hispanic 
Whites. All men, and especially racial minorities, are therefore at increased risk for 
undetected biochemical recurrence as time from surgery increases. Potential future 
educational interventions could target both patients and providers and emphasize the 
importance of developing and following survivorship care plans to increase the 
probability of detecting disease recurrence through PSA testing as early as possible. 
Without timely detection of recurrence, men may receive greater benefit from ART 
following radical prostatectomy; thus, a commitment to a long-term surveillance plan on 
the part of both patient and provider should be established upon receipt of initial 
treatment for men eligible for the wait and see approach to radiation therapy. 
  
 
7. SUMMARY OF FINDINGS, LIMITATIONS, AND FUTURE DIRECTIONS 
This study used population-based Surveillance, Epidemiology, and End Results 
(SEER)-Medicare data, published clinical trial results, and peer-reviewed literature to 
examine patterns of prostate-specific antigen (PSA) surveillance and the implications 
surveillance patterns may have on the decision to implement radiation therapy adjuvant 
to radical prostatectomy or to delay radiation therapy until there is evidence of disease 
recurrence. This study represents one of the first attempts to directly link PSA 
surveillance and secondary treatment decisions. 
7.1. Summary of Findings 
 In Chapter 4, I examined the effect of individual-, tumor-, and community-level 
factors on the likelihood of receiving PSA tests in accordance with National 
Comprehensive Cancer Network (NCCN) Guideline recommendations for prostate 
cancer patients age 65 and older who receive radical prostatectomy for intermediate- 
and high-risk disease. Overall, receipt of PSA testing following treatment was high, with 
96% of men receiving at least one test the first year after treatment and 80% of men 
receiving at least one test in the fifth year after treatment. Non-married men, men with 
less advanced disease, and non-Hispanic Blacks and Hispanics had lower odds of test 
receipt, but the odds associated with these characteristics were much lower than the 
odds associated with time elapsed since treatment. None of the community-level factors 
had a significant effect on the odds of receiving at least one test in a 1-year period, but 
four of the five factors (Medicare health maintenance organization (HMO) penetration, 
population density, social capital, and racial/ethnic isolation/segregation) had a 
significant influence on the odds of receiving a test in a 6-month period.  
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The finding of a racial disparity between non-Hispanic Whites and other groups is 
in accord with previously reported racial differences in prostate cancer treatment and 
mortality,68,69 and the difference in test receipt between non-Hispanic Blacks and non-
Hispanic Whites is in line with the results reported in the only other study to focus on 
post-treatment PSA receipt.70 Although the racial disparity results in no way suggest that 
differences in surveillance lead to differences in mortality, they do suggest that the 
difference in surveillance by race may be clinically significant in addition to statistically 
significant.  
The community-level factors were included in the model to measure access to 
care and social support. The high rate of annual test receipt, combined with the finding 
of no significant effect of the community-level variables on annual test receipt suggests 
that most men do not have difficulty getting an annual PSA test. Access to care and 
social support play a larger role in influencing test receipt in a 6-month period, as semi-
annual testing may require more motivation and resources. However, the magnitude of 
the odds ratios associated with the race/ethnicity and community variables compared to 
the odds ratios associated with the variables measuring time elapsed since treatment 
suggest that decreasing disparities related to individual or community characteristics 
may not be the most efficient strategy to increase overall long-term surveillance. One 
way to improve test receipt may be to focus on creating educational interventions 
underscoring the rationale for follow-up strategies that span many years following 
treatment and to highlight the significance of long-term follow-up as part of a survivorship 
care plan. These educational interventions should target primary care providers as well 
as cancer care providers, as the former may play a larger role in delivering follow-up 
care as time from treatment increases.47  
 Chapter 5 was designed in acknowledgement of changing treatment 
documentation practices in SEER data and increasing interest in using SEER data to 
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measure receipt of radiation therapy adjuvant to radical prostatectomy. This study 
compared SEER treatment data to Medicare claims to determine whether there are 
biases related to the use of SEER data alone rather than the linked SEER-Medicare 
data to study adjuvant radiation therapy (ART). Only a small percentage of men overall 
receive ART (9.7% in SEER, 10.9% in Medicare). Agreement across the two sources 
was high (94.8%) and was found to vary by registry area and disease severity. However, 
almost all men with documentation of ART receipt in SEER had Medicare claims for 
radiation therapy at some point after surgery.  
 In this study, I observed limited bias caused by using SEER data only to study 
ART rather than validating radiation receipt using Medicare claims, particularly for men 
with poorly-differentiated tumors. However, only a small number of cases are affected by 
disagreement, implying that it is reasonable to use SEER data alone to examine ART. 
The low rates of ART among the SEER population reported by previous studies86,87 are 
likely the result of limited adoption of ART as a treatment modality rather than any 
underreporting of ART in SEER data.  
 Chapter 6 tied together the issues of PSA surveillance and ART through a cost-
utility model. I used a Markov cohort model to compare two approaches to radiation 
therapy following radical prostatectomy: ART versus a wait and see approach in which 
salvage radiation therapy (SRT) is initiated only upon evidence of disease recurrence 
(marked by increasing PSA values). Treating all qualifying men with ART following 
radical prostatectomy resulted in an expected cost of $31,021 with a benefit of 10.45 
quality-adjusted life-years (QALYs). Waiting until PSA recurrence to initiate SRT resulted 
in an expected cost of $18,295 with a benefit of 10.95 QALYs. That is, the ART 
approach was more expensive and resulted in slightly worse outcomes in terms of 
QALYs. Although more men developed disease recurrence under the wait and see 
approach, it was associated with lower rates of metastatic disease and death from 
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prostate cancer. These results assume that 75% of men who experience disease 
recurrence in the form of increasing PSA values receive SRT. If this proportion falls to 
36% of men, the two strategies are equivalent in terms of QALYs, but the wait and see 
approach is still the more cost-effective option as it remains less costly. The ART 
approach becomes cost-effective (using a $50,000 per QALY willingness to pay 
threshold) when only 6.9% of the men experiencing recurrence receive SRT. I used the 
results of Chapter 4 to inform the creation of several scenarios, which I then used to 
assign model parameters. Since the results from Chapter 4 indicate that men are less 
likely to receive surveillance PSA testing over time, I allowed the proportion of men who 
receive SRT following recurrence to decrease over time (reflecting that recurrence that is 
not detected through PSA surveillance will not be treated). I also created a scenario in 
which the PSA value at the time of SRT initiation increased over time, reflecting that less 
frequent PSA testing may result in higher PSA values at detection of recurrence. For 
these scenarios, as well as scenarios for men with varying disease characteristics, the 
wait and see approach was almost always the more cost-effective option although it 
often resulted in higher rates of metastatic disease and prostate cancer deaths.  
The success of the wait and see approach in terms of quality-adjusted life 
expectancy, metastases, and prostate cancer deaths depends in part upon two factors 
that are unknown at the time of surgery: the proportion of men experiencing biochemical 
recurrence who receive SRT and PSA level at SRT initiation. Post-operative surveillance 
through frequent PSA testing can increase the likelihood of detecting rising PSA levels 
and help to inform the decision to initiate SRT. The analysis in Chapter 4 suggests that 
PSA surveillance decreases over time and that minority groups have lower odds of 
receiving a PSA test in any given year past radical prostatectomy than non-Hispanic 
Whites. All men, and especially racial minorities, are therefore at increased risk for 
undetected biochemical recurrence as time from surgery increases. Without timely 
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detection of recurrence, men may receive greater benefit from ART following radical 
prostatectomy; thus, a commitment to a long-term surveillance plan on the part of both 
patient and provider should be established upon receipt of initial treatment for men 
eligible for the wait and see approach to radiation therapy.  
7.2. Limitations 
The findings from Chapters 4 and 5 are limited by the use of claims data to 
identify PSA testing and radiation therapy receipt, as claims provide no information on 
test or treatment motivation. That is, it is not possible to distinguish between men who 
are receiving multiple PSA tests to follow-up on previous test results and men who are 
receiving multiple tests due to lack of communication across providers. Furthermore, the 
results of the PSA tests are not available in these data, which limits the ability to draw 
conclusions regarding the frequency of abnormal (in this context, detectable) PSA 
results and any actions (i.e., initiation of salvage treatment) that might be indicated on 
the basis of those results. This relates to one limitation of using claims to examine 
radiation therapy, as it is impossible to know whether radiation therapy delivered within 
180 days of radical prostatectomy was initiated in response to rising PSA levels following 
surgery or was delivered as part of an initial treatment plan.  
Additionally, the limitation of the sample to men with Medicare fee-for-service 
insurance means that results may not be generalizable to the entire prostate cancer 
population or to the entire Medicare population. Results are also only applicable to the 
portion of prostate cancer patients and survivors who receive radical prostatectomy soon 
after diagnosis. As more than 80% of the men in SEER-Medicare with qualifying disease 
characteristics did not meet the surgical inclusion criteria for these studies, the group of 
men to whom these results can be generalized is relatively small. Findings of this 
research may not apply to younger men who are not covered by Medicare as these men 
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may face a different set of competing health risks and experience different treatment 
patterns.16,18  
As with all simulation models, the results presented in Chapter 6 are only as valid 
as the model construction and input values. This model was constructed based on 
previous models of prostate cancer progression112,118 and with input from specialists in 
urology and oncology. When at all possible, input values were representative of the 
population of men for whom ART would be appropriate. There has been one clinical trial 
that has reported on metastasis-free and overall survival associated with ART compared 
to a wait and see approach to radiation therapy,9 but differences in the clinical trial 
inclusion criteria and the characteristics of the hypothetical model cohort make it 
impossible to make meaningful comparisons between trial results and the model output.  
7.3. Future Directions 
I believe that the analyses presented in Chapters 4 and 6 offer the most 
interesting and fruitful extensions for future research. A natural extension of the research 
in Chapter 4 would be to evaluate the validity of using PSA claims as a marker of post-
prostatectomy surveillance. There are currently no studies validating the use of PSA 
claims in the Medicare data. The use of PSA tests as a marker of quality surveillance is 
predicated upon the assumption that men who receive intense PSA surveillance would 
be more likely to initiate secondary therapy than men who do not receive PSA tests. If, 
however, a significant proportion of men receive some form of secondary therapy 
without claims for PSA tests, then PSA claims may not be an indicator of post-
prostatectomy surveillance intensity or quality. The sample for this subgroup analysis 
would be similar to the Chapter 4 sample but would include only those men who 
received either salvage radiation therapy or hormonal therapy at least six months after 
prostatectomy. If the number of men with claims for secondary therapy and no PSA 
surveillance is high, practice patterns in some areas, regions, or among some urologists 
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may indicate the use of secondary therapy without evidence of a rising PSA. I do not, 
however, expect this to be the case as this would assume practice patterns that are not 
guideline-appropriate and do not make use of an easily obtained and highly sensitive 
and specific tumor marker.171 If, however, there are a large number of men with 
secondary treatment and no surveillance PSA claims, future research is warranted.  
To the extent that an abnormal result in this context (any detectable PSA greater 
than 0.1 ng/ml) may not be flagged as “abnormal” on standard laboratory result reports 
(which typically set a threshold of 2.5 or 4.0 ng/ml), the possibility of missed 
opportunities for potentially curative early salvage treatment certainly exists. Future 
studies to evaluate the extent of this potential phenomenon are warranted, given 
evidence supporting optimal efficacy for salvage radiation when delivered at low PSA 
levels, with progressively poorer results for patients receiving salvage treatment at 
progressively higher PSA levels, all below the standard screening-context “normal” 
ranges of PSA.5  
Although PSA values are more directly interpretable following radical 
prostatectomy than other initial therapies, I could expand the sample from the Chapter 4 
analysis to include men who receive radiation or hormonal therapy as an initial 
treatment. The single other study of PSA surveillance testing found that there were 
differences in test receipt by type of initial treatment.70 If men who receive other types of 
treatment do not receive surveillance at the same high rate as radical prostatectomy 
patients, there may be some cause for concern that overall follow-up and survivorship 
care in these other patient groups is lacking.  
The frequency of PSA surveillance testing observed in radical prostatectomy 
patients, along with the suggestion that testing rates are not constant over the course of 
a year (see Figures 6 and 8 in Chapter 4) may indicate that PSA surveillance would best 
be measured in a survival-analysis framework. The primary drawback of using the 
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logistic-based GEE model, in contrast to survival analysis methods designed for 
recurrent events (such as shared frailty and Andersen-Gill Cox models), is the relatively 
clumsy manner in which time can be addressed. In the Chapter 4 analysis, I dropped 
partial periods of data, but continuous time models could make full use of the entire 
surveillance period. Future work could examine the use of survival analysis to address 
PSA surveillance. 
An alternate modeling strategy also could be used to generate additional results 
from the Markov model. In contrast to cohort models, individual-level models (often 
called microsimulations172) evaluate outcomes for one person at a time. Individual, rather 
than cohort, modeling requires more inputs and increases computational burden, but 
produces more accurate estimates of population-level cost, utility, and event 
frequency.173 Additionally, individual-level modeling makes it possible to model the 
dependence of transition probabilities on multiple risk factors and patient histories that 
change over time.174 This allows for the construction of a model that is much more 
representative of the real world than a cohort model. 
The addition of tracker variables, which are global variables that can be 
associated with each individual within the model to keep a record of the time an 
individual spends in each state,175 along with individual-level, rather than cohort 
modeling would help to make my model more representative of the actual disease 
course than the straightforward Markov model used in Chapter 6. Individual-level 
modeling, combined with sensitivity analysis, would combine stochastic uncertainty, 
parameter uncertainty and patient heterogeneity, all three of which are recommended to 
account for uncertainty and variability in medical decision models.172  
For decision-makers, it is not enough to know the probability that a given 
intervention will be the most cost-effective choice. It is also necessary to know the costs 
associated with making the wrong choice.102 The cost of making the wrong decision and 
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the probability of making the wrong decision jointly determine what is referred to as the 
expected opportunity loss of the decision or the expected value of perfect information 
(EVPI).100 EVPI can be thought of as the maximum value added by further research that 
would reduce uncertainty in the model parameters.102 Future research could calculate 
the EVPI and compare it to the cost of conducting a clinical trial of ART versus a wait 
and see approach to salvage radiation therapy. If the EVPI is greater than the cost of a 
trial, then it may be wise to conduct a trial or invest in more research before making 
treatment recommendations based on model outcomes.  
Although the overall EVPI can be informative, it may be much larger than current 
resources available to conduct further research. In this case, calculating the expected 
value of perfect information for parameters (EVPPI) can identify the type of future 
research that would be most useful.100 In the future, I could use a two-level Monte Carlo 
simulation method to calculate the EVPPI. This method uses all possible true values for 
the parameter to calculate opportunity loss and then averages the opportunity loss 
across all possible parameter values.157 The EVPPI can be calculated for individual 
parameters or groups of parameters, with the latter method preferred as a starting 
point.100 Creating groups of related parameters and calculating the EVPPI for the set 
makes sense intuitively, as individual parameters may not be independent, and further 
research on one parameter may yield information on another parameter.  
7.4. Conclusions 
Chapters 4 and 6 particularly call attention to the role of PSA surveillance in 
prostate cancer survivorship care. PSA surveillance is not only essential in the detection 
of disease recurrence, it is one of the most important factors that influences the success 
of SRT in response to recurrence. PSA surveillance, though high overall, especially in 
comparison to surveillance in other cancer survivors, declines over time and is lower in 
some populations of men. Low rates of PSA surveillance can lead to the missed 
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opportunity to detect disease recurrence and to initiate SRT when it has the greatest 
potential to be curative. The most important take-away point from this dissertation 
research is that a long-term plan for disease surveillance is essential for prostate cancer 
patients, particularly those who receive radical prostatectomy as initial therapy. This 
research sets the stage for future educational interventions to target patients and 
providers and convey the importance of survivorship care in prostate cancer.  
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